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Abstract 
The liver is characterized by sexually dimorphic gene expression translating into sex-specific 
differences in lipid, drug, steroid hormone and xenobiotic metabolism, with distinct 
responses of males and females to environmental challenges. Here, we investigated the role 
of the KRAB-associated protein 1 (KAP1) epigenetic regulator in this process. Liver-specific 
KAP1 knockout led to strikingly sexually dimorphic phenotypic disturbances, including male-
predominant steatosis and hepatic tumors with upregulation of AKT and ERK1/2 mitogen-
activated protein kinase signaling. This correlated with sex-specific transcriptional 
dysregulation of a wide range of metabolic genes, notably those involved in retinol and sex 
hormone processing as well as in detoxification. Furthermore, chromatin 
immunoprecipitation followed by deep sequencing indicated that a number of dysregulated 
genes are direct targets of the KRAB/KAP1 repression system. Those genes include sexually 
dimorphic Cyp2d9, Gstπ, Slp Cyp2a, Cyp2b and Cyp3a gene clusters. Additionally, we 
identified a male-restricted KAP1 binding site in the fsp27 (fat specific protein 27) gene, 
correlating with its male-predominant upregulation upon Kap1 deletion, suggesting that the 
latter might be an important trigger in the development of male-specific hepatosteatosis 
and secondary tumorigenesis.   
Conclusion: This work reveals KRAB/KAP1-mediated transcriptional regulation as a central 
event in the metabolic control hormones, drugs and xenobiotics in the liver, and further links 
disturbances in these processes with hepatic carcinogenesis.  
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Metabolism is orchestrated by complex gene regulatory networks, and the liver is central to 
this process. This organ is characterized by sexually dimorphic gene expression, with 
numerous genes transcribed in a sex-dependent manner
1
. In mice, examples of such genes 
include the male-predominant Cyp2d9, which encodes for a testosterone-16-α-hydroxylase 
inactivating the main male sex hormone and various drugs, and the female-predominant 
Cyp2a and Cyp2b genes involved in xenobiotic and drug metabolism
2
. The sex-specific 
expression of these and other classes of enzymes results in the differential response of 
males and females to environmental challenges, with males displaying a higher 




Sexually dimorphic gene expression in the liver is established by sex-specific action of liver 
transcription factors
1
. One of those, regulator of sex limitation (Rsl), belongs to the Krüppel-
associated box zinc finger proteins (KRAB-ZFP) family of tetrapod-specific transcription 
repressors, which counts between 300 and 400 members in mouse and human
5
. KRAB-ZFPs 
are characterized by the presence of an N-terminal KRAB domain required for repression 
and a C-terminal array of DNA-binding ZFs. Few have been assigned a physiological role in 
vivo, yet enough data is available to indicate that these proteins display a wide range of 




Whereas the role and gene targets of the vast majority of KRAB-ZFPs remain ill defined, how 
they repress transcription is comparatively well understood. Many KRAB-ZFPs likely bind 
DNA in a sequence-specific manner via their ZFs and recruit KRAB-associated protein 1 
(KAP1, also known as TIF1β, TRIM28 and KRIP-1), which serves as their universal cofactor. 
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KAP1 in turn acts as a scaffold for a chromatin-remodeling complex comprising the histone 
methyltransferase SETDB1, which catalyses histone 3 lysine 9 tri-methylation (H3K9me3), 
histone deacetylases, nuclear remodeling factors as well as heterochromatin protein 1. The 
formation of heterochromatin ensues, leading to epigenetic silencing
8
.  
In the mouse, constitutive Kap1 knockout is early embryonic lethal, correlating with an 
absence of gastrulation
9
. Deleting Kap1 in ESC leads to loss of pluripotentiality, imprinting 
defects, and failure to silence endogenous and some exogenous retroviruses
6, 8, 10
. In adult 
tissues, KAP1 regulates spermatogenesis and impacts on the management of behavioral 
stress
8, 11
. Furthermore, inbred mice heterozygous for a null mutation in Kap1 were found to 
exhibit greater variance in body weight than wild type littermates, and for some animals 
liver steatosis, adipocyte hypertrophy and impaired glucose tolerance
12
.  
Here, we explored the role of KRAB/KAP1 in liver function. The analysis of hepato-specific 
conditional Kap1 KO mouse revealed a sexually dimorphic metabolic syndrome, with male-
preominant liver steatosis and tumorigenesis. This correlated with sex-specific 
transcriptional dysregulation of genes involved in retinol, xenobiotic and drug metabolism. 
The identification of KAP1-binding sites in the mouse liver further revealed that a number of 
the affected genes are direct KAP1 targets. This study thus unveils the important 
contribution of KRAB/KAP1-mediated regulation to liver function and metabolism.  
 
Experimental Procedures 
Mice generation and phenotyping. Generation and genotyping of mice with a floxable Kap1 
allele (Kap1
fl/fl
) and the Alb.Cre mouse strain have been previously described
9, 13
. Animals 
were housed in standard conditions with water and chow or high fat diet provided ad libitum 
- for details see Supporting Experimental Procedures. All animal experiments were approved 
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by the local veterinary office and carried out in accordance with the European Community 
Council Directive (86/609/EEC) for care and use of laboratory animals. Phenotyping was 
performed on at least 8 males and females. For details see Supplementary Methods. 
Histological tissue processing and analysis. Hematoxylin and erythroeosine and Oil Red O 
(ORO) stainings were performed according to standard procedures. Histopathology 
evaluation, ORO scoring and tumor occurrence analysis were done by a board certified 
pathologist (F.A.). Hepatocellular lesions were classified as foci of cellular alteration, 
hepatocellular adenomas and hepatocellular carcinoma according to established criteria
14
. 
For BrdU pulse-labeling, mice received 3 mg/ml of BrdU in drinking water for 6 days and the 
liver tissue was stained for BrdU (Oxford Biomedical Research). TUNEL assay was performed 
with the Apoptag kit (Millipore) according to manufacturer’s instructions.  
Small scale DNA, RNA and protein analysis. Genotyping, RNA extraction and reverse-
transcription as well as protein analysis were performed according to standard procedures 
as previously described, see Supplemental Methods
11
.  
MicroArray analysis. 8-10-week-old mice were food-deprived at 0700 hrs and liver was 
isolated at 1100-1400 hrs. Total RNA was extracted with the MirVana kit (Ambion) and 
treated with DNAse (Ambion), following manufacturer instructions. Three RNA pools from 9 
mutant and wild type male livers were prepared, while three individual female KO and wild 
type livers were used separately. Microarray analysis was performed as previously 
described
11
. Significantly deregulated genes (p<0.05 by unpaired t-test and fold-change ≥ 2) 
were used to interrogate DAVID bioinformatic database
15
.  
ChIP-sequencing and ChIP-PCR. Liver chromatin was performed as previously described with 
minor modifications
16
. For ChIP-seq, chromatin from two male and female Kap1
fl/fl
 and one 
male and female Alb.Cre Kap1
fl/fl
 control were prepared. Chromatin immunoprecipitation 
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with an affinity-purified rabbit polyclonal antibody kindly provided by Dr. Rauscher
17
 was 
performed as previously described
18
. Details describing sequencing, read alignment and 
subsequent analyses are provided in Supporting Methods.  
Statistical analysis. Body and organ weight measurements as well as plasma biochemistry 
were analyzed with the two-tailed Student’s t test or two-way ANOVA followed by the 
Bonferroni post-test. Contingency testing was done with Fisher’s exact test. For statistical 
analysis of high throughput data see related paragraphs. 
 
Results 




 in a 
mixed C57/Bl6-Sv129 background with animals expressing the Cre recombinase under the 
control of an albumin promoter
13
. We confirmed the liver-specificity of Kap1-deletion by 
locus-specific PCR, and determined that, in whole liver from mutant mice, KAP1 mRNA was 
reduced by more than 75% and protein was undetectable by Western blot, while 
immunohistochemistry confirmed that its loss was restricted to hepatocytes (Supporting 
Fig. 1). Histology combined with Oil Red O (ORO) staining further revealed that 8-10-week-
old male Alb.Cre Kap1
fl/fl
 mice, but not their female counterparts, suffered from mild liver 
steatosis (Supporting Fig. 1). These results suggested that loss of KAP1 perturbed metabolic 
homeostasis in the liver, and pointed to possible sex-specific differences in this process. 
Sex-dependent phenotypic consequences of hepatocyte-specific Kap1 KO. Because of this 
early finding and of known sex-related differences in metabolism and liver function in 
rodents and other mammals including humans
1, 19
, we followed a phenotyping protocol that 
separately examined male and female mice (see Experimental procedures). At 8-10 weeks of 
age, no differences in body weight, food intake and plasma markers of liver function and 





HEP-11-2341   Bojkowska et al 
lipid metabolism between mutant and wild type mice were observed (not illustrated). 
However, histopathology revealed significant fat accumulation with small vacuoles in all of 
12 KO male livers compared with only one third (4 out of 12) of controls (Fisher’s exact test, 
p= 0.0013; not shown), while females were exempt of this pathology. The steatosis noted in 





 animals (not illustrated). 
We then asked whether a metabolic challenge would accentuate the phenotype of 





 littermates with high fat diet (HFD; 60% calories from fat) or chow diet (CD) for 19 
weeks. CD-fed Kap1 KO males displayed progressive hepatosteatosis characterized by 
increased liver weight and fatty change of mild to moderate degree at 6 months of age (Fig. 
1B and 1C, Table 1). In contrast, control littermates exhibited minimal lipid accumulation in 
the liver as revealed by ORO staining (Fig. 1B and 1C). These changes were not accompanied 
by weight gain, increased food intake and only by a trend to upregulation of plasma markers 
of liver function (Fig. 1A and 1D; Table 1 and data not shown). Interestingly, Kap1-KO males 
displayed significantly lower plasma free fatty acid (FFA) concentration than littermate 
controls, suggesting an increased rate of hepatocytic FFA uptake following Kap1 deletion 
(Table 1).  




 males developed severe 
hepatic steatosis (Fig. 1C), but the liver was heavier in Kap1-KO animals, which also 
presented with a bigger epididymal fat pad and a decreased testis weight (Table 1). Although 
this latter trait suggested an impaired sex hormone balance, a condition also observed in 
humans in cases of severe liver steatosis
4
, total plasma testosterone levels were not 
different between KO and WT littermates (Table 1).   
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In contrast to males, CD-fed females did not present significant liver lipid 
accumulation, although Kap1-KO animals showed plasma dyslipidemia and upregulation of 
liver enzymes (Fig. 1A-D and Table 1). When subjected to HFD, Kap1 mutant females 
displayed a higher body weight than littermate controls probably due to increased body fat 
content as assessed by echoMRI (Fig. 1A and Table 1). Furthermore, these mice were 
characterized by i) a moderate degree of liver steatosis (Fig. 1C); ii) mildly elevated plasma 
cholesterol and triglycerides; and iii) significant upregulation of ALT, AST as well as a clear 
trend in the upregulation of other plasma markers of hepatocytic dysfunction (Fig. 1D and 
Table 1). Nevertheless, Kap1-KO females were comparable to their littermates for food 
intake, physical activity and energy expenditure (not illustrated).  
Development of hepatic adenomas in Kap1 KO males. Anatomo-pathological examination 
indicated that male Alb.Cre Kap1
fl/fl
 mice on HFD had a tendency to develop liver tumors that 
occasionally reached large size and formed nodular masses distorting the lobar contour (Fig. 
2A and 2B). Hepatic adenomas were seen in 4/11 HFD-fed and 1/12 CD-fed males at 29 
weeks, while no tumors were found in Kap1
fl/fl
 littermates (n=9 and n=10 on CD and HFD, 
respectively). In one of the HFD-fed Kap1-KO males a 2 mm in diameter hepatocellular 
proliferative focus with features of solid carcinoma was observed. Consistent with the 
previously reported protective effect of female hormones
3
, Kap1-KO female mice appeared 
largely to escape HFD-induced tumorigenesis as only 1/10 HFD-fed KO females had an 
adenoma and no tumor was observed in wild type (n=10 on CD and n=10 on HFD) nor in CD-
fed female KO mice (n=10). To confirm these results, we analyzed the livers of CD-fed mice 
at age of 53-72 weeks (Table 2). Macroscopic examination revealed that Kap1-KO mice 
presented with hepatomegaly (Table 2) and 9/15 (64%) male Alb.Cre Kap1
fl/fl
 mice developed 
tumors compared to 2/13 (15%; p<0.024) wild type controls, while females appeared 
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partially protected against this process with only 4/15 (27%) KO and 1/15 (7%) wild type 
controls showing hepatocellular tumors (Table 2 and Fig. 2C). Histopathological examination 
performed on a subset of animals (13-15 in each subgroup) confirmed that all tumors 
observed in Kap1-deleted mice were adenomas, while focal cellular alterations were 
detected in both control and knockout mice. In addition, minimal infiltration by mixed 
inflammatory cells was noted in about a quarter of the animals, but no significant 
association with Kap1 status was found (not illustrated). We verified that similar results were 
obtained in a C57/Bl6 background (Supporting Fig. 2).  
Although inflammation was not a prominent histological feature of Kap1 KO livers, 
we observed higher intrahepatic levels of pro-inflammatory cytokines IL1β, IL6 and TNFα in 
this setting (Fig. 1E, Tables 1 and 2). IL6 and TNFα contribute to hepato-protection and 
induce hepatocyte proliferation during liver injury
20
 and have been implicated in the 
development of fatty liver and tumors in other mouse models of liver tumorigenesis
3
. Since 
cytokine signaling involves several transduction pathways previously implicated in liver 
oncogenic transformation
21
, we analyzed the activity of the mitogen-activated protein kinase 
(MAPK) pathway, the phosphorylation levels of AKT as well as the expression levels of PTEN,  
key regulators of the PI3 kinase pathway (Fig. 2D and 2E). Total levels of p38 MAPK were 
similar in wild type and KO animals, irrespective of their genetic background. However, levels 
of phosphorylated p38 were increased in knockout livers. As an expected corollary, there 
also was a significant hyperphosphorylation ERK1/2 MAPK and MEK1 in KAP1-depleted 
tissue (Fig. 2D and 2E). Furthermore, tumor tissue harvested from Kap1 KO liver displayed a 
marked upregulation of both total and phosphorylated ERK1/2, despite normal levels of 
activity of other components of the MAPK pathway. Additionally, we observed AKT 
hyperphosphorylation in the tumor tissue despite normal total protein levels. These results 
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suggest that amplification of ERK1/2 and increase of AKT signaling plays a prominent role in 
the development of adenomas in Kap1 KO livers. In contrast, there was no significant change 
in the phosphorylation status of JNK/SAPK nor abnormalities in PTEN levels (Fig. 2D).  
To assess the contribution to the observed phenotype of hepatocyte proliferation 
and hepatic cell death, we performed BrdU pulse in 35- and 68-week-old mice and found 
that hepatocyte proliferation was comparable between KO and controls (Fig. 2F). Similarly, 
histological examination and TUNEL staining in KAP1-depleted livers did not reveal any 
significant signs of cell death in Kap1-KO livers (data not shown). 
In summary these results indicate that loss of KAP1 in the liver leads to sexually 
dimorphic phenotypes, with males exhibiting progressive steatosis and age-related 
tumorigenesis, and females suffering from a less dramatic syndrome with mild metabolic 
defects, including obesity and steatosis revealed only upon exposure to an environmental 
stress.  
Sex-specific gene dysregulation in Kap1 knockout liver. We performed gene expression 
profiling in liver from CD-fed 8- to 10-week-old wild type and mutant male and female mice, 
choosing this young age in order to minimize the potential impact of compensatory changes. 
Loss of KAP1 led to at least two-fold dysregulation of 170 and 149 genes in male and female 
mice, respectively. Interestingly, less than 50% of the deregulated genes were common to 
the two sexes (Fig. 3A), suggesting that the KRAB/KAP1 system targets different genes in 
males and females. Gene ontology analysis of 2-fold dysregulated transcripts (Supporting 
Table 1) indicated that loss of KAP1 impacted on genes encoding protein endowed with 
oxidoreductase activity involved in xenobiotic metabolism by cytochrome P450 (Cyp450) as 
well as the pathways of retinol, drug and arachidonic acid metabolism (Fig. 3B). Additionally, 
GO terms and Kegg pathway analyses singled out genes relevant for steroid hormone 
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biosynthesis and metabolism, peptidase inhibitor activity and PPAR signaling in male KO 
mice, contrasting with genes linked to pheromone binding in their female counterparts. 
About 50% of genes with the highest fold-change differed between male and female mice. 
For example, the most highly upregulated genes in males belong to phenobarbital-inducible 
Cyp2b family, while in females those include Spink3, Krt23 and Cyp2d9 (Fig. 3C). We verified 
that the transcriptional changes noted upon Kap1 deletion were not due to the mixed 
genetic background of the mice nor to Cre expression (Supporting Fig. 2). 
KAP1 controls expression of Rsl-target genes. Female-restricted changes in Cyp2d9, sex-
limited protein (Slp) and major urinary proteins (Mup), are hallmarks of the Rsl loss-of-
function phenotype
5
. While we could document both Cyp2d9 and Slp derepression in female 
Kap1 KO livers (Fig. 3D), Slp appeared affected to a far lower extent than reported in rsl-
deleted female mice, although a direct comparison is difficult owing to differences in the 
mouse strains used in the two studies. Furthermore, we observed a downregulation, rather 
than an upregulation of Mups in Kap1 mutant mice at both RNA and protein level (Fig. 3D 
and Supporting Fig. 3), suggesting that either Rsl2-mediated female-specific repression
5
 is 
not mediated by KAP1 or that Mups are indirect KAP1 or Rsl targets. 
KAP1 binding sites and KAP1-related chromatin modifications in the mouse liver. To 
understand better the molecular mechanisms of KAP1-mediated gene expression control in 
the liver, we performed chromatin immunoprecipitation (ChIP) followed by deep sequencing 
on male and female wild type and KAP1-depleted nuclei, using an antibody directed against 
the RBCC domain of KAP1
8
. False-positive peaks originating from non-hepatocytic cells 
present in the samples were minimized by following a protocol optimized for hepatocyte-
centered ChIP experiments
16
, and data obtained in Kap1-deleted hepatocytes served as a 
control sample for peak calling. We identified 7158 and 5223 KAP1 peaks in male and female 
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livers, respectively (Fig. 4A), a number comparable to that extrapolated from genome-wide 
KAP1 binding studies previously performed in other tissues
22
. Surprisingly few of the 
identified peaks (~10%) were common to males and females (Fig. 4A), consistent with the 
observed sex-specific gene dysregulations induced by the Kap1 knockout (Fig. 2). KAP1 peaks 
were significantly enriched in vicinity of transcriptional start sites (TSS; Fig. 4B).  
We then searched the nearest peak for each of the genes dysregulated at least 1.5-
fold upon KAP1 removal (Supporting Table 1). We observed that relatively few of them had a 
KAP1-binding site in the gene body (less than 20%; not shown), however the average 
distance between both upregulated and downregulated genes and the nearest KAP1 peak 
was significantly shorter than for all protein-coding genes present on our Illumina chip (Fig. 
4C). Furthermore, these peaks were usually found just upstream of the TSS of deregulated 
genes (Fig. 4D). This suggests that KAP1 might directly control many of the genes perturbed 
in its absence, but that it may not always be through repression.   
Surprisingly, for several genes expressed and deregulated in a sex-discriminating 
fashion, KAP1-binding was found in both males and females (Fig. 3 and 5). These included 
peaks in the promoter of the male-predominant Cyp2d9 and Slp genes, both strongly 
upregulated in Kap1 KO females; and in the glutathione S-transferase π (Gstπ) cluster, a late-
phase drug-responsive gene preferentially expressed in males, with strong downregulation 
upon KAP1 removal. Of note, the Gstπ cluster bears a male-specific KAP1 binding site 
downstream of the locus that could explain sex-biased dysregulation. Moreover we 
identified putative KAP1-binding sites in an intron of the gene encoding fat specific protein 
27 (FSP27), which plays a role in lipid droplet formation
23
 and was strongly upregulated in 
male KO livers and in the gene encoding for the cellular homologue of the viral Casitas B-
lineage lymphoma proto-oncogene (c-Cbl), a regulator of various tyrosine kinase signaling 
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pathways
24
 upregulated in KO livers of both sexes (Fig. 3E, 5 and 6A). We also identified 
KAP1 binding sites in a cluster of phenobarbital-responsive, female predominant Cyp2b 
genes that were upregulated in males and downregulated in females upon loss of KAP1 and 
in clusters of other xenobiotics-processing Cyp450 genes, such as Cyp2a and Cyp3a (Fig. 3E, 
5, 6A and Supporting Fig. 4).  
KAP1 recruits the SETDB1 histone methyltransferase, which induces deposition of the 
H3K9me3 repressive mark, and HDAC-containing complexes, which result in histone 
deacetylation
17
. We thus compared the presence of the relevant chromatin marks in wild 
type and Kap1 knockout liver at both nearest KAP-binding site and promoter of a few genes 
suspected to represent direct KAP1 targets. Loss of KAP1 correlated with a loss of H3K9me3 
at the binding site for genes upregulated in Kap1-mutant livers, such as Cyp2d9 in females 
and fsp27, c-Cbl or the Cyp2b cluster in males. However, for male-downregulated Gstπ, 
Cyp2d9 or Slp no change in H3K9me3 at the KAP1-binding site was detected. Notably, gain of 
H3K9me3 at the male KAP1-binding site in the fsp27 locus in female liver suggests local 
chromatin changes that could be the cause of mild female-upregulation of the 
corresponding transcript. Finally, increase in H3Ac at the promoters of Cyp2d9 in females 
and Fsp27 in males coincided with gene dysregulation, however this was not the case for all 
tested KAP1-target loci (Fig. 6B-C). 
 
Discussion 
The present work reveals the prominent role of KRAB/KAP1-mediated regulation in the 
control of liver metabolism and endo/xenobiotics-detoxifying genes. The liver-targeted 
knockout of KAP1, the universal cofactor of KRAB-ZFPs, resulted in a markedly sexually 
dimorphic phenotype in mice, which included male-predominant steatosis and hepatic 
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tumors. This correlated with sex-specific transcriptional dysregulation of a wide range of 
metabolic genes, notably those involved in retinol and sex hormone processing as well as in 
detoxification. An examination of KAP1 genomic binding sites in the liver and of chromatin 
marks at the promoters of some of these genes further revealed that a number of 
detoxifying genes such as Cyp2d9, Gstπ, and the Cyp2a, Cyp2b and Cyp3a gene clusters are 
direct KAP1 targets. Moreover, loss of KAP1 binding at the fsp27 locus was associated with 
the male-predominant upregulation of its product.  
Male liver-specific Kap1 knockout mice displayed early onset hepatosteatosis and 
age-related development of liver adenomas, while their female counterparts exhibited 
milder metabolic disturbances revealed only by a high fat diet challenge and had lower 
incidences of liver adenomas than their male counterparts. This correlates with the reported 
resistance of the female liver to environmental insults, which has been attributed to its 
greater ability to inactivate toxins and neutralize reactive oxygen species, and to the 
protective action of estrogens against inflammation and steatofibrosis, including during the 
course of chronic viral hepatitis
19, 25
. Our results suggest that these mechanisms are 
influenced by KRAB/KAP1-mediated transcriptional control.  
What specific mechanisms account for the accumulation of fat and tumor 
development in the Kap1-deleted male liver remains to be determined. We observed a 
male-predominant, Kap1 deletion-induced upregulation of the fat-specific protein 27 
(FSP27), correlating with a male-restricted strong KAP1 binding site in the body of this gene. 
FSP27 promotes fat droplet formation in adipocytes and its hepatocytic overexpression 
results in hepatosteatosis
23, 26
. This phenotypic abnormality, which represents an early sign 
of hepatocyte suffering common to many pathological circumstances, has been linked to 
increased liver damage, inflammation and development of hepatocellular carcinoma in other 
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mouse models
3
. Interestingly, KAP1 KO mice displayed an upregulation of liver levels of pro-
inflammatory cytokines IL6 and TNFα, which is a sign of response to hepatocyte damage. 
Aberrant activity of signaling pathways downstream of these cytokines have been linked to 
increased fat accumulation in hepatocytes and development of liver tumors and our results 
suggest a role of the MAPK and AKT pathways in the increased incidence of tumors in Kap1 
KO animals
3
. The early development of hepatosteatosis due to de-repression of fsp27 in 
KAP1 KO males may be one important trigger in a cascade of events leading to development 
of liver steatosis and tumors in these mice.  
Indirectly, our analyses suggest that xenobiotic stress, which if prolonged can lead to 
tumorigenesis
27
, might contribute to the observed phenotype. In Kap1-deleted livers, we 
measured a dysregulation of drug and xenobiotic metabolizing phase I genes such as 
members of the Cyp2a, Cyp2b and Cyp3a families, of phase II and III genes such as Gstπ and 
θ, and of genes coding for various UDP-glucuronosyltransferases required for conjugation of 
molecules that need this modification for efficient excretion
2
. We identified KAP1-binding 
sites in the vicinity of several of these genes, suggesting that they are direct targets of the 
transcriptional regulator.  
The combined results of our transcriptome and chromatin analyses exclude a simple 
model for KAP1 action, whereby a given KRAB-ZFP would tether the cofactor to specific 
sequences, with secondary heterochromatin formation and gene silencing. Some sexually 
dimorphic genes, such as the male-predominant Cyp2d9, Gstπ and Slp, carry KAP1 signatures 
inconsistent with such a model. For instance, the Cyp2d9 and Slp genes are Rsl1-targeted, 
male-predominant genes upregulated upon Kap1 KO only in female mice. However, KAP1 
was detected at similar sites, such as the promoter of Cyp2d9, in liver chromatin from both 
sexes. As well, KAP1 binds upstream of the Gstπ locus in both male and female, whereas this 
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gene is highly expressed in the former and strongly repressed in the latter. These 
observations might reflect the effect of sex-specific dominant factors counteracting the 
repressing influence of KAP1, or sex-differential post-translational modifications of the 
transcription regulator. KAP1 SUMOylation appears to be required for its co-repressor 
activity, while phosphorylation stimulates its chromatin-opening properties
8
. In the case of 
Cyp2d9, it could be that phospho-KAP1 keeps the promoter accessible for transcription 
factors in males, whereas SUMO-KAP1 recruits SETDB1 and heterochromatin protein 1 to 
close it down in females.  
It is generally acknowledged that KAP1 exerts its gene repressor activity via an 
interaction with DNA-binding KRAB-ZFP family members. It will be important to identify the 
mediators of its activity in the liver; however it remains that our data strongly suggest that 
KAP1 sometimes acts as a transcriptional activator rather than as a repressor. Future studies 
should explore this possibility, which challenges the current view of KAP1 function. 
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Figure Legends 
Figure 1. Phenotypic analyses of Kap1 KO mice. 
A. Body weight of male (n=9-12; top) and female (n=10; bottom) mice fed indicated diets. *: 
p<0.05 as assessed by two-way ANOVA followed by Bonferroni post-test. CD - chow diet, 
HFD - high fat diet. B. HE staining of liver sample from chow diet-fed 29-week-old indicated 
mice. Inlet: ORO staining. Scale bar: 50 µm. C. Semi-quantitate ORO staining score of male 
(top) and female (bottom) mice fed indicated diets ***: p<0.001 as assessed by two-way 
ANOVA followed by Bonferroni post-test. D. & E. Plasma levels of alanine transaminase (ALT) 
and lactate dehydrogenase (LDH) (n=7-9; D.) and liver protein levels of pro-inflammatory 
cytokines IL6 and TNFα (n=5; E.) in 29-week-old female (left) and male (right) mice. Black 
bars: CD, grey bars: HFD. *: p<0.05 as assessed by two-way ANOVA followed by Bonferroni 
post-test. Error bars represent S.E.M. 
 
Figure 2. Liver tumorigenesis in KAP1 KO mice.  
A. Left, liver adenoma with a well demarcated nodular proliferation and a clear expansile 
growth; right, hepatocellular carcinoma with poorly demarcated irregular borders suggestive 
of infiltrative growth (black solid line), increased anisocytosis and anisokaryosis within the 
tumor, when compared to the adjacent normal hepatocytes (right) in male mouse fed HFD 
for 19 weeks. Scale bar in A: 2 mm. Scale bar in B: 100 µm. B. Macroscopic view of rostral 
(left) and caudal (right) face of livers from indicated CD-fed, 58-week-old male mice. C. Gross 
necropsy analysis of tumor occurrence in livers of mice at age 53-70 weeks. *: p<0.024 by 
Fisher’s exact test. D. Western blot of indicated proteins in Kap1 KO tumor tissue and normal 
liver from WT and Kap1 KO mice (left) with quantification of band intensity normalized to 
actin and represented as fold-change over average WT liver (right). *** - p<0.001 by one-
Page 20 of 164
Hepatology
Hepatology
HEP-11-2341   Bojkowska et al 
way ANOVA E. Phosphorylation status and total protein content of AKT and various MAPK in 
indicated samples determined by ELISA and represented as fold-change over average WT 
liver. *** - p<0.001 by one-way ANOVA F. Hepatocyte proliferation in livers of 35- and 68-
week-old female (n=3-5; left) and male (n=4-5; right) mice. Data represent mean number of 
BrdU-positive nuclei per field of view. Error bars in D., E. and F. represent S.E.M. 
 
Figure 3. Hepato-specific KAP1 deletion leads to sex-specific gene dysregulation. 
A. Venn diagram of genes ≥ 2-fold deregulated in 10-week-old female and male KO vs WT 
mice. Less than 50% of deregulated genes are shared between sexes. B. Functional 
annotation chart of significantly deregulated (fold change ≥ 2) in Kap1-mutant livers. C. Top 
10 up- and down-regulated genes in male (left) and female (right) livers. D. Expression of Rsl-
regulated sexually dimorphic genes in Kap1 KO and WT male and female livers (n≥5). Error 
bars represent SEM. E. Dysregulation of mRNA levels of selected direct KAP1-target genes; 
n=3-4.  Error bars represent SEM. 
 
Figure 4. KAP1 binding sites in mouse liver.  
A. Number of KAP1 peaks on genome from male and female hepatocytes. B. Distribution of 
KAP1 putative binding sites relative to all annotated transcriptional start sites (TSS). For 
distance of -200, 0 and 200 bp relative to TSS KAP1 is significantly enriched (P<0.05) as 
assessed by the Wilcoxon sum rank test. C. KAP1-responsive genes are closer to the nearest 
KAP1 peak than random genes. Distance to the nearest peak was calculated for all KAP1 up- 
or down-regulated genes and compared to the average distance for all genes probed by the 
Illumina chip. D. Frequency of KAP1 peaks in different intervals from the TSS for genes 
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downregulated (left) or upregulated (right) in Kap1 mutant livers. Frequency is defined at 
the % of peaks normalized for the interval size.  
 
Figure 5. Selected KAP1 putative binding sites in mouse liver. 
Screen-shots from the UCSC Genome Browser illustrating the KAP1 ChIP-seq data from 
female and male Kap1 KO (n=1) and WT (n=2) hepatocytes for indicated loci. Direction of 
transcription is indicated by arrow. Regions targeted by primers used for the validation by 
qPCR are shown.  
 
Figure 6. Chromatin studies on KAP1-regulated genes.   
A. qPCR validation of KAP1 binding in female and male livers (n=4). Data are represented as 
an enrichment of wild type over KO sample relative to an average of KAP1 unbound control 
loci (Foxp3, RPS9 and β-actin) at sites depicted in A. Error bar is S.E.M. B. & C. H3K9me3 (B.) 
and H3 acetylation (C.) ChIP-qPCR in female and male nuclei (n=3) of wild type and KAP1-
depleted liver. Data are represented as an enrichment of wild type over KO sample relative 
to an average of three control loci (GAPDH, RPS9 and β-actin). Error bar is S.E.M.  
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Table 1. Plasma markers of lipid metabolism and liver function in 29-week-old mice.  
Parameter 









CD (n =10) 
Male WT CD 
(n=7) 




Body weight (g) 31.4 ± 1.4 30.0 ± 1.4 46.2 ± 2.2 41.0 ± 2.6 38.0 ± 1.4 35.9 ± 1.5 51.5 ± 2.2 52.4 ± 1.2 
Body fat (%) 27.6 ± 3.0 26.1 ± 1.8 48.2 ± 1.4 41.6 ± 2.2 23.0 ± 1.6 23.3 ± 3.0 39.4 ± 0.6 38.6 ± 1.1 
Liver (% BW) 4.1 ± 0.2 3.8 ± 0.2 4.0 ± 0.3٭٭ 3.0 ± 0.2 4.8 ± 0.2 4.0 ± 0.2 6.3 ± 0.4٭ 5.3 ± 0.3 
PG-WAT (% BW) 6.3 ± 0.9 6.4 ± 0.6 10.9 ± 0.3 10.3 ± 0.6 4.7 ± 0.2 4.4 ± 0.4 4.5 ± 0.3 3.8 ± 0.2 
Ovaries/Testes (% BW) 0.33 ± 0.03 0.34 ± 0.03 0.23 ± 0.02 0.25 ± 0.04 0.91 ± 0.03 0.93 ± 0.03 0.62 ± 0.02٭ 0.72 ± 0.04 
Testosterone (ng/ml) ND ND ND ND 3.8 ± 1.4 2.2 ± 0.5 1.3 ± 0.6 4.5 ± 2.4 
Cholesterol (mM) 4.8 ± 0.4 4.5 ± 0.3 6.0 ± 0.6٭ 4.1 ± 0.5 5.7 ± 0.2 4.5 ± 0.3 8.2 ± 0.4 7.9 ± 0.4 
HDL Cholesterol (mM) 1.34 ± 0.25٭ 1.67 ± 0.17 2.11 ± 0.10 1.98 ± 0. 17 2.19 ± 0.09 2.33 ± 0.11 2.11 ± 0.10 2.95 ± 0.08 
LDL Cholesterol (mM) 1.25 ± 0.55٭ 0.86 ± 0.33 0.73 ± 0.18 0.38 ± 0.06 0.44 ± 0.04 0.24 ± 0.03 1.10 ± 0.09٭٭ 0.83 ± 0.06 
Triglycerides (mM) 1.46 ± 0.13٭٭ 1.20 ± 0.09 1.15 ± 0.05٭ 0.86 ± 0.03 1.56 ± 0.15 1.38 ± 0.16 1.10 ± 0.08 0.92 ± 0.09 
Tot. Protein (g/l) 63.4 ± 1.2 63.1 ± 0.7 68.2 ± 1.4٭ 63.5 ± 1.8 63.9 ± 0.7 63.1 ± 1.3 68.6 ± 1.4 67.5 ± 0.7 
Free Fatty Acids (mM) 1.60 ± 0.40 1.70 ± 0.21 1.66 ± 0.14 1.28 ± 0.09 1.06 ± 0.11٭ 1.75 ± 0.40 1.50 ± 0.14 1.77 ± 0.13 
AST (U/l) 252 ± 79 173 ± 50 342 ± 82٭٭ 123 ± 18 118 ± 19 173 ± 67 373 ± 58 239 ± 72 
γGT (U/l) 10.3 ± 2.1٭٭٭ 6.4 ± 1.4 3.7 ± 0.4 4.6 ± 0.5 7.3 ± 0.6 6.3 ± 0.6 6.4 ± 0.5 4.9 ± 0.6 
IL-1β (ng/ml/mg protein) 
4355 ± 106٭ 3881 ± 91 4380 ± 140 4257 ± 180 4234 ± 195 3614 ± 164 4021 ± 241 4485 ± 184 
ALP (U/l) 79.8 ± 5.8 86.8 ± 4.3 104.3 ± 20.0٭ 66.8 ± 5.8 72.5 ± 3.8 67.1 ± 4.8 114.5 ± 14.7٭ 82.1 ± 5.1 
Tot. Bilirubin (µM/l) 2.7 ± 0.6 2.2 ± 0.4 2.7 ± 0.5 1.5 ± 0.3 1.6 ± 0.2 2.1 ± 0.5 2.4 ± 0.4 1.3 ± 0.1 
Glucose (mM) 15.8 ± 0.8 16.1 ± 0.9 17.0 ± 1.4 16.4 ± 1.3 17.5 ± 1.1 18.7 ± 1.2 17.9 ± 0.7 19.1 ± 1.0 
Wild-type mice (WT) and animals bearing liver-specific KAP1 KO were fed chow diet (CD) or high fat diet (HFD) for 19 weeks and 
fasted for 4 hours prior to experiment.  
 - p<0.05; ٭٭ - p<0.01; ٭٭٭ - p<0.001 as compared to control KAP1 WT of the same sex and diet by two-way ANOVA followed by 
Bonferroni post-test 
ND – not determined; WAT – white adipose tissue; HDL – high density lipoprotein; LDL – low density lipoprotein; AST – aspartate 
transaminase; ALT – alanine transaminase; LDH – lactate dehydrogenase; γGT – gamma glutamyl transpeptidase; ALP – alkaline 
phosphatase 
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Body weight 40.1 ± 2.5 46.2 ± 2.7 43.9 ± 2.7 45.9 ±2.8 
Liver weight (% BW) 5.1 ± 0.3٭ 3.8 ± 0.1 6.5 ± 0.7٭ 4.5 ± 0.3 
Age (weeks) 60.3 ± 3.9 59.3 ± 1.6 63.5 ± 1.6 62.1 ± 2.0 
Liver IL1β (ng/ml/mg protein) 1611 ± 95 1606 ± 63 1962 ± 32٭ 1674 ± 78 
Liver  IL6 (ng/ml/mg protein) 1178 ± 79 1258 ± 51 1504 ± 87٭ 1255 ± 47 
Liver TNFα (ng/ml/mg protein) 2085 ±161 2123 ± 156 2682 ±128٭ 2360 ±145 
Wild-type mice (WT) and animals bearing liver-specific KAP1 KO were fed chow diet (CD) and fasted for 4 hours prior to experiment.  
 - significantly different (p<0.05) as compared to control KAP1 WT of the same sex by Student’s t test.  
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Supporting text 
We verified that the transcriptional deregulation observed in Kap1 KO mice was due neither 
to the presence of Cre itself nor to the genetic background of the mice, we bred the original 




 with Alb.Cre mice in a pure C57/Bl6 background
4
and 
validated the deregulation of several genes by RT-qPCR on 8-10-week-old livers. The KAP1 
deletion-associated transcriptional changes were confirmed irrespective of genetic 
background and Cre expression (Supporting Fig. 2).  
 
Detailed description of pathology analysis 
Hepatic adenomas were characterized by well demarcated, unencapsulated, nodular 
proliferations causing distinct compression of the surrounding hepatic parenchyma. 
Neoplastic plates had regular cords, one to two cells thick, frequently impinging at a right or 
oblique angle at the adjacent normal hepatic parenchyma. Portal areas were not seen. 
Neoplastic hepatocytes were well differentiated with minimal anisocytosis, regular nuclei 
having mild anisokaryosis that resembled normal hepatocytes. Tinctorial affinity of the 
cytoplasm was variable among the different nodules with cases having vacuolar changes 
throughout the neoplasm. 
 
Features of solid carcinoma observed in one of Kap1 KO males fed HFD included: disruption 
of lobular architecture by solid plates of hepatocyte-like cells with peripheral infiltrative to 
slightly compressive growth (Fig 2A), increased cellular polymorphism characterized by 
marked anisocytosis and anisokaryosis with larger cells having large hyperchromatic nuclei, 
occasionally oval shaped, alternated to smaller or larger cells than surrounding normal 
hepatocytes with hyperchromatic nuclei, evident mitotic activity, cytoplasmic and nuclear 
vacuolation.    
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 mice were generated in a mix C57/Bl6-129sv background or C57/Bl6 as 
specified by crossing of previously described mouse strains
1, 2
. Mice were housed at 22°C–
24°C with a 12 hr light/12 hr dark cycle (lights on at 0700 hrs) with standard mouse chow 
(Harlan Teklad diet 2919, 3.6 kcal/g digestible energy and 3.4 kcal/g metabolizable energy, 
23% kcal from fat) or high fat diet (Taconic Research Diets, D12492; 5.24 kcal/g, 60% kcal 
from fat) as indicated and water provided ad libitum. All animal experiments were approved 
by the local veterinary office and carried out in accordance with the European Community 
Council Directive (86/609/EEC) for care and use of laboratory animals. 
 
Phenotyping protocol 
Cohorts of at least 8 male and female mice with indicated genotypes were generated and 
body-weight was measured starting at weaning, twice a week for groups sacrificed at 10 
weeks and once a week for those sacrificed at 6 months. For food intake measurements, 
mice were placed in individual cages for a period of 5 says and food intake was measured 
twice for 10-week-old mice.   
For sacrifice, after 4h period of fasting (staring at 0700 hrs), mice were anaesthetized by CO2 
inhalation and blood was collected into a heparinized tube by cardiac puncture, spun for 10 
min at 4°C at 5000 rmp to isolate plasma, which was stored at -80°C until processing. Various 
organs were harvested, weighed and stored at -80°C, including: liver (a piece embedded in 
OCT, fixed in 4% paraformaldehyde, submerged in RNAlater (Ambion) or snap-frozen and 
stored at -80°C), gallbladder, kidney, adipose tissue (subcutaneous, perirenal, epididymal), 
intestines (duodendum, ileum, jejunum, colon), heart, skeletal muscles (gastrocnemius and 
soleus), brain, spleen, adrenal gland, reproductive organs and spleen.  
Determination of energy expenditure, physical activity, food and water intake in the high fat 
diet challenged groups was performed in the Comprehensive Lab Animal Monitoring System 
(CLAMS) with the set-up of 16 cages (Columbus Instruments, Columbus, OH, USA). Mice at 
age of 24-25 weeks were placed in individual cages for a 22h period of habituation staring at 
1300 hrs (room temperature 22 ± 1°C), followed by a measurement period of 22 hrs: 1 entire 
dark cycle (12 hrs) at room temperature (15°C±1°C). Parameters measured during CLAMS 
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include: i) oxygen consumption (VO2 in mL/Kg/h): VO2 is directly correlated to energy 
expenditure. Oxygen consumption is measured every 40 min thanks to a zirconia oxide 
based oxygen sensor; ii) carbon dioxide production (VCO2 in mL/Kg/h). CO2 production is 
measured every 40 min thanks to a single beam non dispersed infra-red beam based sensor; 
iii) Respiratory Exchange Ratio (RER): VCO2 / VO2: RER is an indicator of the use of energy 
substrate. In a steady state, RER is equivalent to the Respiratory Quotient (RQ). Pure 
carbohydrate use gives RER=1, whereas pure fat burning yields an RER=0.7. A mixed diet 
gives a RER=0.85; iv) ambulatory activity is measured thanks to infra-red beams surrounding 
the cages on the X and Z axis. Every 40 min, the system compiles the data corresponding to 
the number of breaks of the infra-red beams by the animal inside the cage; v) water intake 
and food intake are measured thanks to high precision scales. Body composition was 
measured via EchoMRI 3-in-1 (Echo Medical Systems, Houston, TX, USA) according to 
manufacturers’ instructions. Body weight was simultaneously recorded to allow 
normalization for total body weight.  
Levels of metabolic parameters in the plasma, such as Alanine transaminase (ALAT), 
Aspartate transaminase (ASAT), lactate dehydrogenase (LDH), D-glucose, creatinine, free-
fatty-acids, total cholesterol, high density lipoprotein (HDL) and low density lipoprotein 
cholesterol (LDL) cholesterol, triglycerides, total protein, albumin, gamma-
glutamyltransferase (γGT) and bilirubin were determined with the Dimension Xpand 
automat, (Siemens Healthcare Diagnostics,  Deerfield, IL, USA) according to manufacturer’s 
instructions. Liver levels of cytokines were determined as previously described
3
. Total 
testosterone was measured with the Testosterone ELISA kit (Fitzgerald Industries 
International, cat. Number 55R-RE52151) according to manufacturer’s instructions. 
 
Histological tissue processing and analysis 
For hematoxylin and erythroeosine (HE) staining and KAP1 immunohistochemistry (IHC), 
liver tissue was fixed overnight in 4% PFA in PBS and, upon dehydratation, embedded in 
paraffin before being cut into 4 µm sections on a microtome. For HE staining, liver sections 
were de-waxed and hydrated to water before being placed in Harris hematoxylin for 5 min, 
washed and differentiated in 1% acid-alcohol followed by cytoplasm staining with 0.25% 
erythrosine, dehydration, clearing and mounting. KAP1 immunohistochemistry on paraffin-
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embedded liver sections was performed with the polyclonal anti-TRIM28 antibody 
(Proteintech, UK). 
For Oil Red O staining fresh liver tissue was directly embedded in OCT (Medite), frozen on 
dry ice and 10 µm sections were cut on a cryostat. Sections were fixed in 4% PFA incubated 
in 50% Ethanol for 3 min then in Oil Red O (Sigma) for 15 min for fat staining, washed in 50% 
Ethanol for 1 min and Distilled water for 2 min and nuclear staining was performed in 
Mayer’s Hematoxyline (Medite) for 2 min. Slides were then washed in tap water for 5 min 
before mounting with aqueous mounting media (Aquamount).   
Histopathology evaluation of histology sections was performed in a blind fashion by a board 
certified pathologist (F.A.). Degree of vacuolar change was considered as mild, moderate or 
marked according to extent of the affected hepatocytes and degree of cytoplasmic 
vacuolation in the single hepatocytes. Semiquantitative measurement of fat accumulation 
within hepatocytes was performed on ORO stained liver sections and arbitrative values of 1 
(mild), 2 (moderate) and 3 (marked) were assigned according to the intensity of stained 




Small scale DNA, RNA and protein analysis 
For genotyping, DNA from an ear punch was extracted with the TissueDirectTM Multiplex kit 
(Genscript) and subjected to a PCR reaction with HotMasterMix mix (Vwr) and primers for 
KAP1 previously described in
1
 or cre and x-globin primers (Supporting Table 2). RNA was 
extracted with the RNeasy kit (Qiagen), treated with Dnase (Turbo Dna-free kit, Ambion), 
reverse transcribed with the Superscript II RT (Qiagen) and the qPCR was performed on 
7900HT Fast Real-Time PCR (Applied Biosystem) using SybrGreen Master Mix (Roche). 
Primer specificity was confirmed by dissociation curve analysis. β-actin and RPS9 were used 
for normalization. Primers used in this work are listed in the Supporting Table 2
5-7
. For 
protein analysis total liver, or hepatocyte nuclei isolated with the buffer containing 10mM 
Tris, 10mM NaCl, 0.2% NP-40, protease inhibitors (PIC; Roche) and 1 mM PMSF (Sigma), 
were lysed in RIPA buffer containing PIC and PMSF by sonication or glass-glass potter 
homogenization and, upon BCA quantification (Pierce), equal amounts of protein were 
loaded on 4-12% B-T NuPage gels (Invitrogen). After the transfer on a nitrocellulose 
membrane, proteins were stained with primary monoclonal rabbit anti-KAP1 (anti-TRIM28; 
Proteintech labs, UK), mouse anti-ERK1/2 MAPK (Zymed Laboratories), rabbit anti-p38 MAPK 
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(Cell Signaling), goat anti-PTEN (Santa Cruz), mouse anti-pan-actin (Sigma) antibodies as 
loading controls, followed by HRP-conjugated anti-mouse or anti-rabbit Ig secondary 
antibodies. HA-tag Western blot was performed with the anti-HA-HRP conjugated antibody 
and revealed with the SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific). Phospho-protein ELISA was performed with PathScan Signaling Nodes Multi-
Target Sandwich ELISA Kit or PathScan MAP Kinase Multi-Target Sandwich ELISA Kit 
according to manufacturer’s instructions using 50 µg of liver protein extract (Cell Signaling). 
 
MicroArray analysis 
8-10-week-old mice were food-deprived at 0700 hrs and liver was isolated at 1100-1400 hrs. 
Total RNA was extracted with the MirVana kit (Ambion) and treated with DNAse (Turbo DNA 
free kit, Ambion), following manufacturer instructions. After quality control for RNA integrity 
by capillary electrophoresis on Agilent 2100 Bioanalyzer, three RNA pools from 9 mutant and 
wild type male livers were prepared, while three individual female KO and wild type livers 
were used separately. 100 ng of RNA was amplified and labeled using the Illumina TotalPrep 
RNA Amplification kit (Ambion). cRNA quality was assessed by capillary electrophoresis on 
Agilent 2100 Bioanalyzer. Hybridization on Mouse WG 6 v2 expression arrays (Illumina) was 
carried out according to the manufacturer’s instructions. Data were normalized and 
analyzed using Illumina Beadstudio 3.1.3 (background correction and quantile 
normalization). Expression profiles of each sample were imported into GeneSpringGX 7.3.1 
(Agilent Technologies, USA). In addition to expression values, Illumina BeadStudio software 
computes a detection p-value. Based on this, each probe was assigned a detection flag (P 
(present): p < 0.045; M (Marginal): p between 0.050 and 0.045, A (Absent): p>0.05). 
Expression values below a defined threshold (i.e. 20) are set to the threshold in order to 
remove negative values after background correction. To identify deregulated genes in KO 
mice (i.e. differentially expressed transcripts between KO and control samples), t-test and/or 
ANOVA and additional steps of filtering were carried out. Significantly deregulated genes (p 
value <0.05 by unpaired t-test and fold-change ≥ 2) were used to interrogate DAVID 
bioinformatic database 
8
, where analysis was performed by using medium default 
stringency.  
 
ChIP-sequencing and ChIP-PCR 
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Liver ChIP was performed as previously described with minor modifications 
9
. Livers from 8-
10-week-old mice were dounce homogenized in 6 ml per liver of 1x PBS including 1% 
formaldehyde for 10 min at room temperature. Cross-linking was stopped by the addition of 
24 ml of ice-cold 2.2 M sucrose in 150 mM glycine, 10 mM HEPES pH 7.6, 15 mM KCl, 2 mM 
EDTA, 0.15 mM spermine, 0.5 mM spermidine, 0.5 mM DTT and 0.5 mM PMSF. The 
homogenate was layered on top of a 7 ml cushion of 2.05 M sucrose (containing the same 
ingredients and including 10% glycerol and 125 mM glycine) and centrifuged for 60 min at 
24,000 rpm at 4 °C in a Beckmann SW28 rotor. The nuclei were resuspended in 1 ml of 20 
mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, and spun at 5000 rpm for 30 sek prior to 
storage at -80C. For sonication, they were counted and 2 x10
7
 nuclei were resuspended in 
300 µl per liver of the same buffer supplemented with 1% SDS. Nuclei were sonicated for 20 
s on ice ten times. The fragmented cross-linked chromatin was then diluted tenfold in the 
ChIP buffer 
10
. Chromatin was immunoprecipitated with an affinity-purified rabbit polyclonal 
antibody raised against KAP1 amino acids 20–418 (RBCC) kindly provided by Dr. Rauscher 
11
. 
Detailed protocol for Chromatin immunoprecipitation is described elsewhere 
10
. After de-
crosslinking of both IP and total input, DNA was quantified with the Qubit fluorometer 
(Invitrogen) and 10 ng were used to prepare libraries for sequencing, following the ChIP Seq 
library preparation protocol (including End Repair for blunted end fragments, addition of “A” 
base to the 3’ end and ligation of adapters to DNA fragments (kit IP-102-1001). Ligation 
products were then purified on 2% E Gels Size Select (Invitrogen, fragments of 200 bp 
recovered), followed by enrichment of DNA fragments by PCR (18 cycles). No more than two 
libraries were loaded per gel to avoid cross contamination. Libraries were purified on AMP 
XP beads (Agencourt), quantified with Qubit fluorometer and size distribution determined 
on the Agilent Bioanalyzer (High Sensitivity DNA chip). Sequencing was performed on an 
Illumina Genome Analyzer IIx with each library sequenced in a 38 bases single read run.  
Reads with less than five matches were aligned to the Mus musculus genome (assembly 
NCBI37/mm9) using bowtie
12
. Peak calling was performed with the model-based analysis of 
ChIP-seq algorithm
13
 for wild type samples, using as a background the KO control. The male 
and female peak lists were intersected and any two peaks distant by <1kb were called 
overlapping. Distribution of KAP1 peaks around TSS was done with Chip-Cor tool 
(http://ccg.vital-it.ch/chipseq/chip_cor.html) using M. musculus ENSEMBL59 TSS collection 
as the input feature. For intersection with transcriptome analysis, Illumina probes were 
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mapped to their corresponding ENSEMBL genes and overlapping peaks annotated with the 
bioconductor package ChIPpeakAnno (PMID: 20459804) were identified.  Comparison 
between the distance of deregulated genes and all the UCSC annotated genes (used as 
control) was done using a Wilcoxon rank sum test. Frequency of KAP1 peaks was calculated 
as a percentage of peaks found in a given region divided by the region length in kb. 
Correction for multiple testing issues was done using the Benjamini-Hochberg procedure
14
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SUPPLEMENTAL FIGURE LEGENDS  
Supporting Fig. 1. KAP1 deletion in Alb.Cre Kap1
fl/fl
 mice is specific to hepatocytes and 
causes male-specific hepatosteatosis at age of 10 weeks.  
A. Top: KAP1 recombination PCR in various organs of Alb.Cre Kap1
fl/fl
 mice. Upper band 
corresponds to the PCR product from the deleted locus upon Cre-mediated recombination, 
while the lower band to the unrecombined Kap1
fl
 locus. Bottom: Cre-specific PCR (upper 
band). X-globin was used as an internal control in Cre-specific PCR reactions (lower band). B. 




 livers of female (left) and 





 livers of male (left) and female (right) mice. Blotting against β-actin was 
done for loading control. D. Liver KAP1 immunohistochemistry in an Alb.Cre Kap1
fl/fl
 male 
(left) and a KapP1
fl/fl
 littermate (right). Positive staining in the interstitial cells in the Alb.Cre 
Kap1
fl/fl
 liver indicates that KAP1 KO is specific to hepatocytes. Scale bar is 100 µm. E. HE 
staining of liver sample from chow diet-fed 10-week-old indicated mice. Inlet: ORO staining. 
Arrows indicate intrahepatic lipid droplets. 
Supporting Table 1. List of genes dysregulated in KAP1-mutant mice.  
Supporting Table 2. List of primers used in the current study.   
Supporting Fig. 2. Phenotype of mice with liver-specific KAP1 deletion is background 
independent. A. Gross necropsy analysis of C57/Bl6 Kap1-KO mice at age of 53-70 weeks. 
Top: characteristics of mice used in the study, **: p<0.01 as assessed by Students t-test. Data 
are represented as mean ± S.E.M. Bottom: Quantification of tumor occurrence in C57/Bl6 
Kap1-KO mice. B. Histopathological analysis of tumor occurrence in C57/Bl6 Kap1-KO mice at 
age of 53-70 weeks. Indicated p-value was obtained by Fisher’s exact test.  C. and D. 
Correlation between gene deregulation in Kap1 KO vs wild-type mice generated in mixed 




 is plotted against 
the Log2 ratio of C57/Bl6 Alb.Cre Kap1
fl/fl
 vs Alb.Cre Kap1
wt/wt
 for males (C) and females (D). 
A. Comparisons between male KAP1-responsive genes and STAT5b, STAT5a and Rsl-
regulated. B. Similar comparisons as in A but with female gene expression data.    
Supporting Fig. 3. KAP1 binding at chosen loci in male and female hepatocytes. 
Screen-shots from the UCSC illustrating KAP1 binding sites in xenobiotic and drug 
metabolizing cytochrome P450 (Cyp) clusters, Cyp2a and Cyp3a. Green rectangles indicate 
peaks identified by a peak calling program using KO sample as a background reference.  
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BeadChip Mouse WG-6 v2    
Annotation file Mouse WG-6_v2_0_R2_11278593_A    
    
Gene identification 
Illumina ID beadtype identifier    
Illumina's probe design pipeline makes use of alternative splicing information documented in the RefSeq database 
"A" all isoforms meaning the probe will hit all splice isoforms of the gene 
"I" isoform 
specific 
meaning the probe is designed to a gene with multiple 
isoforms, but will hit only one specific isoform 
Probe Type 
"S" single isoform meaning that the gene has only one splice isoform recorded 
Gene Symbol approved gene symbol    
Description sequence definition, extracted from the RefSeq record    
Chr chromosomal location 
Representative ID identifier for the sequence record in the NCBI RefSeq database used in probe design 
     
Compilation of the comparisons 
Fold Change -   
Female KO vs WT mean of KAP1 -KO replicates / mean of KAP1-WT replicates 
Welch t-test p-value - 
Female KO vs WT p-value of the Welch t-test between the KAP1-KO mean and the KAP1-WT mean in log2 scale 
     

















normalization background subtraction & quantile normalization (BeadStudio 
software)    
Expression values below a defined threshold (i.e. 20) are set to the threshold in order to remove negative values after background correction. 





Genes dysregulated in KAP1-mutant females  
 
Illumina ID Probe Type Gene 
Symbol 
Description Chr Representative ID Fold 
Change - 
Female 
KO vs WT 
Fold 
Change - 







value - Male KO 
vs WT 
ILMN_2708477 S Spink3   NM_009258.2 38,60 8,38 0,0061 0,0211 
ILMN_2671165 S Krt23 Mus musculus 
keratin 23 (Krt23), 
mRNA. 
11 NM_033373.1 17,72 5,60 0,0008 0,0013 
ILMN_2687507 S Cyp2d9 Mus musculus 
cytochrome P450, 
family 2, subfamily d, 
polypeptide 9 
(Cyp2d9), mRNA. 
15 NM_010006.1 14,15 1,25 0,0138 0,0211 
ILMN_1253860 S Mas1 Mus musculus MAS1 
oncogene (Mas1), 
mRNA. 
17 NM_008552.3 14,02 9,27 0,0052 0,0046 
ILMN_2728134 S 5430433G21R
ik 
PREDICTED: Mus musculus 
RIKEN cDNA 5430433G21 
gene (5430433G21Rik), 
mRNA. 
XM_001480745.1 8,51 3,74 0,0026 0,0021 
ILMN_2625279 S Pacrg Mus musculus Park2 
co-regulated (Pacrg), 
mRNA. 
17 NM_027032.2 7,63 2,50 0,0168 0,0165 




variant 1, mRNA. 
17 NM_207649.1 6,40 3,36 0,0007 0,0010 
ILMN_2736539 S Cyp2c55 Mus musculus cytochrome NM_028089.3 5,07 1,74 0,0072 0,0864 
















P450, family 2, subfamily c, 
polypeptide 55 (Cyp2c55), 
mRNA. 
ILMN_1230375 S LOC383125  XM_356890.1 5,02 4,14 0,0063 0,0042 
ILMN_2875737 S Cyp2d12 Mus musculus 
cytochrome P450, 
family 2, subfamily d, 
polypeptide 12 
(Cyp2d12), mRNA. 
15 NM_201360.1 5,01 1,98 0,0071 0,0683 
ILMN_1236308 S LOC268730  XM_193754.2 4,61 5,80 0,0323 0,0045 
ILMN_2611027 S Pmm1 Mus musculus 
phosphomannomuta
se 1 (Pmm1), 
mRNA. 
15 NM_013872.2 4,58 4,46 0,0041 0,0017 
ILMN_1225985 S Serpina7 Mus musculus serine 
(or cysteine) 
peptidase inhibitor, 
clade A (alpha-1 
antiproteinase, 
antitrypsin), member 
7 (Serpina7), mRNA. 
X NM_177920.4 4,49 4,32 0,0234 0,0196 
ILMN_3122845 A H1fx Mus musculus H1 
histone family, 
member X (H1fx), 
mRNA. 
6 NM_198622.1 4,36 2,56 0,0222 0,0262 




16 NM_019413.2 4,36 4,16 0,0002 0,0135 
ILMN_2974041 S Pmm1 Mus musculus 
phosphomannomuta
se 1 (Pmm1), 
mRNA. 
15 NM_013872.1 4,33 3,75 0,0037 0,0099 
ILMN_3023451 I LOC433801 Mus musculus similar to 
RIKEN cDNA 6330416L07 
gene (LOC433801), mRNA. 
NM_001013808.1 4,20 2,35 0,0301 0,0028 




variant 1, mRNA. 
17 NM_207649.1 4,17 2,07 0,0305 0,0082 
















ILMN_1238820 S LOC332788  XM_285750.2 4,06 4,19 0,0447 0,0060 
ILMN_1258330 S LOC384348  XM_357593.1 4,01 3,65 0,0040 0,0033 
ILMN_2738699 S Cblc Mus musculus 
Casitas B-lineage 
lymphoma c (Cblc), 
mRNA. 
7 NM_023224.4 3,99 3,47 0,0003 0,0039 
ILMN_1246061 S LOC239727  XM_156408.2 3,84 1,74 0,0268 0,2146 
ILMN_2718638 S Hao3 Mus musculus 
hydroxyacid oxidase 
(glycolate oxidase) 3 
(Hao3), mRNA. 
3 NM_019545.3 3,81 1,00 0,0152 NA 
ILMN_1253233 S Dsg1c   NM_181680 3,80 1,67 0,0197 0,0365 





2 NM_015730.4 3,71 3,25 0,0203 0,0601 
ILMN_1228211 S Tff2 Mus musculus trefoil 
factor 2 (spasmolytic 
protein 1) (Tff2), 
mRNA. 
17 NM_009363.3 3,68 2,61 0,0253 0,0093 
ILMN_2618148 S C330008K14Rik  XM_128979 3,55 1,45 0,0045 0,4983 
ILMN_2425229 S Serpina7   NM_177920 3,47 2,25 0,0321 0,0705 
ILMN_1244169 S Sftpd Mus musculus 
surfactant 
associated protein D 
(Sftpd), mRNA. 
14 NM_009160.1 3,42 2,99 0,0325 0,0038 
ILMN_2535566 S LOC382691  XM_356627.1 3,40 2,63 0,0144 0,0292 




member 4 (Abcc4), 
mRNA. 
14 NM_001033336.2 3,13 1,79 0,0185 0,0098 
ILMN_2491526 S Zkscan3 Mus musculus zinc 
finger with KRAB 
and SCAN domains 
3 (Zkscan3), mRNA. 
13 NM_023685.3 3,12 1,20 0,0496 0,4954 
ILMN_1247074 S Gm379 PREDICTED: Mus musculus 
gene model 379, (NCBI) 
XM_908711.1 3,08 -1,08 0,0153 0,6071 

















ILMN_2627328 S Dnase2a   NM_010062 2,93 2,60 0,0058 0,0069 
ILMN_2591342 S BC021614 Mus musculus cDNA 
sequence BC021614 
(BC021614), mRNA. 
19 NM_144869.2 2,93 1,98 0,0230 0,0031 
ILMN_2440679 S D1Ertd471e   2,87 2,14 0,0070 0,0029 
ILMN_1254927 S Ly6c1 Mus musculus 
lymphocyte antigen 
6 complex, locus C1 
(Ly6c1), mRNA. 
15 NM_010741.2 2,86 2,63 0,0292 0,0295 
ILMN_1215877 S Extl1   NM_019578 2,79 4,07 0,0065 0,0016 
ILMN_2748680 S Fhit Mus musculus fragile 
histidine triad gene 
(Fhit), mRNA. 
14 NM_010210.2 2,74 2,28 0,0103 0,0303 




11 NM_010299.2 2,73 2,48 0,0030 0,0001 
ILMN_2874352 S Cyp17a1 Mus musculus 
cytochrome P450, 
family 17, subfamily 
a, polypeptide 1 
(Cyp17a1), mRNA. 
19 NM_007809.2 2,58 4,26 0,0133 0,0380 
ILMN_2893081 S Mbd1 Mus musculus 
methyl-CpG binding 
domain protein 1 
(Mbd1), mRNA. 
18 NM_013594.1 2,57 2,59 0,0001 0,0003 
ILMN_1223880 S Tmprss2 Mus musculus 
transmembrane 
protease, serine 2 
(Tmprss2), mRNA. 
16 NM_015775.2 2,51 2,07 0,0047 0,0288 
ILMN_2864290 S BC049806 Mus musculus cDNA 
sequence BC049806 
(BC049806), mRNA. 
1 NM_172513.2 2,50 1,99 0,0256 0,0096 
ILMN_1230557 S D2Wsu81e Mus musculus DNA 





2 NM_172660.2 2,50 2,85 0,0283 0,0081 
















ILMN_3079804 I Cyp2a5 Mus musculus 
cytochrome P450, 
family 2, subfamily a, 
polypeptide 5 
(Cyp2a5), mRNA. 
7 NM_007812.2 2,47 1,77 0,0190 0,0553 
ILMN_2939652 S Selenbp2 Mus musculus 
selenium binding 
protein 2 (Selenbp2), 
mRNA. 
3 NM_019414.2 2,47 1,60 0,0061 0,0492 
ILMN_2674620 S Ela2a Mus musculus 
elastase 2A (Ela2a), 
mRNA. 
4 NM_007919.2 2,39 -1,52 0,0086 0,0460 
ILMN_1247646 S H1fx Mus musculus H1 
histone family, 
member X (H1fx), 
mRNA. 
6 NM_198622.1 2,38 1,64 0,0383 0,0615 
ILMN_2628629 S Cdh1 Mus musculus 
cadherin 1 (Cdh1), 
mRNA. 
8 NM_009864.2 2,37 1,21 0,0293 0,2318 
ILMN_2596421 S A430079E08  NM_175018.2 2,37 -1,27 0,0148 0,2937 
ILMN_2632073 S Sfxn5 Mus musculus 
sideroflexin 5 
(Sfxn5), mRNA. 
6 NM_178639.2 2,35 1,51 0,0097 0,2683 




beta 3 (Gabrb3), 
transcript variant 2, 
mRNA. 
7 NM_001038701.1 2,33 3,53 0,0117 0,0023 





5 NM_144914.2 2,29 2,59 0,0015 0,0032 
ILMN_2623536 S Golm1 Mus musculus golgi 
membrane protein 1 
(Golm1), transcript 
variant 1, mRNA. 
13 NM_027307.4 2,28 2,09 0,0059 0,0148 
ILMN_2829250 S Serpinb8 Mus musculus serine 
(or cysteine) 
1 NM_011459.2 2,23 1,40 0,0450 0,2666 

















clade B, member 8 
(Serpinb8), mRNA. 
ILMN_2646369 S Slc13a2 Mus musculus solute carrier 
family 13 (sodium-dependent 
dicarboxylate transporter), 
member 2 (Slc13a2), mRNA. 
NM_022411.3 2,20 -1,13 0,0194 0,6482 
ILMN_2535582 S LOC382707  XM_356635.1 2,18 3,46 0,0242 0,0120 
ILMN_1244281 S D2Wsu81e Mus musculus DNA 





2 NM_172660.2 2,17 1,79 0,0119 0,0463 
ILMN_2971479 S Trp53inp1 Mus musculus 
transformation 




4 NM_021897.1 2,13 1,48 0,0122 0,3608 





15 NM_015744.1 2,11 1,16 0,0044 0,1039 
ILMN_1219440 S Rdh16 Mus musculus retinol 
dehydrogenase 16 
(Rdh16), mRNA. 
10 NM_009040.2 2,09 2,44 0,0072 0,0041 
ILMN_2907214 S Tcea3 Mus musculus 
transcription 
elongation factor A 
(SII), 3 (Tcea3), 
mRNA. 
4 NM_011542.1 2,09 1,43 0,0063 0,0008 




19 NM_028029.2 2,09 2,05 0,0247 0,0700 
ILMN_2650428 S 4833442J19Rik  NM_177101.2 2,08 1,18 0,0079 0,0808 
ILMN_1241789 S Sucnr1 Mus musculus 
succinate receptor 1 
(Sucnr1), mRNA. 
3 NM_032400.1 2,08 1,00 0,0298 0,9652 
















ILMN_2747886 S Ndufb11 Mus musculus 
NADH 
dehydrogenase 
(ubiquinone) 1 beta 
subcomplex, 11 
(Ndufb11), mRNA. 
X NM_019435.2 2,04 1,11 0,0078 0,7556 
ILMN_2683138 S Smek2 Mus musculus 
SMEK homolog 2, 
suppressor of mek1 
(Dictyostelium) 
(Smek2), mRNA. 
11 NM_134034.1 2,03 -1,17 0,0217 0,1536 
ILMN_2802952 S Narg2 Mus musculus 
NMDA receptor-
regulated gene 2 
(Narg2), mRNA. 
9 NM_145618.3 2,03 1,19 0,0110 0,3349 




4 NM_026837.2 2,02 1,42 0,0021 0,0228 
ILMN_2598715 S Tubb2b Mus musculus 
tubulin, beta 2b 
(Tubb2b), mRNA. 








15 NM_001039720.1 2,00 2,41 0,0298 0,0209 
ILMN_3143358 A Adora1 Mus musculus 
adenosine A1 
receptor (Adora1), 
transcript variant 1, 
mRNA. 
1 NM_001008533.2 1,98 -1,19 0,0014 0,3970 
ILMN_2421064 S Gtf3c4   NM_172977 1,98 1,10 0,0235 0,7185 
ILMN_1228849 S Hist2h2aa1  NM_013549 1,97 -1,02 0,0187 0,9390 





9 NM_021481.2 1,97 2,48 0,0120 0,0292 
ILMN_1222760 S Zfp579 Mus musculus zinc 
finger protein 579 
7 NM_026741.2 1,97 2,40 0,0008 0,0128 

















ILMN_1240515 S Wipi2 Mus musculus WD repeat 
domain, phosphoinositide 
interacting 2 (Wipi2), mRNA. 
NM_178398.4 1,96 1,34 0,0148 0,0938 
ILMN_2965613 S Abca6 Mus musculus ATP-
binding cassette, 
sub-family A (ABC1), 
member 6 (Abca6), 
mRNA. 
11 NM_147218.1 1,96 1,13 0,0165 0,3273 









11 XM_126343.5 1,94 1,78 0,0007 0,0012 
ILMN_2492961 S 6530401N04Rik  NM_029545 1,93 1,81 0,0184 0,1392 
ILMN_2747820 S Dhrs7 Mus musculus 
dehydrogenase/reductase 
(SDR family) member 7 
(Dhrs7), mRNA. 
NM_025522.3 1,93 2,38 0,0246 0,0078 
ILMN_2742152 S Gadd45a Mus musculus 
growth arrest and 
DNA-damage-
inducible 45 alpha 
(Gadd45a), mRNA. 
6 NM_007836.1 1,93 1,93 0,0223 0,0116 
ILMN_1239129 S A530076E23Rik  AK041063 1,93 -1,25 0,0104 0,3269 
ILMN_2589350 S Ces5 Mus musculus 
carboxylesterase 5 
(Ces5), mRNA. 
8 NM_172759.2 1,92 2,57 0,0336 0,0011 




protein 2 (G3bp2), 
transcript variant 1, 
mRNA. 
5 NM_011816.3 1,92 1,80 0,0221 0,0169 
ILMN_2505095 S Usp48   XM_485461 1,92 1,16 0,0051 0,1535 
ILMN_2710139 S Ppargc1a Mus musculus 
peroxisome 
5 NM_008904.1 1,91 1,44 0,0127 0,1521 



















1 alpha (Ppargc1a), 
mRNA. 
ILMN_2489360 S Pdia6 Mus musculus protein 
disulfide isomerase 
associated 6 (Pdia6), mRNA. 
NM_027959.3 1,91 1,09 0,0271 0,6704 
ILMN_1229267 S Cyp2a5 Mus musculus cytochrome 
P450, family 2, subfamily a, 
polypeptide 5 (Cyp2a5), 
mRNA. 
NM_007812.4 1,91 1,69 0,0062 0,0055 
ILMN_1213456 S Dhrs7 Mus musculus 
dehydrogenase/reductase 
(SDR family) member 7 
(Dhrs7), mRNA. 
NM_025522.3 1,91 2,46 0,0126 0,0026 
ILMN_2939702 S Dhrs7 Mus musculus 
dehydrogenase/redu
ctase (SDR family) 
member 7 (Dhrs7), 
mRNA. 
12 NM_025522.1 1,90 2,73 0,0124 0,0145 
ILMN_2534783 S LOC245069  XM_159529.3 1,89 1,83 0,0052 0,0500 
ILMN_2776283 S Tcea3   NM_011542 1,89 1,54 0,0021 0,0002 
ILMN_2856157 S Pgam1 Mus musculus 
phosphoglycerate 
mutase 1 (Pgam1), 
mRNA. 
19 NM_023418.2 1,89 1,75 0,0057 0,0051 
ILMN_2808751 S Bcl9 Mus musculus B-cell 
CLL/lymphoma 9 
(Bcl9), mRNA. 
3 NM_029933.3 1,88 -1,05 0,0322 0,6500 
ILMN_1235255 S Klf15 Mus musculus 
Kruppel-like factor 
15 (Klf15), mRNA. 
6 NM_023184.3 1,88 -1,05 0,0291 0,8054 
ILMN_3148550 A Golm1 Mus musculus golgi 
membrane protein 1 
(Golm1), transcript 
variant 2, mRNA. 
13 NM_001035122.2 1,88 1,63 0,0057 0,0073 




5 NM_011816.3 1,88 1,52 0,0265 0,0397 
















protein 2 (G3bp2), 
transcript variant 1, 
mRNA. 
ILMN_2671689 S Cox7b Mus musculus 
cytochrome c 





X NM_025379.2 1,87 -1,14 0,0117 0,4732 




4 NM_026837.1 1,85 1,49 0,0195 0,0007 
ILMN_1239180 S Rprd1a Mus musculus 












6 NM_026894.1 1,83 1,51 0,0182 0,1524 




8 NM_001081390.1 1,82 1,46 0,0391 0,0492 
ILMN_2853739 S Nadsyn1 Mus musculus NAD 
synthetase 1 
(Nadsyn1), mRNA. 
7 NM_030221.1 1,82 1,10 0,0195 0,6135 
ILMN_2608043 S Hes6 Mus musculus hairy 
and enhancer of split 
6 (Drosophila) 
(Hes6), mRNA. 
1 NM_019479.3 1,82 1,66 0,0234 0,0328 
ILMN_1213185 S LOC385792  XM_358947.1 1,81 1,99 0,0183 0,0374 
ILMN_2587863 I 2410091N08Rik  XM_146886.1 1,80 -1,68 0,0332 0,0266 
ILMN_2506012 S Trp53inp1 Mus musculus 
transformation 
related protein 53 
inducible nuclear 
4 NM_021897.1 1,80 1,28 0,0105 0,1055 























4 NM_133880.1 1,79 1,53 0,0068 0,0063 
ILMN_1230710 S C730039N23Rik  AK050344 1,79 -1,96 0,0477 0,0009 




transcript variant 2, 
mRNA. 
6 NM_201244.1 1,78 -1,15 0,0489 0,5887 
ILMN_2977903 S BC057627 Mus musculus cDNA 
sequence BC057627 
(BC057627), mRNA. 
7 NM_198631.1 1,78 1,18 0,0092 0,5610 
ILMN_1222258 S Mid2 Mus musculus 
midline 2 (Mid2), 
mRNA. 
X NM_011845.2 1,78 1,47 0,0036 0,1093 




14 NM_013768.2 1,78 1,03 0,0494 0,8824 
ILMN_2755915 S Pet112l Mus musculus PET112-like 
(yeast) (Pet112l), mRNA. 
NM_144896.4 1,76 1,20 0,0014 0,2074 




14 NM_177815.3 1,76 1,09 0,0035 0,3714 
ILMN_2589770 S Fam179a Mus musculus family with 
sequence similarity 179, 
member A (Fam179a), 
mRNA. 
NM_177087.4 1,76 -1,11 0,0227 0,7249 
ILMN_2711045 S Sirt5 Mus musculus sirtuin 
5 (silent mating type 
information 
regulation 2 
homolog) 5 (S. 
cerevisiae) (Sirt5), 
mRNA. 
13 NM_178848.3 1,76 1,78 0,0188 0,0023 
















ILMN_1257020 S Aldh1b1 Mus musculus 
aldehyde 
dehydrogenase 1 





4 NM_028270.4 1,76 1,03 0,0258 0,4497 
ILMN_2526042 S LOC217372  XM_126827.4 1,75 -1,20 0,0493 0,5909 
ILMN_1242689 S LOC236371  XM_135639.2 1,75 2,15 0,0319 0,0463 
ILMN_2763983 S Sds Mus musculus serine 
dehydratase (Sds), 
mRNA. 
5 NM_145565.1 1,75 -1,04 0,0463 0,8396 
ILMN_1232093 S LOC386330  XM_359173.1 1,75 -1,20 0,0130 0,0050 




variant 1, mRNA. 
3 NM_053170.2 1,75 -1,08 0,0313 0,5618 
ILMN_1250364 S Cyp2a4 Mus musculus 
cytochrome P450, 
family 2, subfamily a, 
polypeptide 4 
(Cyp2a4), mRNA. 
7 NM_009997.2 1,75 10,95 0,0337 0,1208 




2 NM_145527.3 1,74 1,42 0,0263 0,1936 
ILMN_2602687 S Rpa2 Mus musculus 
replication protein A2 
(Rpa2), mRNA. 
4 NM_011284.3 1,74 1,36 0,0349 0,1533 
ILMN_2606415 S Adra1b   NM_007416 1,74 1,13 0,0357 0,6613 
ILMN_2747311 S Atp6v0a2 Mus musculus ATPase, H+ 
transporting, lysosomal V0 
subunit A2 (Atp6v0a2), 
mRNA. 
NM_011596.4 1,74 1,27 0,0396 0,1987 




11 NM_133706.2 1,74 1,46 0,0026 0,0352 
















ILMN_2692942 S Sntb2 Mus musculus 
syntrophin, basic 2 
(Sntb2), mRNA. 
8 NM_009229.2 1,74 -1,51 0,0335 0,2066 
ILMN_1236941 S Csnk2a1-rs3  AK031617 1,73 1,04 0,0479 0,7347 
ILMN_2487358 S Eif3s6   NM_008388 1,73 -1,20 0,0079 0,4302 
ILMN_2586024 S Nup98   AK089973 1,73 -1,28 0,0498 0,2040 
ILMN_1255363 S Fkbp14 Mus musculus 
FK506 binding 
protein 14 (Fkbp14), 
mRNA. 
6 NM_153573.1 1,73 1,05 0,0220 0,5261 
ILMN_2734598 S Cyp2a5 Mus musculus cytochrome 
P450, family 2, subfamily a, 
polypeptide 5 (Cyp2a5), 
mRNA. 
NM_007812.4 1,73 1,85 0,0036 0,0101 
ILMN_1256271 S Atp13a3 PREDICTED: Mus 
musculus ATPase 
type 13A3, transcript 
variant 1 (Atp13a3), 
mRNA. 
16 XM_001480958.1 1,72 -1,03 0,0149 0,8462 
ILMN_2945374 S Gm806 Mus musculus gene 
model 806, (NCBI) 
(Gm806), mRNA. 
13 NM_001033400.1 1,72 1,22 0,0476 0,2197 




8 NM_011130.1 1,72 -1,22 0,0440 0,5765 
ILMN_2490536 S Aldh5a1   NM_172532 1,72 1,65 0,0001 0,0000 
ILMN_2727309 S LOC1000442
04 




XM_001471696.1 1,71 1,45 0,0368 0,0481 




4 NM_026837.2 1,71 -1,02 0,0050 0,9299 
ILMN_1216900 S Rabl3 Mus musculus RAB, 
member of RAS 
oncogene family-like 
3 (Rabl3), mRNA. 
16 NM_001042499.1 1,71 1,16 0,0481 0,5394 
ILMN_2844963 S Nos1ap Mus musculus nitric oxide 
synthase 1 (neuronal) adaptor 
NM_027528.1 1,71 -1,27 0,0262 0,2712 
















protein (Nos1ap), mRNA. 
XM_994037 
ILMN_2728255 S 6430526O11Rik  XM_110937.4 1,71 1,21 0,0456 0,5553 
ILMN_2707079 S Sirt5 Mus musculus sirtuin 
5 (silent mating type 
information 
regulation 2 
homolog) 5 (S. 
cerevisiae) (Sirt5), 
mRNA. 
13 NM_178848.3 1,70 1,90 0,0001 0,0171 





X NM_172779.1 1,70 -1,02 0,0009 0,8531 




3 NM_019957.3 1,68 1,63 0,0378 0,0019 
ILMN_2536687 S LOC383077  XM_356845.1 1,68 1,22 0,0223 0,3258 
ILMN_1244477 S Garnl4 Mus musculus 
GTPase activating 
RANGAP domain-
like 4 (Garnl4), 
mRNA. 
11 NM_001015046.2 1,68 1,26 0,0435 0,2537 
ILMN_2674001 S Smyd2 Mus musculus SET 
and MYND domain 
containing 2 
(Smyd2), mRNA. 
1 NM_026796.1 1,68 1,39 0,0198 0,0337 
ILMN_1215965 S Ubr1   AK086900 1,67 -1,10 0,0080 0,4226 
ILMN_2791952 S Hes6 Mus musculus hairy 
and enhancer of split 
6 (Drosophila) 
(Hes6), mRNA. 
1 NM_019479.2 1,67 1,25 0,0342 0,2520 
ILMN_2757641 S Efna5 Mus musculus 
ephrin A5 (Efna5), 
transcript variant 2, 
mRNA. 
17 NM_010109.2 1,67 1,80 0,0141 0,0162 
ILMN_2527923 S LOC228966  XM_141580.1 1,66 -1,13 0,0193 0,6422 
ILMN_2820703 S Scarf1 Mus musculus 
scavenger receptor 
11 NM_001004157.2 1,66 1,04 0,0093 0,8431 
















class F, member 1 
(Scarf1), mRNA. 





9 NM_177460.3 1,66 1,89 0,0469 0,0052 
ILMN_2431619 S Ube2l6   NM_019949 1,66 1,57 0,0461 0,0062 
ILMN_2774690 S LOC677317 PREDICTED: Mus musculus 
similar to Mod1 protein, 
transcript variant 4 
(LOC677317), mRNA. 
XM_001004685.1 1,66 2,11 0,0341 0,0123 
ILMN_1245447 S Abcd1 Mus musculus ATP-
binding cassette, 
sub-family D (ALD), 
member 1 (Abcd1), 
mRNA. XM_973409 
X NM_007435.1 1,66 1,12 0,0236 0,3710 
ILMN_1244847 S Cyp2a5 Mus musculus cytochrome 
P450, family 2, subfamily a, 
polypeptide 5 (Cyp2a5), 
mRNA. 
NM_007812.4 1,66 1,63 0,0017 0,0014 
ILMN_2605013 S Sec14l4 Mus musculus 
SEC14-like 4 (S. 
cerevisiae) 
(Sec14l4), mRNA. 
11 NM_146013.1 1,64 1,14 0,0127 0,3773 
ILMN_2562109 S A630091F01Rik  AK042432 1,64 1,41 0,0249 0,0343 




2 NM_177157.4 1,63 1,80 0,0136 0,0114 








7 NM_175319.2 1,63 1,21 0,0212 0,4226 
ILMN_1247075 S Npc1 Mus musculus 
Niemann Pick type 
C1 (Npc1), mRNA. 
18 NM_008720.2 1,62 1,09 0,0009 0,2599 
ILMN_1226783 S Irak4 Mus musculus 
interleukin-1 
15 NM_029926.4 1,62 -1,23 0,0104 0,2957 





















PREDICTED: Mus musculus 
similar to CDNA sequence 
BC052040, transcript variant 
1 (LOC100048589), mRNA. 
XM_001480260.1 1,62 1,25 0,0320 0,1979 




6 NM_009148.3 1,62 1,70 0,0232 0,1558 
ILMN_2581065 S 6030460N08Rik  AK077954 1,62 -1,21 0,0356 0,2651 
ILMN_2752624 S Ccrl2 Mus musculus 
chemokine (C-C 
motif) receptor-like 2 
(Ccrl2), mRNA. 
9 NM_017466.4 1,62 1,45 0,0074 0,0085 
ILMN_1214126 S Hes6 Mus musculus hairy 
and enhancer of split 
6 (Drosophila) 
(Hes6), mRNA. 
1 NM_019479.2 1,62 1,57 0,0408 0,0540 




subunit H (Atp6v1h), 
mRNA. 
1 NM_133826.2 1,62 1,21 0,0399 0,1691 




2 NM_177157.4 1,61 1,43 0,0033 0,0040 
ILMN_1224408 S Eif2ak3   AK046355 1,61 -1,15 0,0269 0,6766 
ILMN_2993473 S Sp6 Mus musculus trans-
acting transcription 
factor 6 (Sp6), 
mRNA. 
11 NM_031183.1 1,61 1,18 0,0473 0,6508 
ILMN_1234693 S Nipbl Mus musculus 
Nipped-B homolog 
(Drosophila) (Nipbl), 
transcript variant A, 
mRNA. 
15 NM_027707.2 1,61 1,14 0,0453 0,1072 
ILMN_1256775 S Thrsp Mus musculus 7 NM_009381.2 1,60 2,05 0,0368 0,1520 




















ILMN_2637203 S Rfc5 Mus musculus 
replication factor C 
(activator 1) 5 (Rfc5), 
mRNA. 
5 NM_028128.1 1,60 1,45 0,0154 0,0483 
ILMN_1221288 S Lgals8 Mus musculus lectin, 
galactose binding, 
soluble 8 (Lgals8), 
mRNA. 
13 NM_018886.3 1,60 1,46 0,0258 0,0025 
ILMN_2622761 S Pccb Mus musculus 
propionyl Coenzyme 






9 NM_025835.2 1,60 -1,46 0,0403 0,0557 
ILMN_2534278 S LOC327992  XM_282974.2 1,60 -1,26 0,0069 0,4226 
ILMN_2908485 S Ap1s3 Mus musculus 
adaptor-related 
protein complex AP-
1, sigma 3 (Ap1s3), 
mRNA. 
1 NM_183027.1 1,60 -1,19 0,0071 0,5077 
ILMN_1244292 S Sox13 Mus musculus SRY-
box containing gene 
13 (Sox13), mRNA. 
1 NM_011439.2 1,60 -1,05 0,0345 0,8752 
ILMN_2453120 S C130065N10Rik   1,59 1,79 0,0011 0,0025 
ILMN_2933022 S Plekhb1 Mus musculus 
pleckstrin homology 
domain containing, 
family B (evectins) 
member 1 (Plekhb1), 
mRNA. 
7 NM_013746.1 1,59 1,57 0,0259 0,0141 
ILMN_2589556 S Ikbkb   NM_010546 1,59 1,00 0,0062 0,9820 




12 XM_484171.3 1,59 -1,55 0,0226 0,0553 


















ILMN_1218042 S LOC383483  XM_357088.1 1,59 -1,13 0,0120 0,6428 
ILMN_2425032 S Zfp445   NM_173364.3 1,59 1,08 0,0100 0,6740 




10 XM_137041.6 1,58 1,02 0,0274 0,4226 
ILMN_1217489 S LOC671878 PREDICTED: Mus 




X XM_001473434.1 1,58 1,27 0,0360 0,0494 
ILMN_2524100 S Zswim6   XM_358311 1,58 1,16 0,0285 0,6639 
ILMN_1214224 S Zfp1 Mus musculus zinc 
finger protein 1 
(Zfp1), transcript 
variant 1, mRNA. 
8 NM_001037665.2 1,58 1,10 0,0486 0,6673 
ILMN_1239770 S Peli1 Mus musculus 
pellino 1 (Peli1), 
mRNA. 
11 NM_023324.2 1,58 1,58 0,0432 0,0664 





12 NM_183294.1 1,57 -1,27 0,0378 0,1986 
ILMN_2674924 S Pcca Mus musculus 
propionyl-Coenzyme 
A carboxylase, alpha 
polypeptide (Pcca), 
mRNA. 
14 NM_144844.1 1,57 1,27 0,0016 0,0270 
ILMN_1257291 S D030029J20Rik   1,57 1,16 0,0469 0,2400 
ILMN_1242852 S Wdr45l Mus musculus 
Wdr45 like (Wdr45l), 
mRNA. 
11 NM_025793.2 1,57 1,51 0,0118 0,0912 
ILMN_2865016 S Cd83 Mus musculus CD83 
antigen (Cd83), 
mRNA. 






11 XM_001481024.1 1,56 1,59 0,0164 0,0635 



















ILMN_1221362 S Esr1   AK039911 1,55 -1,08 0,0379 0,4226 
ILMN_2551945 S E130209G04Rik  AK021406 1,55 1,10 0,0281 0,4410 
ILMN_1240738 S Rdh19 Mus musculus retinol 
dehydrogenase 19 
(Rdh19), mRNA. 
10 NM_147222.2 1,55 1,00 0,0068 0,9919 
ILMN_2873862 S Lrrc30 Mus musculus 
leucine rich repeat 
containing 30 
(Lrrc30), mRNA. 
17 NM_001033340.1 1,55 -1,32 0,0185 0,2806 
ILMN_1213636 S C330023D02Rik  AK049320 1,55 1,02 0,0176 0,8129 
ILMN_1235366 S LOC1000456
28 
PREDICTED: Mus musculus 
similar to X-linked PEST-
containing transporter 
(LOC100045628), misc RNA. 
XR_031850.1 1,55 1,02 0,0365 0,9474 
ILMN_2937261 S Mod1 Mus musculus malic 
enzyme, supernatant 
(Mod1), mRNA. 
9 NM_008615.1 1,54 1,88 0,0022 0,0364 
ILMN_2860242 S Klhl24 Mus musculus kelch-
like 24 (Drosophila) 
(Klhl24), mRNA. 
16 NM_029436.3 1,54 1,20 0,0446 0,3019 




2 NM_029692.1 1,54 1,06 0,0494 0,4644 




7 NM_025408.2 1,54 1,52 0,0026 0,0061 
ILMN_1237758 S LOC382153  XM_356249.1 1,53 1,68 0,0385 0,0268 
ILMN_2486267 S Ube2l6 Mus musculus 
ubiquitin-conjugating 
enzyme E2L 6 
(Ube2l6), mRNA. 
2 NM_019949.1 1,53 1,99 0,0035 0,0251 
ILMN_1256868 S C130005N09Rik  AK081324 1,53 -1,18 0,0434 0,5649 
ILMN_1238995 S BC062650   NM_177650.2 1,52 -1,06 0,0370 0,8355 
ILMN_2946410 S Slc36a2 Mus musculus solute 
carrier family 36 
11 NM_153170.1 1,52 -1,21 0,0365 0,2460 


















2 (Slc36a2), mRNA. 




transcript variant 3, 
mRNA. 
8 NM_001037878.1 1,52 1,31 0,0337 0,2685 
ILMN_2473692 S 1110059G02Rik   1,52 1,43 0,0118 0,0149 
ILMN_2879614 S Zbp1 Mus musculus Z-
DNA binding protein 
1 (Zbp1), mRNA. 
2 NM_021394.1 1,51 -1,02 0,0454 0,8625 
ILMN_1234020 S scl0002007.1_97   1,51 1,26 0,0447 0,1245 
ILMN_2747381 S Ddx24 Mus musculus 
DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
24 (Ddx24), mRNA. 
12 NM_020494.2 1,51 1,04 0,0095 0,7959 
ILMN_2560602 S Centd1 PREDICTED: Mus musculus 
centaurin, delta 1, transcript 
variant 5 (Centd1), mRNA. 
XM_001001363.1 1,51 -1,16 0,0072 0,4909 
ILMN_2640752 S Ces1 Mus musculus 
carboxylesterase 1 
(Ces1), mRNA. 
8 NM_021456.2 1,51 -1,06 0,0143 0,7371 
ILMN_2425691 S A930009E05Rik  XM_489135 -1,50 -1,16 0,0377 0,2111 





4 NM_019489.2 -1,51 1,16 0,0374 0,1012 
ILMN_1220036 S C130032M10Rik  AK048065 -1,51 1,02 0,0189 0,9126 
ILMN_2700550 S Ddx11   XM_128714.3 -1,51 -1,07 0,0430 0,5757 
ILMN_2637094 S Pcsk6 PREDICTED: Mus musculus 
proprotein convertase 
subtilisin/kexin type 6, 
transcript variant 4 (Pcsk6), 
mRNA. 
XM_919493.2 -1,51 -1,17 0,0128 0,1208 
ILMN_3003631 S Ppap2c Mus musculus 
phosphatidic acid 
phosphatase type 2c 
10 NM_015817.2 -1,51 -1,40 0,0045 0,0102 






















X NM_010941.3 -1,51 -1,23 0,0443 0,0917 
ILMN_2773936 S Edg5   NM_010333 -1,51 1,03 0,0334 0,3811 





9 NM_031874.4 -1,52 -1,01 0,0429 0,9407 
ILMN_2532923 S LOC245066  XM_142398.1 -1,52 1,04 0,0087 0,4226 
ILMN_1214166 S Odf2   BC057001 -1,52 -1,25 0,0370 0,4790 
ILMN_2630710 S Zfp623 Mus musculus zinc 
finger protein 623 
(Zfp623), mRNA. 
15 NM_030199.3 -1,52 -1,44 0,0021 0,0242 
ILMN_1254827 S D830041I17Rik  AK052921 -1,53 -1,59 0,0436 0,0847 


















2 NM_029475.1 -1,53 1,18 0,0394 0,1555 
ILMN_1242246 S Scamp5 Mus musculus 
secretory carrier 
membrane protein 5 
(Scamp5), mRNA. 
9 NM_020270.2 -1,53 -1,49 0,0145 0,0702 


















PREDICTED: Mus musculus 
RIKEN cDNA 1110038B12 
gene, transcript variant 6 
(1110038B12Rik), mRNA. 
XM_922038.2 -1,53 -1,13 0,0086 0,3205 
ILMN_2774563 S Mug4 PREDICTED: Mus musculus 
murinoglobulin 4 (Mug4), 
misc RNA. 
XR_035729.1 -1,53 -1,52 0,0107 0,0017 
ILMN_2707782 S Afg3l1 Mus musculus 
AFG3(ATPase family 
gene 3)-like 1 (yeast) 
(Afg3l1), mRNA. 
8 NM_054070.2 -1,55 1,24 0,0392 0,4234 
ILMN_1224110 S Bst2 Mus musculus bone 
marrow stromal cell 
antigen 2 (Bst2), 
mRNA. 
8 NM_198095.2 -1,55 -1,20 0,0322 0,1516 
ILMN_2709392 S Zfp707 Mus musculus zinc 
finger protein 707 
(Zfp707), mRNA. 
15 NM_001081065.1 -1,56 -1,39 0,0153 0,0504 
ILMN_2534207 S LOC380706  XM_354621.1 -1,56 -1,29 0,0459 0,1030 
ILMN_1247450 S B430005K18Rik  AK046551 -1,56 -1,43 0,0084 0,0486 
ILMN_2635348 S Iqcb1 Mus musculus IQ 
calmodulin-binding 
motif containing 1 
(Iqcb1), mRNA. 
16 NM_177128.3 -1,56 -1,11 0,0256 0,3012 
ILMN_2539511 S Mpeg1   XM_129176.3 -1,57 -1,23 0,0083 0,4226 
ILMN_1236610 S Socs6 Mus musculus 
suppressor of 
cytokine signaling 6 
(Socs6), mRNA. 
18 NM_018821.3 -1,57 -1,01 0,0300 0,9651 





17 NM_178589.2 -1,57 -1,26 0,0069 0,5203 
ILMN_1241328 S Kcnd1   NM_008423 -1,57 -1,37 0,0303 0,0985 
ILMN_2699052 S Nrn1 Mus musculus 
neuritin 1 (Nrn1), 
mRNA. 
13 NM_153529.1 -1,57 -2,42 0,0155 0,0038 
ILMN_2714222 S Elovl2 Mus musculus 
elongation of very 
long chain fatty acids 
13 NM_019423.1 -1,57 -1,54 0,0423 0,0427 


















like 2 (Elovl2), 
mRNA. 
ILMN_1232151 S C130023I09Rik  AK047956 -1,57 -1,21 0,0249 0,2496 
ILMN_2460653 S Unc93b1 Mus musculus unc-
93 homolog B1 (C. 
elegans) (Unc93b1), 
mRNA. 








14 NM_021437.1 -1,57 -1,12 0,0419 0,3240 
ILMN_2790144 S Tomm34 Mus musculus 




2 NM_025996.1 -1,57 -1,09 0,0430 0,0780 




7 NM_033174.2 -1,58 1,18 0,0086 0,0530 
ILMN_3041906 I Timm9 Mus musculus 








variant 2, mRNA. 
12 NM_001024853.1 -1,58 -1,50 0,0480 0,0597 
ILMN_2915689 S Dhx58 Mus musculus 
DEXH (Asp-Glu-X-
His) box polypeptide 
58 (Dhx58), mRNA. 







12 XM_001476158.1 -1,59 1,06 0,0216 0,7151 


















ILMN_1236246 S D4Wsu132e Mus musculus DNA 






4 NM_138590.2 -1,59 1,00 0,0066 0,9981 




15 NM_033612.1 -1,59 -1,50 0,0223 0,0875 
ILMN_2423372 S 2310014D11Rik   -1,59 1,09 0,0250 0,7254 
ILMN_1220307 S LOC1000460
25 
PREDICTED: Mus musculus 
similar to mKIAA1230 protein, 
transcript variant 1 
(LOC100046025), mRNA. 
XM_001475823.1 -1,60 -1,82 0,0104 0,0106 
ILMN_1243900 S LOC626152 PREDICTED: Mus musculus 
similar to epiplakin 
(LOC626152), misc RNA. 
XR_032670.1 -1,60 -1,21 0,0388 0,1544 
ILMN_2760619 S Tinagl1 Mus musculus 
tubulointerstitial 
nephritis antigen-like 
1 (Tinagl1), mRNA. 
4 NM_023476.2 -1,60 -1,01 0,0284 0,9264 
ILMN_1250837 S Rangap1   NM_011241 -1,60 -1,15 0,0147 0,2237 





9 NM_011678.1 -1,60 -1,14 0,0015 0,4089 
ILMN_1242437 S C130090G16Rik  AK081969 -1,60 -1,15 0,0255 0,4226 
ILMN_1244991 S Fbxo21 Mus musculus F-box 
protein 21 (Fbxo21), 
mRNA. 








7 NM_001081022.1 -1,61 -1,32 0,0145 0,0544 
ILMN_1222734 S Aldh1a1 Mus musculus 19 NM_013467.3 -1,61 -1,06 0,0438 0,7363 


















family 1, subfamily 
A1 (Aldh1a1), 
mRNA. 





7 NM_001037822.1 -1,61 -1,31 0,0398 0,2277 
ILMN_2682928 S Rai14 Mus musculus 
retinoic acid induced 
14 (Rai14), mRNA. 
15 NM_030690.2 -1,61 -1,47 0,0272 0,0488 
ILMN_2920800 S Sip1 Mus musculus 
survivor of motor 
neuron protein 
interacting protein 1 
(Sip1), mRNA. 
12 NM_025656.1 -1,62 -1,46 0,0025 0,2301 




11 NM_029537.1 -1,62 -1,20 0,0244 0,3805 
ILMN_2476174 S Zfp264   XM_486050 -1,62 -1,06 0,0268 0,7924 
ILMN_1252776 S LOC1000448
12 
PREDICTED: Mus musculus 
similar to cornichon homolog 
2 (Drosophila) 
(LOC100044812), mRNA. 
XM_001473093.1 -1,62 -1,29 0,0342 0,4299 
ILMN_2548010 S Hopx Mus musculus HOP 
homeobox (Hopx), 
mRNA. 
5 NM_175606.2 -1,63 -1,17 0,0068 0,0360 
ILMN_2588882 S Slc41a2 Mus musculus solute 
carrier family 41, 
member 2 (Slc41a2), 
mRNA. 








7 NM_029609.1 -1,63 -1,28 0,0427 0,1144 
ILMN_2494707 S LOC381232  XM_358531 -1,63 1,09 0,0332 0,4226 
ILMN_1226216 S Rnf123 Mus musculus ring 9 NM_032543.1 -1,64 1,06 0,0174 0,7823 
















finger protein 123 
(Rnf123), mRNA. 




1 NM_001029977.2 -1,64 1,14 0,0424 0,4770 







group 1 (Ercc1), 
mRNA. 
7 NM_007948.1 -1,64 1,21 0,0263 0,5058 




18 NM_201362.1 -1,65 -1,28 0,0438 0,1922 
ILMN_1235585 S D930040M24Rik  NM_177278 -1,65 -1,31 0,0279 0,4257 
ILMN_2907964 S Crim2 Mus musculus 
cysteine rich BMP 
regulator 2 (chordin 
like) (Crim2), mRNA. 
6 NM_001029985.1 -1,65 -1,67 0,0061 0,0125 
ILMN_2597778 S Gna14 Mus musculus 
guanine nucleotide 
binding protein, 
alpha 14 (Gna14), 
mRNA. 
19 NM_008137.3 -1,65 -2,05 0,0068 0,0728 
ILMN_2677792 S Cyp2c39 Mus musculus 
cytochrome P450, 
family 2, subfamily c, 
polypeptide 39 
(Cyp2c39), mRNA. 
19 NM_010003.1 -1,65 1,02 0,0164 0,4226 
ILMN_1249666 S Ppap2c Mus musculus 
phosphatidic acid 
phosphatase type 2c 
(Ppap2c), mRNA. 
10 NM_015817.2 -1,66 -1,55 0,0108 0,0163 
ILMN_1231939 S Ccbl2 Mus musculus 
cysteine conjugate-
beta lyase 2 (Ccbl2), 
3 NM_173763.3 -1,66 -2,36 0,0072 0,0010 

















ILMN_3115677 A Ilf3 Mus musculus 
interleukin enhancer 
binding factor 3 (Ilf3), 
transcript variant 3, 
mRNA. 
9 NM_001042708.1 -1,66 -1,04 0,0205 0,8180 




7 NM_025347.2 -1,67 -1,24 0,0136 0,3231 
ILMN_2785454 S Hist2h2ab Mus musculus 
histone cluster 2, 
H2ab (Hist2h2ab), 
mRNA. 
3 NM_178213.3 -1,67 -1,46 0,0395 0,0155 
ILMN_1218058 S Atp1a1 Mus musculus 
ATPase, Na+/K+ 
transporting, alpha 1 
polypeptide 
(Atp1a1), mRNA. 
3 NM_144900.1 -1,68 -1,78 0,0029 0,0017 
ILMN_1218551 S Mapk3 Mus musculus 
mitogen-activated 
protein kinase 3 
(Mapk3), mRNA. 
7 NM_011952.2 -1,68 1,21 0,0404 0,5653 




member 3 (Rassf3), 
mRNA. 
10 NM_138956.3 -1,68 -3,03 0,0026 0,0027 
ILMN_2635105 S Nme7 Mus musculus non-
metastatic cells 7, 




variant 1, mRNA. 
1 NM_138314.2 -1,68 -1,24 0,0484 0,1349 
ILMN_2825020 S Rassf5 Mus musculus Ras 
association 
(RalGDS/AF-6) 
domain family 5 
(Rassf5), mRNA. 
1 NM_018750.2 -1,69 -1,29 0,0389 0,1097 
















ILMN_2962584 S Tspan4 Mus musculus 
tetraspanin 4 
(Tspan4), mRNA. 
7 NM_053082.2 -1,69 1,09 0,0022 0,7562 
ILMN_3027751 I Sorbs1 Mus musculus sorbin 
and SH3 domain 
containing 1 
(Sorbs1), transcript 
variant 5, mRNA. 
19 NM_001034964.1 -1,69 1,34 0,0009 0,0665 
ILMN_1240839 S Golt1a Mus musculus golgi 
transport 1 homolog 
A (S. cerevisiae) 
(Golt1a), mRNA. 
1 NM_026680.4 -1,69 -1,62 0,0204 0,0390 
ILMN_1219717 S Sort1 Mus musculus 
sortilin 1 (Sort1), 
mRNA. 
3 NM_019972.2 -1,69 -1,60 0,0386 0,0184 
ILMN_1259939 S Trim3 Mus musculus 
tripartite motif-
containing 3 (Trim3), 
mRNA. 
7 NM_018880.2 -1,69 1,08 0,0220 0,8074 
ILMN_2776922 S Glrx1   NM_053108 -1,70 -1,60 0,0051 0,0030 
ILMN_1249775 S Lrp8 Mus musculus low density 
lipoprotein receptor-related 
protein 8, apolipoprotein e 
receptor (Lrp8), transcript 
variant 2, mRNA. 
NM_001080926.1 -1,70 1,11 0,0430 0,4226 
ILMN_1228189 S Med14 Mus musculus 
mediator complex 
subunit 14 (Med14), 
transcript variant 2, 
mRNA. 
X NM_012005.3 -1,70 -1,09 0,0026 0,8079 
ILMN_1220360 S Unc13b Mus musculus unc-
13 homolog B (C. 
elegans) (Unc13b), 
mRNA. 
4 NM_001081413.1 -1,72 -1,72 0,0307 0,0610 
ILMN_1216145 S Np220   AK043029 -1,73 -1,06 0,0248 0,4226 
ILMN_2707694 S D10Wsu102e Mus musculus DNA 





10 NM_026579.2 -1,73 -1,19 0,0106 0,1342 

















ILMN_1247430 S LOC383681  XM_357183.1 -1,74 1,19 0,0216 0,4605 
ILMN_1239742 S Atp2a2 Mus musculus 
ATPase, Ca++ 
transporting, cardiac 
muscle, slow twitch 2 
(Atp2a2), mRNA. 
5 NM_009722.2 -1,74 -1,28 0,0439 0,0420 





7 NM_009737.1 -1,75 -1,13 0,0108 0,6196 
ILMN_1257953 S 5730598B06  XM_135809.3 -1,76 -1,02 0,0036 0,9337 
ILMN_2463006 S LOC1000472
08 
PREDICTED: Mus musculus 
similar to trypsinogen 15 
(LOC100047208), mRNA. 
XM_001477976.1 -1,76 -1,12 0,0323 0,5565 
ILMN_3071907 I Nme2 Mus musculus non-




variant 1, mRNA. 
11 NM_008705.4 -1,77 -1,01 0,0380 0,9592 
ILMN_2710449 S Crip2 Mus musculus 
cysteine rich protein 
2 (Crip2), mRNA. 
12 NM_024223.1 -1,77 -1,58 0,0216 0,0101 
ILMN_2526468 S LOC217591  XM_138082.2 -1,77 -1,30 0,0314 0,2597 
ILMN_1231483 S D230017B08Rik  AK051900 -1,77 1,00 0,0341 NA 




8 NM_001039514.1 -1,77 -1,20 0,0026 0,2282 
ILMN_2660364 S Nudt14 Mus musculus nudix 
(nucleoside diphosphate 
linked moiety X)-type motif 14 
(Nudt14), mRNA. 
NM_025399.3 -1,78 -1,01 0,0313 0,9535 
ILMN_2773835 S LOC670044 PREDICTED: Mus musculus 
similar to Mothers against 
decapentaplegic homolog 6 
(SMAD 6) (Mothers against 
DPP homolog 6) (Smad6) 
XM_978692.1 -1,78 -1,78 0,0472 0,0379 
















(Mad homolog 7) 
(LOC670044), mRNA. 





11 NM_030207.2 -1,78 -1,12 0,0385 0,3218 
ILMN_2907878 S H2afx Mus musculus H2A 
histone family, 
member X (H2afx), 
mRNA. 
9 NM_010436.2 -1,78 -1,08 0,0287 0,6958 
ILMN_2449986 S EG640530 PREDICTED: Mus musculus 
predicted gene, EG640530 
(EG640530), mRNA. 
XM_917532.3 -1,78 -1,53 0,0236 0,0025 








4 NM_025582.3 -1,80 -1,79 0,0057 0,0077 
ILMN_2769877 S Reck   NM_016678 -1,80 -1,44 0,0180 0,1834 








5 NM_027323.1 -1,81 1,15 0,0080 0,6954 
ILMN_2903734 S Siah1b Mus musculus seven 
in absentia 1B 
(Siah1b), mRNA. 
X NM_009173.1 -1,82 -1,18 0,0441 0,5724 
ILMN_2496163 S LOC1000441
65 




XM_001471936.1 -1,83 1,00 0,0412 NA 
ILMN_2597469 S LOC544904 PREDICTED: Mus musculus 
similar to idiotypic anti-NP 
IgG(1) heavy chain V-D-J 
(LOC544904), mRNA. 
XM_914633.2 -1,83 -1,03 0,0087 0,8567 
ILMN_2642339 S Slc1a2 Mus musculus solute 2 NM_011393.2 -1,83 -1,48 0,0295 0,0836 




















2 (Slc1a2), transcript 
















2 NM_030135.2 -1,84 -1,33 0,0231 0,3423 
ILMN_2667091 S Ppp1r3c Mus musculus protein 
phosphatase 1, regulatory 
(inhibitor) subunit 3C 
(Ppp1r3c), mRNA. 
NM_016854.2 -1,84 -2,03 0,0250 0,0025 
ILMN_2686700 S Abca8a Mus musculus ATP-binding 
cassette, sub-family A 
(ABC1), member 8a 
(Abca8a), mRNA. 
NM_153145.3 -1,86 -1,49 0,0273 0,0263 
ILMN_1227403 S Rtn4rl1 Mus musculus 
reticulon 4 receptor-
like 1 (Rtn4rl1), 
mRNA. 
11 NM_177708.5 -1,86 -1,14 0,0408 0,5632 
ILMN_2739843 S Metrn   NM_133719 -1,86 -1,55 0,0242 0,0103 
ILMN_2945940 S Rapgef4 Mus musculus Rap 
guanine nucleotide 
exchange factor 
(GEF) 4 (Rapgef4), 
mRNA. 
2 NM_019688.1 -1,87 1,00 0,0059 0,9792 
ILMN_2945348 S Glrx Mus musculus 
glutaredoxin (Glrx), 
mRNA. 
13 NM_053108.2 -1,87 -1,65 0,0007 0,0159 
ILMN_1231720 S Zfp385a Mus musculus zinc 
finger protein 385A 
(Zfp385a), mRNA. 
15 NM_013866.2 -1,87 -1,25 0,0445 0,0699 
ILMN_3064283 I Pde4dip Mus musculus 3 NM_001039376.1 -1,87 -1,40 0,0494 0,0498 




















variant 1, mRNA. 
ILMN_2961216 S Slco2a1 Mus musculus solute carrier 
organic anion transporter 
family, member 2a1 
(Slco2a1), mRNA. 
NM_033314.2 -1,89 -2,49 0,0181 0,0053 
ILMN_2692927 S Srd5a1   NM_175283.2 -1,89 -1,85 0,0148 0,0008 




variant 3, mRNA. 
10 NM_001003910.1 -1,89 -1,22 0,0016 0,5165 








X NM_001033472.2 -1,89 -1,11 0,0380 0,5816 
ILMN_2918732 S Ugt3a1 Mus musculus UDP 
glycosyltransferases 
3 family, polypeptide 
A1 (Ugt3a1), mRNA. 
15 NM_207216.1 -1,90 -1,35 0,0136 0,1093 
ILMN_2678355 S Amigo2 Mus musculus 
adhesion molecule 
with Ig like domain 2 
(Amigo2), mRNA. 
15 NM_178114.3 -1,90 -1,83 0,0478 0,0094 
ILMN_1236522 S Cbr1 Mus musculus 
carbonyl reductase 1 
(Cbr1), mRNA. 
16 NM_007620.2 -1,90 -1,57 0,0204 0,0010 
ILMN_1256103 S Ccbl2 Mus musculus 
cysteine conjugate-
beta lyase 2 (Ccbl2), 
mRNA. 
3 NM_173763.3 -1,90 -2,18 0,0090 0,0140 
ILMN_1241208 S C030017I19Rik  AK047722 -1,90 -1,32 0,0017 0,3939 
ILMN_2685203 S Mrgprg Mus musculus MAS-
related GPR, 
member G (Mrgprg), 
mRNA. 
7 NM_203492.2 -1,91 -1,11 0,0001 0,7860 
















ILMN_2918317 S Adck5 Mus musculus aarF 
domain containing 
kinase 5 (Adck5), 
mRNA. 
15 NM_172960.1 -1,91 -1,03 0,0257 0,8920 




1 NM_001081079.1 -1,91 -1,64 0,0248 0,0026 
ILMN_2436561 S Tmem19 Mus musculus 
transmembrane protein 19 
(Tmem19), mRNA. 
NM_133683.3 -1,92 -2,68 0,0220 0,0011 





1 NM_010476.3 -1,92 -1,38 0,0254 0,0392 




14 NM_178747.2 -1,93 -1,99 0,0071 0,0001 
ILMN_3138743 A Acsl3 Mus musculus acyl-
CoA synthetase 
long-chain family 
member 3 (Acsl3), 
transcript variant 1, 
mRNA. 
1 NM_028817.2 -1,93 -2,27 0,0491 0,0037 
ILMN_1227386 S Aig1 Mus musculus 
androgen-induced 1 
(Aig1), mRNA. 
10 NM_025446.1 -1,93 -1,40 0,0491 0,1299 
ILMN_1222039 S Dhx58 Mus musculus 
DEXH (Asp-Glu-X-
His) box polypeptide 
58 (Dhx58), mRNA. 
11 NM_030150.2 -1,93 -1,42 0,0144 0,1396 
ILMN_1218662 S Tpp2   AK040859 -1,94 1,10 0,0321 0,4063 
ILMN_1213148 S Slc2a8 Mus musculus solute 
carrier family 2, 
(facilitated glucose 
transporter), member 
8 (Slc2a8), mRNA. 
2 NM_019488.4 -1,95 -1,35 0,0196 0,0194 
ILMN_2535846 S LOC383738  XM_357217.1 -1,95 -1,74 0,0182 0,0671 
ILMN_1240671 S LOC382058  XM_356133.1 -1,96 1,09 0,0381 0,7865 
























19 NM_001013820.2 -1,96 -1,54 0,0452 0,0018 
ILMN_1250776 S Arhgap6   AK048162 -1,97 -1,88 0,0365 0,0219 
ILMN_2605819 S Egln3 Mus musculus EGL 
nine homolog 3 (C. 
elegans) (Egln3), 
mRNA. 
12 NM_028133.1 -2,00 -1,44 0,0365 0,0202 
ILMN_2691067 S Dhdds Mus musculus 
dehydrodolichyl diphosphate 
synthase (Dhdds), mRNA. 
NM_026144.4 -2,01 -1,15 0,0158 0,5467 
ILMN_2531212 S LOC232619  XM_145207.2 -2,01 -1,17 0,0206 0,3675 
ILMN_2961221 S Slco2a1 Mus musculus solute carrier 
organic anion transporter 
family, member 2a1 
(Slco2a1), mRNA. 
NM_033314.2 -2,01 -1,90 0,0310 0,0010 
ILMN_1214193 S D430006M22Rik  AK084896 -2,01 -1,24 0,0454 0,5527 
ILMN_1254358 S Igfbp5 Mus musculus 
insulin-like growth 
factor binding protein 
5 (Igfbp5), mRNA. 
1 NM_010518.2 -2,02 1,01 0,0348 0,9504 








2 NM_173180.3 -2,03 -1,04 0,0422 0,9115 
ILMN_2521965 S Slc30a3   NM_011773 -2,04 -1,70 0,0173 0,0748 
ILMN_2900617 S Tle6 Mus musculus 
transducin-like 




10 NM_053254.2 -2,04 -1,22 0,0082 0,1901 
















ILMN_2761046 S Slc25a33 Mus musculus solute 
carrier family 25, 
member 33 
(Slc25a33), mRNA. 
4 NM_027460.2 -2,05 -1,13 0,0238 0,4411 
ILMN_2671435 S LOC223672  XM_128064.4 -2,06 -3,17 0,0153 0,0025 
ILMN_2627733 S Slc46a3 Mus musculus solute 
carrier family 46, 
member 3 (Slc46a3), 
mRNA. 
5 NM_027872.3 -2,06 -2,41 0,0068 0,0144 
ILMN_1257220 S Mfn2 PREDICTED: Mus musculus 
mitofusin 2, transcript variant 
9 (Mfn2), mRNA. 








19 NM_177002.2 -2,07 -1,52 0,0442 0,0025 
ILMN_1258442 S Adh4 Mus musculus 
alcohol 
dehydrogenase 4 
(class II), pi 
polypeptide (Adh4), 
mRNA. 





segment, Chr 16, 













8 NM_197988.1 -2,12 -1,45 0,0079 0,0267 
ILMN_3123195 A Slc1a2 Mus musculus solute carrier 
family 1 (glial high affinity 
glutamate transporter), 
member 2 (Slc1a2), transcript 
variant 1, mRNA. 
NM_001077514.1 -2,12 -1,57 0,0160 0,0508 
















ILMN_2617625 S Cyp2b9 Mus musculus 
cytochrome P450, 
family 2, subfamily b, 
polypeptide 9 
(Cyp2b9), mRNA. 
7 NM_010000.2 -2,14 96,77 0,0007 0,0006 
ILMN_2723190 S Guca1a Mus musculus 
guanylate cyclase 
activator 1a (retina) 
(Guca1a), mRNA. 
17 NM_008189.2 -2,15 -1,69 0,0466 0,1557 
ILMN_2569894 S D630011D02Rik  AK052644 -2,16 -1,26 0,0297 0,2902 
ILMN_1218127 S Pcp4l1 PREDICTED: Mus 
musculus Purkinje 
cell protein 4-like 1 
(Pcp4l1), mRNA. 
1 XM_484933.5 -2,17 -1,23 0,0244 0,4392 
ILMN_2484679 S Prei4 Mus musculus 
preimplantation 
protein 4 (Prei4), 
transcript variant 4, 
mRNA. 
2 NM_001042672.1 -2,17 -1,21 0,0368 0,2502 
ILMN_2793806 S Mug2 Mus musculus 
murinoglobulin 2 
(Mug2), mRNA. 
6 NM_008646.1 -2,20 -1,91 0,0244 0,0001 
ILMN_3076439 I Slc1a2 Mus musculus solute 




2 (Slc1a2), transcript 
variant 2, mRNA. 
2 NM_001077515.1 -2,21 -1,56 0,0030 0,0811 
ILMN_2686513 S Cbara1   NM_144822.1 -2,21 -1,21 0,0292 0,2849 
ILMN_2634667 S Mep1b   NM_008586 -2,23 -1,14 0,0384 0,4226 




5 NM_001039678.1 -2,25 -1,59 0,0305 0,0171 
ILMN_2692527 S 5730593N15Rik  NM_175263 -2,28 -1,76 0,0482 0,0232 
ILMN_1250358 S Acot8 Mus musculus acyl-
CoA thioesterase 8 
(Acot8), mRNA. 
2 NM_133240.1 -2,28 2,11 0,0249 0,0376 
ILMN_2793062 S Rasl11b Mus musculus RAS-
like, family 11, 
5 NM_026878.1 -2,29 -1,63 0,0298 0,0925 


















ILMN_2658355 S Ugt3a2 Mus musculus UDP 
glycosyltransferases 
3 family, polypeptide 
A2 (Ugt3a2), mRNA. 
15 NM_144845.3 -2,30 -1,69 0,0071 0,0026 
ILMN_2986051 S Ccbl1 Mus musculus 
cysteine conjugate-
beta lyase 1 (Ccbl1), 
mRNA. 
2 NM_172404.2 -2,32 -1,75 0,0132 0,0125 
ILMN_1243129 S Slc11a2   AK049856 -2,33 -1,40 0,0117 0,0190 
ILMN_2749717 S Bcl3 Mus musculus B-cell 
leukemia/lymphoma 
3 (Bcl3), mRNA. 
7 NM_033601.1 -2,34 -2,62 0,0336 0,0169 
ILMN_2614432 S Egfr   NM_207655.1 -2,34 -1,71 0,0170 0,0153 
ILMN_2685043 S Mug2 Mus musculus murinoglobulin 
2 (Mug2), mRNA. 
NM_008646.3 -2,34 -2,30 0,0331 0,0011 
ILMN_2598103 S Emp2 Mus musculus 
epithelial membrane 
protein 2 (Emp2), 
mRNA. 
16 NM_007929.2 -2,35 -1,77 0,0158 0,2209 
ILMN_2683613 S Nlk Mus musculus nemo 
like kinase (Nlk), 
mRNA. 
11 NM_008702.2 -2,39 -1,30 0,0468 0,5149 
ILMN_3143404 A Mup2 Mus musculus major 
urinary protein 2 
(Mup2), transcript 
variant 1, mRNA. 
4 NM_008647.3 -2,39 1,07 0,0340 0,1440 
ILMN_1242024 S Setd4 Mus musculus SET 
domain containing 4 
(Setd4), mRNA. 
16 NM_145482.2 -2,40 -1,38 0,0009 0,2990 
ILMN_1217352 S EG381806 Mus musculus predicted 
gene, EG381806 (EG381806) 
on chromosome 6. 









4 NM_001009550.1 -2,44 -4,37 0,0212 0,0001 
ILMN_2819424 S Prhoxnb Mus musculus 5 NM_001039678.1 -2,45 -1,56 0,0056 0,0366 



















ILMN_2433848 S Slco2a1   NM_033314 -2,46 -2,41 0,0112 0,0039 
ILMN_1221533 S 5830445I20Rik  AK030893 -2,47 -1,02 0,0260 0,8993 
ILMN_3125606 A D12Ertd647e Mus musculus DNA 
segment, Chr 12, 
ERATO Doi 647, 
expressed 
(D12Ertd647e), 
transcript variant 5, 
mRNA. 
12 NM_194069.1 -2,52 -2,77 0,0015 0,0037 




variant 1, mRNA. 
11 NM_207655.2 -2,53 -1,95 0,0211 0,0078 
ILMN_2814865 S Qpct Mus musculus glutaminyl-
peptide cyclotransferase 
(glutaminyl cyclase) (Qpct), 
mRNA. 
NM_027455.1 -2,60 -1,52 0,0014 0,0392 
ILMN_2881620 S Nfe2 Mus musculus 
nuclear factor, 
erythroid derived 2 
(Nfe2), mRNA. 
15 NM_008685.2 -2,63 -1,43 0,0329 0,2186 
ILMN_1254902 S Rdh9 Mus musculus retinol 
dehydrogenase 9 
(Rdh9), mRNA. 
10 NM_153133.2 -2,68 -2,44 0,0043 0,0040 
ILMN_2711948 S LOC1000476
19 
PREDICTED: Mus musculus 
similar to solute carrier family 
7 (cationic amino acid 
transporter, y+ system), 
member 5 (LOC100047619), 
misc RNA. 
XR_033736.1 -2,71 -1,63 0,0055 0,0710 




18 NM_175164.4 -2,71 -3,74 0,0055 0,0283 
ILMN_2622856 S Apol9b Mus musculus 
apolipoprotein L 9b 
(Apol9b), mRNA. 
15 NM_173743.3 -2,77 -4,34 0,0077 0,0001 
















ILMN_2976211 S Cyp2b23 Mus musculus 
cytochrome P450, 
family 2, subfamily b, 
polypeptide 23 
(Cyp2b23), mRNA. 
7 NM_001081148.1 -2,77 23,54 0,0033 0,0027 
ILMN_2681232 S D12Ertd647e Mus musculus DNA 
segment, Chr 12, 
ERATO Doi 647, 
expressed 
(D12Ertd647e), 
transcript variant 4, 
mRNA. 
12 NM_194068.1 -2,81 -3,14 0,0011 0,0095 
ILMN_2618176 S Socs3 Mus musculus 
suppressor of 
cytokine signaling 3 
(Socs3), mRNA. 
11 NM_007707.2 -2,84 -1,33 0,0248 0,5701 





6 NM_011146.2 -2,86 -1,25 0,0353 0,2762 




member 3 (Abcc3), 
mRNA. 
11 NM_029600.3 -2,87 -2,22 0,0116 0,0109 
ILMN_2684316 S P2ry1 Mus musculus purinergic 
receptor P2Y, G-protein 
coupled 1 (P2ry1), mRNA. 
NM_008772.4 -2,89 1,11 0,0137 0,5978 
ILMN_2623735 S Ccbl1 Mus musculus 
cysteine conjugate-
beta lyase 1 (Ccbl1), 
mRNA. 
2 NM_172404.2 -2,91 -1,87 0,0295 0,0051 
ILMN_1246137 S 1810005K13Rik   -2,97 -3,14 0,0176 0,0019 





14 NM_207131.1 -3,05 -4,66 0,0050 0,0032 
ILMN_2696026 S Npr2 Mus musculus 4 NM_173788.3 -3,10 -2,45 0,0141 0,0233 

















receptor 2 (Npr2), 
mRNA. 
ILMN_3000236 S F11 Mus musculus 
coagulation factor XI 
(F11), mRNA. 
8 NM_028066.1 -3,23 -2,99 0,0002 0,0044 




variant 2, mRNA. 
11 NM_007912.4 -3,25 -1,76 0,0020 0,0005 
ILMN_1239293 S Sulf2 Mus musculus 
sulfatase 2 (Sulf2), 
mRNA. 
2 NM_028072.4 -3,29 -4,12 0,0085 0,0016 
ILMN_3138904 A Ntrk2 Mus musculus 
neurotrophic tyrosine 
kinase, receptor, 
type 2 (Ntrk2), 
transcript variant 1, 
mRNA. 
13 NM_001025074.1 -3,29 1,12 0,0148 0,4226 
ILMN_2609762 S F11 Mus musculus 
coagulation factor XI 
(F11), mRNA. 
8 NM_028066.1 -3,32 -3,41 0,0000 0,0003 
ILMN_1225528 S Trib3 Mus musculus 
tribbles homolog 3 
(Drosophila) (Trib3), 
mRNA. 
2 NM_175093.2 -3,34 -4,74 0,0366 0,0366 




variant 2, mRNA. 
11 NM_007912.4 -3,37 -1,77 0,0025 0,0140 
ILMN_1257851 S LOC384273  XM_357532.1 -3,43 -2,41 0,0041 0,0189 
ILMN_1241818 S Cyp2c54 Mus musculus 
cytochrome P450, 
family 2, subfamily c, 
polypeptide 54 
(Cyp2c54), mRNA. 
19 NM_206537.1 -3,44 -1,71 0,0065 0,0162 
ILMN_1241496 S 9030024J15Rik   -3,45 -1,82 0,0049 0,0238 
ILMN_1220301 S Cebpe Mus musculus 
CCAAT/enhancer 
14 NM_207131.1 -3,52 -2,91 0,0062 0,0065 



















ILMN_1226469 S Cyp2g1 Mus musculus 
cytochrome P450, 
family 2, subfamily g, 
polypeptide 1 
(Cyp2g1), mRNA. 
7 NM_013809.1 -3,62 -1,74 0,0179 0,1810 
ILMN_1243228 S Il1rap Mus musculus 
interleukin 1 receptor 
accessory protein 
(Il1rap), transcript 
variant 2, mRNA. 
16 NM_134103.1 -3,75 -4,43 0,0065 0,0013 
ILMN_2744879 S Dnaic1 Mus musculus 
dynein, axonemal, 
intermediate chain 1 
(Dnaic1), mRNA. 
4 NM_175138.3 -3,77 -2,05 0,0366 0,2189 
ILMN_1227404 S C8b Mus musculus 
complement 
component 8, beta 
polypeptide (C8b), 
mRNA. 
4 NM_133882.2 -3,78 -1,62 0,0201 0,0063 
ILMN_2740465 S Il1rap Mus musculus 
interleukin 1 receptor 
accessory protein 
(Il1rap), transcript 
variant 1, mRNA. 
16 NM_008364.1 -3,84 -4,28 0,0011 0,0004 
ILMN_2621752 S Irf5 Mus musculus interferon 
regulatory factor 5 (Irf5), 
mRNA. 
NM_012057.3 -3,94 -4,74 0,0017 0,0096 
ILMN_2641201 S Sp5 Mus musculus trans-
acting transcription 
factor 5 (Sp5), 
mRNA. 
2 NM_022435.2 -4,00 -1,78 0,0108 0,0967 
ILMN_2504842 S Ugt1a12   NM_201644 -4,08 -3,03 0,0144 0,0017 
ILMN_2740464 S Il1rap Mus musculus 
interleukin 1 receptor 
accessory protein 
(Il1rap), transcript 
variant 1, mRNA. 
16 NM_008364.1 -4,09 -4,08 0,0014 0,0013 
ILMN_2931918 S 4432416J03R Mus musculus 9 NM_030069.1 -4,14 -2,26 0,0014 0,0067 

























1 NM_009539.2 -4,28 -4,36 0,0146 0,0001 
ILMN_1236044 S F11 Mus musculus 
coagulation factor XI 
(F11), mRNA. 
8 NM_028066.1 -4,28 -3,90 0,0002 0,0006 




10 NM_016847.2 -4,41 -4,74 0,0058 0,0047 
ILMN_2903945 S Gadd45g Mus musculus 
growth arrest and 
DNA-damage-
inducible 45 gamma 
(Gadd45g), mRNA. 
13 NM_011817.1 -4,50 -3,37 0,0418 0,1872 
ILMN_2424150 S 1500017E21Rik   -4,60 -3,72 0,0316 0,0057 
ILMN_1226650 S Il1rap Mus musculus 
interleukin 1 receptor 
accessory protein 
(Il1rap), transcript 
variant 2, mRNA. 









4 NM_001012323.1 -4,71 -1,45 0,0164 0,0374 
ILMN_1227225 S Trim28 Mus musculus 
tripartite motif protein 
28 (Trim28), mRNA. 
7 NM_011588.2 -5,36 -5,15 0,0078 0,0013 
ILMN_1254622 S Pcp4l1 PREDICTED: Mus 
musculus Purkinje 
cell protein 4-like 1 
(Pcp4l1), mRNA. 
1 XM_484933.5 -5,48 -5,02 0,0176 0,0123 
ILMN_2654582 S Cyp2c44 Mus musculus 19 NM_001001446.2 -5,56 -5,41 0,0012 0,0006 

















family 2, subfamily c, 
polypeptide 44 
(Cyp2c44), mRNA. 
ILMN_2706269 S Hspb1 Mus musculus heat 
shock protein 1 
(Hspb1), mRNA. 
5 NM_013560.1 -5,72 -4,47 0,0077 0,0002 
ILMN_2601215 S Cyp7b1 Mus musculus 
cytochrome P450, 
family 7, subfamily b, 
polypeptide 1 
(Cyp7b1), mRNA. 
3 NM_007825.3 -6,20 -10,15 0,0072 0,0053 
ILMN_2959757 S Cyp2g1 Mus musculus 
cytochrome P450, 
family 2, subfamily g, 
polypeptide 1 
(Cyp2g1), mRNA. 
7 NM_013809.1 -6,32 -1,92 0,0053 0,0556 




14 NM_010024.1 -6,61 -7,50 0,0047 0,0017 




10 NM_016847.2 -7,01 -3,27 0,0002 0,0108 
ILMN_2592166 S Mup4 Mus musculus major 
urinary protein 4 
(Mup4), mRNA. 
4 NM_008648.1 -7,24 -1,12 0,0276 0,4385 





1 NM_009539.2 -9,00 -6,08 0,0093 0,0132 




14 NM_010024.2 -9,25 -8,57 0,0107 0,0165 
ILMN_1214531 S Cyp2b13 Mus musculus 
cytochrome P450, 
family 2, subfamily b, 
polypeptide 13 
7 NM_007813.1 -13,91 12,62 0,0030 0,0124 






















1 (Rarres1), mRNA. 
3 XM_001475793.1 -15,35 -48,08 0,0005 0,0005 
 
















Genes dysregulated in KAP1-mutant males  
Illumina ID Probe Type Gene Symbol Description Chr Representativ
e ID 
Fold Change -  
Female KO vs 
WT 
Fold Change -  
Male KO vs WT 
Welch t-test p-
value - Female 
KO vs WT 
Welch t-test p-
value - Male 
KO vs WT 
ILMN_2617625 S Cyp2b9 Mus musculus 
cytochrome 





7 NM_010000.2 -2,14 96,77 0,0007 0,0006 
ILMN_2976211 S Cyp2b23 Mus musculus 
cytochrome 







-2,77 23,54 0,0033 0,0027 
ILMN_2594926 S Cyp2b10 Mus musculus 
cytochrome 







7 NM_009999.3 3,44 14,47 0,0843 0,0036 
ILMN_1214531 S Cyp2b13 Mus musculus 
cytochrome 





7 NM_007813.1 -13,91 12,62 0,0030 0,0124 




17 NM_008552.3 14,02 9,27 0,0052 0,0046 























6 NM_178373.3 1,05 9,03 0,1990 0,0109 
ILMN_2708477 S Spink3   NM_009258.2 38,60 8,38 0,0061 0,0211 
ILMN_1236308 S LOC268730  XM_193754.2 4,61 5,80 0,0323 0,0045 
ILMN_2671165 S Krt23 Mus musculus 
keratin 23 
(Krt23), mRNA. 
11 NM_033373.1 17,72 5,60 0,0008 0,0013 




6 NM_153508.2 2,02 5,39 0,0876 0,0150 




2 NM_153558.1 1,00 5,33 NA 0,0044 





15 NM_013872.2 4,58 4,46 0,0041 0,0017 











X NM_177920.4 4,49 4,32 0,0234 0,0196 





19 NM_007809.2 2,58 4,26 0,0133 0,0380 


















ILMN_1238820 S LOC332788  XM_285750.2 4,06 4,19 0,0447 0,0060 






16 NM_019413.2 4,36 4,16 0,0002 0,0135 
ILMN_1230375 S LOC383125  XM_356890.1 5,02 4,14 0,0063 0,0042 
ILMN_1215877 S Extl1   NM_019578 2,79 4,07 0,0065 0,0016 
ILMN_2709810 S Acnat2 Mus musculus 
acyl-coenzyme 





4 NM_145368.2 1,22 4,04 0,2550 0,0310 





15 NM_013872.1 4,33 3,75 0,0037 0,0099 
ILMN_2728134 S 5430433G21Ri
k 
PREDICTED: Mus musculus 





8,51 3,74 0,0026 0,0021 
ILMN_1258330 S LOC384348  XM_357593.1 4,01 3,65 0,0040 0,0033 












2,33 3,53 0,0117 0,0023 
ILMN_2738699 S Cblc Mus musculus 
Casitas B-
lineage 
7 NM_023224.4 3,99 3,47 0,0003 0,0039 


















ILMN_2535582 S LOC382707  XM_356635.1 2,18 3,46 0,0242 0,0120 







17 NM_207649.1 6,40 3,36 0,0007 0,0010 
ILMN_1245604 S LOC10004421
8 






1,15 3,36 0,2877 0,0115 
ILMN_2960044 S Cyp4a31 Mus musculus 
cytochrome 





4 NM_201640.1 1,20 3,34 0,3381 0,0018 
ILMN_1251714 S LOC673589 PREDICTED: Mus musculus 
similar to Cytochrome P450 
2B9 (CYPIIB9) (Testosterone 
16-alpha hydroxylase) (P450-




-1,41 3,28 0,2528 0,0333 








9 NM_207668.2 3,48 3,20 0,0763 0,0216 






9 NM_028060.2 1,28 3,07 0,4226 0,0030 























16 NM_019466.3 1,18 3,04 0,2006 0,0250 







2 NM_015730.4 4,82 3,03 0,0557 0,0086 





14 NM_009160.1 3,42 2,99 0,0325 0,0038 
ILMN_3156010 A Pdzrn3 Mus musculus 
PDZ domain 
containing 
RING finger 3 
(Pdzrn3), 
mRNA. 
6 NM_018884.1 1,39 2,97 0,2234 0,0006 




4 NM_019578.1 1,74 2,96 0,1884 0,0017 








1,26 2,95 0,5932 0,0066 
ILMN_1229577 S Sstr2   NM_009217.1 1,00 2,89 0,4226 0,0019 





19 NM_172637.1 1,33 2,87 0,3034 0,0116 
















ILMN_1230557 S D2Wsu81e Mus musculus 
DNA segment, 






2 NM_172660.2 2,50 2,85 0,0283 0,0081 









4 NM_145711.3 -1,02 2,84 0,9047 0,0008 











1,17 2,83 0,4507 0,0064 







12 NM_025522.1 1,90 2,73 0,0124 0,0145 
ILMN_2526851 S LOC227393  XM_129965.3 1,55 2,66 0,0905 0,0016 
ILMN_2535566 S LOC382691  XM_356627.1 3,40 2,63 0,0144 0,0292 






15 NM_010741.2 2,86 2,63 0,0292 0,0295 
















ILMN_1228211 S Tff2 Mus musculus 




17 NM_009363.3 3,68 2,61 0,0253 0,0093 
ILMN_2627328 S Dnase2a   NM_010062 2,93 2,60 0,0058 0,0069 






18 NM_013594.1 2,57 2,59 0,0001 0,0003 






7 NM_153577.2 2,18 2,59 0,1689 0,0007 






18 NM_013594.1 1,17 2,59 0,4226 0,0023 
ILMN_2591264 S Orm2   NM_011016.1 2,03 2,59 0,0635 0,0010 
ILMN_2894396 S Tmem184a Mus musculus 
transmembran
e protein 184a 
(Tmem184a), 
mRNA. 
5 NM_144914.2 2,29 2,59 0,0015 0,0032 
ILMN_2589350 S Ces5 Mus musculus 
carboxylestera
se 5 (Ces5), 
mRNA. 
8 NM_172759.2 1,92 2,57 0,0336 0,0011 
ILMN_1219079 S Serpina9   NM_027997 1,13 2,56 0,2006 0,0169 





6 NM_198622.1 4,36 2,56 0,0222 0,0262 
ILMN_2673332 S 9530051K01Rik  XM_485965 1,03 2,54 0,4226 0,0431 
















ILMN_1233860 S Tmem162 Mus musculus 
transmembran
e protein 162 
(Tmem162), 
mRNA. 
7 NM_175240.3 1,93 2,50 0,1674 0,0045 





17 NM_027032.2 7,63 2,50 0,0168 0,0165 







11 NM_010299.2 2,73 2,48 0,0030 0,0001 






9 NM_021481.2 1,97 2,48 0,0120 0,0292 
ILMN_1213456 S Dhrs7 Mus musculus 
dehydrogenase/reductase 
(SDR family) member 7 
(Dhrs7), mRNA. 
NM_025522.3 1,91 2,46 0,0126 0,0026 





10 NM_009040.2 2,09 2,44 0,0072 0,0041 








3 NM_031368.3 1,63 2,44 0,2478 0,0199 
ILMN_1214448 S 9030619P08Ri Mus musculus 15 NM_00103972 2,00 2,41 0,0298 0,0209 



























1,00 2,41 NA 0,0433 





7 NM_026741.2 1,97 2,40 0,0008 0,0128 
ILMN_2747820 S Dhrs7 Mus musculus 
dehydrogenase/reductase 
(SDR family) member 7 
(Dhrs7), mRNA. 
NM_025522.3 1,93 2,38 0,0246 0,0078 
ILMN_2665715 S Gstt3 Mus musculus 
glutathione S-
transferase, 
theta 3 (Gstt3), 
mRNA. 
10 NM_133994.3 1,63 2,36 0,0614 0,0064 
ILMN_3023451 I LOC433801 Mus musculus similar to RIKEN 




4,20 2,35 0,0301 0,0028 
ILMN_2573694 S B430219N15Rik  AK046650 1,19 2,32 0,2725 0,0454 
ILMN_2421890 S Acacb   NM_133904 1,08 2,30 0,7034 0,0028 
ILMN_2852756 S Rbm26 Mus musculus 
RNA binding 
motif protein 26 
(Rbm26), 
mRNA. 
14 NM_134077.4 1,43 2,30 0,2228 0,0074 




14 NM_010210.2 2,74 2,28 0,0103 0,0303 
ILMN_2756311 S 1110006G14Ri
k 
PREDICTED: Mus musculus 
RIKEN cDNA 1110006G14 
gene (1110006G14Rik), 
mRNA. 
XM_989766.1 1,88 2,27 0,0913 0,0432 
ILMN_2772070 S Dio1 Mus musculus 4 NM_007860.3 1,24 2,26 0,2097 0,0012 


















type I (Dio1), 
mRNA. 






3 NM_178418.2 1,32 2,25 0,3300 0,0383 




2 NM_011675.1 2,38 2,22 0,0729 0,0030 









11 XM_181343.5 2,10 2,18 0,0532 0,0009 
ILMN_1242689 S LOC236371  XM_135639.2 1,75 2,15 0,0319 0,0463 
ILMN_2440679 S D1Ertd471e   2,87 2,14 0,0070 0,0029 
ILMN_2435392 S Dnase2a   NM_010062 1,52 2,13 0,0647 0,0056 





2 NM_133240.1 -2,28 2,11 0,0249 0,0376 




2 NM_011125.2 -1,05 2,11 0,9182 0,0481 
ILMN_1256676 S Ddah1   NM_026993 1,44 2,11 0,0673 0,0013 
ILMN_2774690 S LOC677317 PREDICTED: Mus musculus 
similar to Mod1 protein, 




1,66 2,11 0,0341 0,0123 





















9 NM_019922.1 2,07 2,09 0,1233 0,0071 








13 NM_027307.4 2,28 2,09 0,0059 0,0148 
ILMN_2771219 S LOC669660 PREDICTED: Mus musculus 
similar to PDZ and LIM domain 
protein 5 (Enigma homolog) 
(Enigma-like PDZ and LIM 
domains protein) (LOC669660), 
mRNA. 
XM_976375.1 -1,14 2,09 0,6798 0,0243 
ILMN_2693827 S Atg16l2 PREDICTED: 
Mus musculus 
autophagy 









1,70 2,09 0,0846 0,0077 
ILMN_3077758 I Unc93a Mus musculus 
unc-93 




17 NM_199252.1 1,48 2,08 0,2698 0,0125 







1,01 2,08 0,4226 0,0037 
ILMN_1212612 S Rcan2 Mus musculus 17 NM_207649.1 4,17 2,07 0,0305 0,0082 






















ILMN_2647234 S Dio1 Mus musculus 
deiodinase, 
iodothyronine, 
type I (Dio1), 
mRNA. 
4 NM_007860.3 1,49 2,07 0,0488 0,0131 






16 NM_015775.2 2,51 2,07 0,0047 0,0288 






14 NM_025341.3 1,39 2,05 0,3100 0,0045 
ILMN_1249246 S LOC384022  XM_357375.1 1,74 2,04 0,0619 0,0298 
ILMN_2453351 S Ugt1a5   NM_201643 -1,35 2,03 0,0381 0,0042 
ILMN_2543657 S Mbd1   AK007371 1,08 2,03 0,4226 0,0077 
ILMN_1213185 S LOC385792  XM_358947.1 1,81 1,99 0,0183 0,0374 






1 NM_172513.2 2,50 1,99 0,0256 0,0096 
ILMN_2486267 S Ube2l6 Mus musculus 
ubiquitin-
conjugating 
enzyme E2L 6 
(Ube2l6), 
mRNA. 





11 NM_152807.1 1,34 1,98 0,1415 0,0169 


























19 NM_144869.2 2,93 1,98 0,0230 0,0031 







7 NM_030566.2 1,07 1,98 0,7842 0,0031 
ILMN_2432458 S Top3b Mus musculus 
topoisomerase 
(DNA) III beta 
(Top3b), 
mRNA. 
16 NM_011624.2 1,19 1,97 0,6004 0,0014 
ILMN_2800813 S Cabc1 Mus musculus 
chaperone, 
ABC1 activity 
of bc1 complex 






1 NM_023341.2 -1,05 1,97 0,9076 0,0437 
ILMN_1242101 S Tmem184a Mus musculus 
transmembran
e protein 184a 
(Tmem184a), 
mRNA. 
5 NM_144914.2 1,35 1,97 0,4601 0,0275 




4 NM_024198.3 2,17 1,97 0,0835 0,0257 
























1,11 1,96 0,3974 0,0147 
ILMN_2619107 S Lgals1   NM_008495.1 1,82 1,95 0,0762 0,0275 







17 NM_026053.1 1,38 1,95 0,3240 0,0276 








6 NM_007836.1 1,31 1,94 0,1390 0,0400 
ILMN_2619307 S LOC10004705
2 
PREDICTED: Mus musculus 




-1,02 1,93 0,9522 0,0269 










16 NM_144852.3 1,61 1,93 0,3069 0,0454 








6 NM_007836.1 1,93 1,93 0,0223 0,0116 























X NM_008062.2 1,19 1,93 0,5889 0,0066 





15 NM_029787.2 1,38 1,93 0,1552 0,0037 






7 NM_183257.1 -1,30 1,92 0,0658 0,0338 
ILMN_2479690 S 1700048O20Rik   1,14 1,92 0,4292 0,0284 






7 NM_133351.1 2,21 1,91 0,0884 0,0164 
ILMN_2974720 S Igf2bp2 Mus musculus 
insulin-like 





16 NM_183029.1 -1,02 1,91 0,9223 0,0013 
ILMN_2707079 S Sirt5 Mus musculus 




homolog) 5 (S. 
cerevisiae) 
(Sirt5), mRNA. 
13 NM_178848.3 1,70 1,90 0,0001 0,0171 
ILMN_1226366 S Uck1 Mus musculus 2 NM_011675.1 1,24 1,90 0,4036 0,0105 


























9 NM_177460.3 1,66 1,89 0,0469 0,0052 







17 NM_018887.3 1,40 1,89 0,3073 0,0356 





9 NM_008615.1 1,54 1,88 0,0022 0,0364 
ILMN_1256967 S AI875142    1,38 1,88 0,0044 0,0084 
ILMN_2544603 S 2610015J01Rik  AK011403 1,32 1,87 0,2269 0,0095 






17 NM_030561.2 -1,04 1,87 0,8735 0,0213 






7 NM_010915.2 1,20 1,87 0,5047 0,0206 





4 NM_133880.1 1,80 1,86 0,0849 0,0031 
















e 2 (Pafah2), 
mRNA. 






1 NM_172513.2 1,49 1,86 0,0131 0,0142 
ILMN_2734598 S Cyp2a5 Mus musculus cytochrome 
P450, family 2, subfamily a, 
polypeptide 5 (Cyp2a5), mRNA. 
NM_007812.4 1,73 1,85 0,0036 0,0101 







-1,08 1,84 0,5914 0,0051 







1,57 1,84 0,0782 0,0404 








1 NM_013701.1 -1,28 1,84 0,1180 0,0009 








3 NM_031368.3 1,21 1,84 0,4226 0,0176 






1,13 1,83 0,7828 0,0159 





















ILMN_2786567 S Nln Mus musculus 
neurolysin 
(metallopeptida
se M3 family) 
(Nln), mRNA. 
13 NM_029447.1 1,38 1,83 0,0292 0,0203 








13 NM_008247.2 1,70 1,83 0,0860 0,0072 
ILMN_2685569 S Pus10 Mus musculus 
pseudouridylat





11 NM_028304.2 -1,01 1,82 0,9547 0,0231 








1 NM_027534.1 1,05 1,81 0,7034 0,0370 








11 NM_029704.1 -1,11 1,81 0,4226 0,0207 
























2 NM_026091.2 1,49 1,80 0,0288 0,0482 







10 NM_025705.2 -1,04 1,80 0,8895 0,0070 



















6 NM_173737.2 2,14 1,80 0,1254 0,0002 






2 NM_177157.4 1,63 1,80 0,0136 0,0114 






17 NM_010109.2 1,67 1,80 0,0141 0,0162 




















factor (GEF) 5 
(Rapgef5), 
mRNA. 
12 NM_175930.4 -1,02 1,80 0,9267 0,0391 















1,52 1,80 0,3077 0,0271 
ILMN_1244281 S D2Wsu81e Mus musculus 
DNA segment, 






2 NM_172660.2 2,17 1,79 0,0119 0,0463 
ILMN_1225154 S Ugt1a5 Mus musculus UDP 
glucuronosyltransferase 1 
family, polypeptide A5 
(Ugt1a5), mRNA. 
NM_201643.2 -1,13 1,79 0,1843 0,0022 










3,13 1,79 0,0185 0,0098 
ILMN_2636832 S Cyb5r3 Mus musculus 15 NM_029787.2 1,29 1,79 0,0781 0,0096 






























11 XM_126343.5 1,94 1,78 0,0007 0,0012 
ILMN_2524167 S 4631434O19Rik  XM_130859.4 1,27 1,78 0,3249 0,0302 
ILMN_1249959 S Tom1l1 Mus musculus 
target of myb1-
like 1 (chicken) 
(Tom1l1), 
mRNA. 
11 NM_028011.2 1,27 1,78 0,4917 0,0334 
ILMN_1246471 S Ctr9 Mus musculus Ctr9, Paf1/RNA 
polymerase II complex 
component, homolog (S. 
cerevisiae) (Ctr9), mRNA. 
NM_009431.2 1,11 1,78 0,4226 0,0236 
ILMN_2711045 S Sirt5 Mus musculus 




homolog) 5 (S. 
cerevisiae) 
(Sirt5), mRNA. 
13 NM_178848.3 1,76 1,78 0,0188 0,0023 






1 NM_011267.2 1,64 1,77 0,2333 0,0052 





4 NM_133880.1 1,46 1,77 0,2301 0,0482 
















e 2 (Pafah2), 
mRNA. 
ILMN_2701991 S Dscr1   NM_019466.2 1,38 1,77 0,1032 0,0263 






11 NM_033475.2 1,02 1,75 0,9673 0,0171 
ILMN_1218317 S LOC10004861
6 
PREDICTED: Mus musculus 
similar to regulatory factor X 




-1,00 1,75 0,9973 0,0319 
ILMN_2856157 S Pgam1 Mus musculus 
phosphoglycer
ate mutase 1 
(Pgam1), 
mRNA. 
19 NM_023418.2 1,89 1,75 0,0057 0,0051 
ILMN_2506757 S LOC10004828
0 
PREDICTED: Mus musculus 
similar to crooked legs 
CG14938-PB, transcript variant 
1 (LOC100048280), mRNA. 
XM_00148014
9.1 
1,25 1,75 0,1552 0,0047 
ILMN_1223710 S Pmm1   AK013805 1,05 1,75 0,4226 0,0329 
ILMN_2720429 S Pla2g6 Mus musculus 
phospholipase 
A2, group VI 
(Pla2g6), 
mRNA. 
15 NM_016915.3 2,25 1,74 0,0550 0,0057 





10 NM_023304.1 1,22 1,74 0,4373 0,0155 






6 NM_175098.2 1,26 1,74 0,4847 0,0497 
ILMN_1246446 S Lrrc59 Mus musculus 
leucine rich 
11 NM_133807.1 1,01 1,74 0,4226 0,0122 




















ILMN_1252131 S Klk1b27 Mus musculus kallikrein 1-
related peptidase b27 
(Klk1b27), mRNA. 
NM_020268.3 1,00 1,74 NA 0,0368 






3 NM_025663.2 1,42 1,73 0,1664 0,0252 





9 NM_020559.1 1,16 1,73 0,6807 0,0402 
ILMN_3029727 I Shf Mus musculus Src homology 2 




1,53 1,73 0,0990 0,0187 
ILMN_2704285 S Pklr Mus musculus 
pyruvate 
kinase liver 
and red blood 
cell (Pklr), 
mRNA. 











2 NM_023057.1 -1,04 1,72 0,8200 0,0076 
ILMN_2711410 S Pmf1 Mus musculus polyamine-
modulated factor 1 (Pmf1), 
mRNA. 
NM_025928.3 1,26 1,72 0,2476 0,0133 
ILMN_2592496 S Dis3l2 Mus musculus 
DIS3 mitotic 
control 
1 NM_153530.1 1,70 1,71 0,0550 0,0307 


























7 NM_011068.1 1,06 1,71 0,6988 0,0230 
ILMN_2587638 S C230080E09Rik  AK082664 1,03 1,71 0,4226 0,0224 






14 NM_183208.2 1,00 1,70 NA 0,0354 





2 NM_009564.1 -1,10 1,70 0,7100 0,0167 





17 NM_194269.1 1,21 1,70 0,4155 0,0324 
ILMN_1222599 S Zubr1 PREDICTED: 
Mus musculus 
zinc finger, 







1,19 1,70 0,1202 0,0350 






2 NM_010274.2 1,30 1,69 0,1206 0,0084 





















ILMN_1229267 S Cyp2a5 Mus musculus cytochrome 
P450, family 2, subfamily a, 
polypeptide 5 (Cyp2a5), mRNA. 
NM_007812.4 1,91 1,69 0,0062 0,0055 




2 NM_011675.1 1,19 1,69 0,1231 0,0075 









2 NM_172665.3 1,11 1,68 0,2267 0,0013 
ILMN_1237758 S LOC382153  XM_356249.1 1,53 1,68 0,0385 0,0268 
ILMN_2470799 S LOC10004757
9 
PREDICTED: Mus musculus 
similar to transmembrane 




-1,13 1,68 0,6603 0,0482 






13 NM_146041.2 1,59 1,68 0,0529 0,0068 





2 NM_146342.1 1,02 1,68 0,9567 0,0240 




19 NM_177319.2 -1,18 1,68 0,5925 0,0074 























8 NM_029965.2 -1,16 1,68 0,3834 0,0228 
ILMN_2684388 S 1700034H14Ri
k 
Mus musculus RIKEN cDNA 
1700034H14 gene 
(1700034H14Rik), mRNA. 
NM_025969.3 -1,08 1,68 0,7722 0,0039 









5 NM_028211.1 1,29 1,67 0,4455 0,0074 





9 NM_019922.1 2,04 1,67 0,2502 0,0087 
ILMN_2673889 S Mcm7   NM_008568.1 -1,10 1,67 0,6605 0,0317 















2 NM_173397.2 1,24 1,66 0,1275 0,0240 
ILMN_2561986 S A130046C05Rik  AK037745 -1,11 1,66 0,6982 0,0222 




protein like 1 
12 NM_00104333
5.1 
1,25 1,65 0,5136 0,0031 





























ILMN_1241980 S Cdc2l1 Mus musculus 
cell division 
cycle 2-like 1 
(Cdc2l1), 
mRNA. 
4 NM_007661.3 1,25 1,65 0,2525 0,0289 
ILMN_1245424 S Ppat PREDICTED: Mus musculus 
phosphoribosyl pyrophosphate 
amidotransferase, transcript 
variant 8 (Ppat), mRNA. 
XM_00100288
6.2 
1,61 1,65 0,0801 0,0031 
ILMN_1256633 S LOC10004556
7 
PREDICTED: Mus musculus 





1,48 1,65 0,0027 0,0101 
ILMN_2760979 S Tgfbr2 Mus musculus 
transforming 
growth factor, 





9 NM_009371.2 1,09 1,65 0,4032 0,0349 
ILMN_2490536 S Aldh5a1   NM_172532 1,72 1,65 0,0001 0,0000 






11 NM_026071.2 1,04 1,65 0,4226 0,0187 































19 NM_030197.1 -1,17 1,64 0,4564 0,0467 









8 NM_199323.2 1,32 1,64 0,1962 0,0067 





9 NM_175325.2 1,49 1,64 0,1288 0,0193 






7 NM_015814.2 1,25 1,64 0,5458 0,0322 










1,88 1,63 0,0057 0,0073 


























1,55 1,63 0,2831 0,0094 
ILMN_3139693 A Rab11fip5 Mus musculus 
RAB11 family 
interacting 







1,26 1,63 0,0911 0,0322 
ILMN_2517060 S 9630015D15Rik  NM_181401 1,17 1,63 0,0914 0,0259 
ILMN_2467578 S scl000416.1_19  AK049709.1 1,22 1,63 0,2613 0,0072 




2 NM_010236.1 -1,01 1,63 0,9498 0,0203 
ILMN_2598990 S Lnx2 Mus musculus 
ligand of numb-
protein X 2 
(Lnx2), mRNA. 
5 NM_080795.3 1,21 1,63 0,3681 0,0334 
ILMN_2603377 S Dnase2b Mus musculus 
deoxyribonucle
ase II beta 
(Dnase2b), 
mRNA. 
3 NM_019957.3 1,68 1,63 0,0378 0,0019 
ILMN_1244847 S Cyp2a5 Mus musculus cytochrome 
P450, family 2, subfamily a, 
polypeptide 5 (Cyp2a5), mRNA. 
NM_007812.4 1,66 1,63 0,0017 0,0014 
ILMN_2707198 S As3mt   NM_020577.1 1,32 1,62 0,0178 0,0035 






8 NM_010442.1 1,11 1,62 0,6448 0,0015 
















ILMN_2470039 S D930001I22Rik  NM_173397 1,22 1,62 0,1877 0,0040 
ILMN_2756113 S Nln Mus musculus 
neurolysin 
(metallopeptida
se M3 family) 
(Nln), mRNA. 
13 NM_029447.1 1,30 1,62 0,0720 0,0074 
ILMN_1231651 S LOC10004543
9 
PREDICTED: Mus musculus 
similar to testis-specific 




1,04 1,61 0,3894 0,0385 
ILMN_2614966 S Rab27a Mus musculus RAB27A, 
member RAS oncogene family 
(Rab27a), mRNA. 
NM_023635.4 1,82 1,61 0,0989 0,0131 
ILMN_2659415 S Atp8b2 Mus musculus 
ATPase, class 






-1,50 1,61 0,2657 0,0270 







7 XR_034036.1 -1,03 1,61 0,7930 0,0257 
ILMN_2756379 S Aqp8 Mus musculus 
aquaporin 8 
(Aqp8), mRNA. 
7 NM_007474.1 1,08 1,61 0,7983 0,0488 





3 NM_019414.2 2,47 1,60 0,0061 0,0492 
ILMN_1254631 S AI481316   XM_148986.1 1,45 1,60 0,0067 0,0046 




1 NM_008250.1 1,00 1,59 NA 0,0187 
ILMN_1232972 S Stk19 Mus musculus 
serine/threonin
17 NM_019442.3 -1,11 1,59 0,2050 0,0259 
















e kinase 19 
(Stk19), 
mRNA. 









3 NM_008418.1 1,09 1,59 0,5023 0,0484 




5 NM_008439.3 1,23 1,58 0,0362 0,0010 







1,26 1,58 0,4250 0,0320 
ILMN_2648100 S LOC676974 PREDICTED: Mus musculus 
similar to Glucose phosphate 
isomerase 1, transcript variant 
2 (LOC676974), mRNA. 
XM_00100315
4.1 
1,12 1,58 0,2030 0,0112 




8 NM_146207.1 1,36 1,58 0,1745 0,0384 





2 NM_009564.1 -1,16 1,58 0,7127 0,0192 









1,44 1,58 0,0725 0,0260 
























1,01 1,58 0,4226 0,0327 
ILMN_2472708 S 5730402C02Rik  NM_027442 1,27 1,58 0,0999 0,0409 
ILMN_1220641 S Pgrmc2 PREDICTED: Mus musculus 
progesterone receptor 
membrane component 2, 
transcript variant 3 (Pgrmc2), 
mRNA. 
XM_911696.2 1,16 1,57 0,2381 0,0065 
















17 NM_028543.1 1,75 1,57 0,1491 0,0271 







X NM_011591.2 1,00 1,57 NA 0,0147 











1,14 1,57 0,6847 0,0164 
ILMN_2933022 S Plekhb1 Mus musculus 
pleckstrin 
7 NM_013746.1 1,59 1,57 0,0259 0,0141 
























ILMN_1240471 S Retsat Mus musculus 
retinol saturase 





6 NM_026159.4 1,33 1,57 0,1602 0,0156 




6 NM_018815.1 1,42 1,57 0,0088 0,0022 
ILMN_2588055 S Actb Mus musculus actin, beta 
(Actb), mRNA. 
NM_007393.3 -1,39 1,57 0,4101 0,0281 






1 NM_144875.1 1,24 1,57 0,0029 0,0446 





e 2 (Pafah2), 
mRNA. 
4 NM_133880.1 1,38 1,57 0,1649 0,0197 





12 NM_134247.2 1,05 1,57 0,8637 0,0477 
ILMN_2721083 S Catsper2 Mus musculus 
cation channel, 
2 NM_153075.2 1,39 1,56 0,2371 0,0219 




































8 NM_028018.1 -1,17 1,56 0,6951 0,0146 






15 NM_153407.2 1,00 1,56 NA 0,0377 
ILMN_2641032 S Epb7.2   NM_013515.1 1,39 1,56 0,3715 0,0121 
ILMN_2667550 S Ppil1 Mus musculus peptidylprolyl 
isomerase (cyclophilin)-like 1 
(Ppil1), mRNA. 
NM_026845.3 1,21 1,56 0,1534 0,0233 






1 NR_002858.1 1,00 1,56 NA 0,0301 








4 NM_026172.3 -1,27 1,56 0,1870 0,0002 


















ILMN_3004221 S Cyp2u1 Mus musculus cytochrome 
P450, family 2, subfamily u, 
polypeptide 1 (Cyp2u1), mRNA. 
NM_027816.1 1,42 1,56 0,2161 0,0341 
ILMN_2653696 S Abcd3   NM_008991 -1,01 1,56 0,8749 0,0001 
ILMN_3159131 A Cyp2a5 Mus musculus 
cytochrome 





7 NM_007812.2 1,30 1,55 0,0051 0,0198 








1 NM_145079.2 1,27 1,55 0,2118 0,0002 





13 NM_175654.1 1,29 1,55 0,4080 0,0021 
ILMN_2606825 S Cmah   NM_007717.1 1,34 1,55 0,2183 0,0381 
ILMN_2497067 S Zmynd11   NM_144516.1 1,59 1,55 0,1019 0,0378 
ILMN_2549039 S 4930487N19Rik  AK015640 1,28 1,54 0,2014 0,0105 




9 NM_026599.4 1,00 1,54 NA 0,0492 
ILMN_3031099 I Coq10b Mus musculus 
coenzyme Q10 








1,46 1,54 0,2963 0,0372 
























-1,16 1,54 0,5043 0,0336 








1,42 1,54 0,1325 0,0096 
ILMN_2776283 S Tcea3   NM_011542 1,89 1,54 0,0021 0,0002 
ILMN_2628271 S LOC10004596
7 
PREDICTED: Mus musculus 
hypothetical protein 
LOC100045967 
(LOC100045967), misc RNA. 
XR_032154.1 1,25 1,54 0,0140 0,0014 





18 NM_207255.1 1,21 1,54 0,0477 0,0292 






15 NM_010271.2 -1,68 1,54 0,1134 0,0076 






9 NM_011876.3 -1,04 1,54 0,8387 0,0314 







18 NM_009280.1 1,14 1,53 0,5846 0,0081 
















ILMN_1229225 S D030016E14Rik  NM_177240.2 1,11 1,53 0,7878 0,0151 















17 NM_026633.1 1,25 1,53 0,1879 0,0048 
ILMN_1226755 S E030007N04Rik  AK086880 -1,16 1,53 0,4226 0,0364 





e 2 (Pafah2), 
mRNA. 
4 NM_133880.1 1,79 1,53 0,0068 0,0063 















6 NM_026637.3 1,25 1,53 0,2699 0,0146 
ILMN_1231810 S Ube2e1 Mus musculus 
ubiquitin-
conjugating 





14 NM_009455.3 1,16 1,53 0,4633 0,0027 



















PREDICTED: Mus musculus 




1,49 1,52 0,0510 0,0498 










5 NM_011816.3 1,88 1,52 0,0265 0,0397 
ILMN_2688888 S Gca Mus musculus 
grancalcin 
(Gca), mRNA. 
2 NM_145523.3 1,00 1,52 NA 0,0088 




X NM_016675.3 1,19 1,52 0,1092 0,0045 
ILMN_1232601 S Cyb561 Mus musculus cytochrome b-
561 (Cyb561), mRNA. 
NM_007805.4 1,46 1,52 0,2309 0,0452 






4 XM_884359.3 -1,01 1,52 0,8992 0,0027 




15 NM_023475.2 1,17 1,52 0,0913 0,0400 




7 NM_025408.2 1,54 1,52 0,0026 0,0061 
ILMN_1258834 S Chd1   AK042202 1,00 1,52 NA 0,0100 
ILMN_3068197 I Slc12a2 Mus musculus 
solute carrier 
family 12, 
18 NM_009194.2 -1,12 1,52 0,6279 0,0375 


























7 NM_022024.2 1,40 1,51 0,0974 0,0135 
ILMN_1244836 S Tmem41a Mus musculus transmembrane 
protein 41a (Tmem41a), 
mRNA. 
NM_025693.3 1,43 1,51 0,0490 0,0228 
ILMN_1228641 S E330022B15Rik  AK054393 1,40 1,51 0,2252 0,0028 






7 NM_013808.3 -1,03 1,51 0,9086 0,0027 





6 NM_024251.3 1,10 1,51 0,6631 0,0212 







2 NM_009849.1 -1,01 1,51 0,9870 0,0041 




11 NM_027827.2 1,26 1,51 0,5146 0,0458 





7 NM_011068.1 -1,01 1,50 0,9640 0,0015 

















ILMN_1234241 S Mrap Mus musculus melanocortin 2 
receptor accessory protein 
(Mrap), mRNA. 
NM_029844.3 1,30 1,50 0,0257 0,0411 




2 NM_010236.1 1,16 1,50 0,4169 0,0214 




18 NM_201600.2 -1,22 1,50 0,2962 0,0391 





2 NM_133240.1 1,08 1,50 0,5759 0,0016 




11 NM_031871.1 1,29 1,50 0,2652 0,0274 
ILMN_2633096 S Gstm6 Mus musculus 
glutathione S-
transferase, 
mu 6 (Gstm6), 
mRNA. 
3 NM_008184.3 -1,29 -1,50 0,1662 0,0006 








17 NM_030597.2 -1,10 -1,50 0,6440 0,0342 
ILMN_2558520 S A430104D08Rik  AK040509 1,20 -1,50 0,4467 0,0433 
ILMN_2461871 S scl0003651.1_17  XM_356680.1 1,01 -1,50 0,9389 0,0422 





15 NM_026759.2 -1,52 -1,51 0,1997 0,0091 

















ILMN_1230318 S Cbs   NM_144855.1 -1,26 -1,51 0,1218 0,0447 
ILMN_1243997 S A530052I19Rik  AK040969 -1,16 -1,51 0,4218 0,0005 
ILMN_1245352 S Dclk3 Mus musculus doublecortin-like 
kinase 3 (Dclk3), mRNA. 









7 NM_175250.4 -1,44 -1,51 0,0350 0,0089 
ILMN_1245382 S Tmem102 Mus musculus transmembrane 




-1,44 -1,51 0,3992 0,0032 
ILMN_2751948 S Hist2h2aa1  NM_013549 -1,79 -1,51 0,0087 0,0440 







5 NM_023142.1 -1,05 -1,52 0,7285 0,0256 
ILMN_2622209 S Rnaseh2b Mus musculus 
ribonuclease 
H2, subunit B 
(Rnaseh2b), 
mRNA. 
14 NM_026001.2 -1,25 -1,52 0,4106 0,0055 





2 NM_146587.2 1,11 -1,52 0,7410 0,0305 







11 NM_175263.3 -2,49 -1,52 0,0532 0,0098 
ILMN_1245112 S Aldh16a1 Mus musculus 
aldehyde 
7 NM_145954.1 -1,18 -1,52 0,3467 0,0009 































13 NM_133219.1 -1,25 -1,52 0,0962 0,0110 






11 NM_011308.2 1,00 -1,52 NA 0,0075 




4 NM_007919.2 2,39 -1,52 0,0086 0,0460 
ILMN_1214703 S Nme7 Mus musculus 
non-metastatic 









1 NM_138314.2 -1,18 -1,52 0,1499 0,0193 





3 NM_145394.2 -1,36 -1,52 0,3129 0,0269 

























19 NM_177002.2 -2,07 -1,52 0,0442 0,0025 




6 NM_146173.2 -1,90 -1,52 0,1206 0,0383 
ILMN_2814865 S Qpct Mus musculus glutaminyl-
peptide cyclotransferase 
(glutaminyl cyclase) (Qpct), 
mRNA. 
NM_027455.1 -2,60 -1,52 0,0014 0,0392 
ILMN_2774563 S Mug4 PREDICTED: Mus musculus 
murinoglobulin 4 (Mug4), misc 
RNA. 
XR_035729.1 -1,53 -1,52 0,0107 0,0017 






19 XR_034247.1 -1,05 -1,52 0,7901 0,0184 
ILMN_2631423 S H2-Ab1 Mus musculus 
histocompatibili
ty 2, class II 
antigen A, beta 
1 (H2-Ab1), 
mRNA. 
17 NM_207105.2 1,24 -1,53 0,3786 0,0357 





1 NM_025424.1 -1,45 -1,53 0,1003 0,0339 
ILMN_1241278 S Rdh11   NM_021557 -1,60 -1,53 0,0983 0,0312 
ILMN_2607675 S LOC641240 PREDICTED: Mus musculus 
similar to MHC class II antigen 
beta chain (LOC641240), 
mRNA. 
XM_918601.3 1,20 -1,53 0,5256 0,0481 
ILMN_2982764 S Ugt2a3 Mus musculus 5 NM_028094.1 -1,23 -1,53 0,1292 0,0110 





























18 NM_011937.1 1,06 -1,53 0,8088 0,0121 





3 NM_013549.1 -1,35 -1,53 0,0046 0,0016 
ILMN_2449986 S EG640530 PREDICTED: Mus musculus 
predicted gene, EG640530 
(EG640530), mRNA. 
XM_917532.3 -1,78 -1,53 0,0236 0,0025 







4 NM_013497.3 -1,08 -1,54 0,5089 0,0494 
ILMN_2714222 S Elovl2 Mus musculus 
elongation of 







13 NM_019423.1 -1,57 -1,54 0,0423 0,0427 
ILMN_2540844 S LOC385583  XM_358296.1 -1,08 -1,54 0,8243 0,0109 





-1,96 -1,54 0,0452 0,0018 






















ILMN_2651831 S 2310039L15Rik  XM_290098.1 1,02 -1,54 0,9582 0,0085 






4 NM_011673.2 -1,23 -1,54 0,3586 0,0102 
ILMN_1236517 S Il18 Mus musculus 
interleukin 18 
(Il18), mRNA. 
9 NM_008360.1 -1,35 -1,54 0,0841 0,0040 





9 NM_021567.2 -1,22 -1,55 0,0979 0,0066 
ILMN_1244515 S Tmem50b Mus musculus 
transmembran
e protein 50B 
(Tmem50b), 
mRNA. 
16 NM_030018.3 -1,48 -1,55 0,0040 0,0222 














18 NM_028341.2 1,33 -1,55 0,0932 0,0390 




10 NM_015817.2 -1,66 -1,55 0,0108 0,0163 



















ILMN_2739843 S Metrn   NM_133719 -1,86 -1,55 0,0242 0,0103 






17 XM_139904.6 -1,12 -1,55 0,6830 0,0085 














18 NM_028341.2 1,24 -1,56 0,1172 0,0313 
ILMN_1236107 S Ogfrl1 PREDICTED: Mus musculus 
opioid growth factor receptor-
like 1 (Ogfrl1), mRNA. 
XM_973033.1 -1,18 -1,56 0,2199 0,0025 







-2,45 -1,56 0,0056 0,0366 
ILMN_1252204 S Sepw1 Mus musculus 
selenoprotein 
W, muscle 1 
(Sepw1), 
mRNA. 
7 NM_009156.2 -1,25 -1,56 0,3405 0,0062 
ILMN_2775885 S Calm2   NM_007589 -1,28 -1,56 0,2201 0,0469 
ILMN_2776278 S Ly6e   NM_008529 -1,37 -1,56 0,0372 0,0114 
ILMN_2454339 S 2310010J17Rik   1,13 -1,57 0,7299 0,0444 
ILMN_1229329 S 2700049H19Rik   -1,30 -1,57 0,0141 0,0158 
ILMN_1236522 S Cbr1 Mus musculus 
carbonyl 
16 NM_007620.2 -1,90 -1,57 0,0204 0,0010 


















ILMN_2668778 S Use1 Mus musculus 
unconventional 
SNARE in the 






8 NM_029768.3 -1,21 -1,57 0,4874 0,0443 
ILMN_1236588 S Car1 Mus musculus carbonic 
anhydrase 1 (Car1), transcript 
variant 1, mRNA. 
NM_009799.4 -1,54 -1,57 0,3076 0,0269 




6 NM_177296.4 -1,13 -1,58 0,6544 0,0153 




12 NM_024223.1 -1,77 -1,58 0,0216 0,0101 




3 NM_027810.2 -1,51 -1,58 0,1335 0,0464 
ILMN_2645662 S Tmem86a Mus musculus transmembrane 
protein 86A (Tmem86a), 
mRNA. 
NM_026436.3 -1,35 -1,58 0,2195 0,0216 









-1,14 -1,59 0,2258 0,0108 







-2,25 -1,59 0,0305 0,0171 






















14 NM_145741.2 -1,62 -1,59 0,0947 0,0100 
ILMN_2546596 S 2310076E21Rik  AK010195 1,60 -1,59 0,1854 0,0385 








X NM_019668.3 -1,02 -1,60 0,8608 0,0095 
ILMN_2520174 S 6530402F18Rik   -1,01 -1,60 0,9751 0,0313 
ILMN_2776922 S Glrx1   NM_053108 -1,70 -1,60 0,0051 0,0030 





e repeats 3 
(Ifit3), mRNA. 
19 NM_010501.1 -1,65 -1,60 0,1051 0,0010 
ILMN_2678755 S Rpl22l1 Mus musculus 
ribosomal 
protein L22 like 
1 (Rpl22l1), 
mRNA. 
3 NM_026517.2 1,00 -1,60 NA 0,0450 
ILMN_3123759 A Gas2l1 Mus musculus 
growth arrest-





11 NM_144560.2 -1,57 -1,60 0,1403 0,0114 
ILMN_1219717 S Sort1 Mus musculus 
sortilin 1 
(Sort1), mRNA. 
3 NM_019972.2 -1,69 -1,60 0,0386 0,0184 
ILMN_2921383 S Serpina6 Mus musculus 
serine (or 
12 NM_007618.2 -1,13 -1,60 0,6448 0,0411 
























PREDICTED: Mus musculus 
RIKEN cDNA 1700007B13 
gene (1700007B13Rik), mRNA. 
XM_913577.2 -1,46 -1,61 0,0754 0,0231 










3 NM_009709.3 -1,03 -1,61 0,4226 0,0142 





10 NM_145152.3 -1,59 -1,61 0,0646 0,0152 
ILMN_1255490 S D930042J21Rik  AK086627 1,23 -1,61 0,3553 0,0489 
ILMN_2511089 S Ugcg   NM_011673 -1,37 -1,61 0,2051 0,0074 
ILMN_1242167 S Hist2h2aa2 Mus musculus histone cluster 
2, H2aa2 (Hist2h2aa2), mRNA. 
NM_178212.1 -1,32 -1,62 0,0305 0,0061 
ILMN_1253316 S Polr3f   NM_027417 -1,22 -1,62 0,1544 0,0061 








10 NM_019725.1 -1,19 -1,62 0,3079 0,0260 
ILMN_1249158 S Nfs1 Mus musculus 
nitrogen 
fixation gene 1 
(S. cerevisiae) 
2 NM_010911.1 1,03 -1,62 0,9436 0,0203 






















17 NM_010220.2 -1,61 -1,62 0,1200 0,0049 
ILMN_1240839 S Golt1a Mus musculus 
golgi transport 




1 NM_026680.4 -1,69 -1,62 0,0204 0,0390 






4 NM_133882.2 -3,78 -1,62 0,0201 0,0063 







13 NM_010872.1 -1,25 -1,63 0,2952 0,0325 
ILMN_2771331 S Hao1 Mus musculus 
hydroxyacid 
oxidase 1, liver 
(Hao1), mRNA. 
2 NM_010403.2 -1,33 -1,63 0,0501 0,0070 





4 NM_008649.2 -1,73 -1,63 0,0962 0,0021 
ILMN_1246194 S LOC667370 PREDICTED: Mus musculus 
similar to interferon-induced 
protein with tetratricopeptide 




-1,98 -1,63 0,2163 0,0253 
ILMN_1247377 S Mpeg1 Mus musculus 
macrophage 
19 NM_010821.1 1,03 -1,63 0,7867 0,0036 






























17 NM_013585.2 -1,39 -1,64 0,0895 0,0247 













1,01 -1,64 0,9517 0,0068 
ILMN_1213448 S LOC669658 PREDICTED: Mus musculus 
similar to melanoma antigen 
(LOC669658), mRNA. 
XM_976371.1 -1,15 -1,64 0,7626 0,0393 








9 NM_027418.1 -1,04 -1,64 0,8435 0,0393 
ILMN_3145814 A Ogfrl1 Mus musculus 
opioid growth 
factor receptor-




-1,91 -1,64 0,0248 0,0026 
















ILMN_2445548 S C330006A16Rik   -1,60 -1,64 0,0655 0,0152 




X NM_177201.2 -1,62 -1,64 0,2233 0,0404 
ILMN_2591782 S LOC10004831
3 
PREDICTED: Mus musculus 
similar to ABC transporter, 




-1,14 -1,65 0,4946 0,0131 
ILMN_2945348 S Glrx Mus musculus 
glutaredoxin 
(Glrx), mRNA. 
13 NM_053108.2 -1,87 -1,65 0,0007 0,0159 
ILMN_1221501 S 5730469M10Ri
k 
Mus musculus RIKEN cDNA 
5730469M10 gene 
(5730469M10Rik), mRNA. 
NM_027464.3 -1,40 -1,65 0,0377 0,0001 
ILMN_1230893 S LOC10004554
2 
PREDICTED: Mus musculus 
similar to FERMRhoGEF 
(Arhgef) and pleckstrin domain 




-1,47 -1,65 0,0412 0,0203 
ILMN_2686069 S Gyg Mus musculus 
glycogenin 
(Gyg), mRNA. 
3 NM_013755.2 1,10 -1,66 0,3850 0,0035 
ILMN_1229183 S Nubp1   AK020876 1,04 -1,66 0,7813 0,0373 







5 NM_011677.2 -1,01 -1,66 0,9697 0,0350 
ILMN_2939681 S Lyzs Mus musculus 
lysozyme 
(Lyzs), mRNA. 
10 NM_017372.2 2,13 -1,66 0,1608 0,0408 
ILMN_3127932 A Tmem77 Mus musculus 
transmembran





3 NM_026013.2 1,01 -1,67 0,9233 0,0141 






















7 NM_023258.3 1,03 -1,67 0,8423 0,0293 
ILMN_1242134 S D330003G07Rik  AK052176 -1,08 -1,67 0,8474 0,0397 





11 NM_008300.3 1,00 -1,67 NA 0,0239 
ILMN_2907964 S Crim2 Mus musculus 
cysteine rich 
BMP regulator 





-1,65 -1,67 0,0061 0,0125 
ILMN_1256128 S LOC10004646
9 
PREDICTED: Mus musculus 
similar to Plec1 protein, 




-1,18 -1,68 0,3992 0,0156 
ILMN_2587863 I 2410091N08Rik  XM_146886.1 1,80 -1,68 0,0332 0,0266 
ILMN_2538010 S LOC385989  XM_359026.1 1,06 -1,68 0,8313 0,0233 






8 NM_021506.2 1,05 -1,68 0,8022 0,0317 





12 NM_021557.2 -1,61 -1,68 0,1680 0,0121 
ILMN_2658355 S Ugt3a2 Mus musculus 
UDP 
glycosyltransfe
rases 3 family, 
polypeptide A2 
(Ugt3a2), 
15 NM_144845.3 -2,30 -1,69 0,0071 0,0026 























1 NM_016702.2 1,14 -1,69 0,4531 0,0165 





19 NM_013541.1 1,08 -1,69 0,3134 0,0170 











15 NM_008732.1 -1,03 -1,69 0,4727 0,0478 
ILMN_1245637 S A930015C19Rik  AK044477 -1,15 -1,69 0,5418 0,0114 






1 NM_010518.2 -1,32 -1,70 0,3234 0,0453 
ILMN_1259808 S LOC386235  XM_359130.1 1,25 -1,70 0,6603 0,0487 




6 NM_008285.3 -1,14 -1,70 0,7318 0,0067 





homolog 1 (C. 
10 XM_359260.3 1,15 -1,70 0,5908 0,0361 



















ILMN_1253156 S LOC381502  XM_355459.1 1,17 -1,70 0,5419 0,0406 





3 NM_175662.1 -1,35 -1,71 0,0657 0,0030 
ILMN_2576431 S Lpin2   AK048657 -1,13 -1,71 0,5947 0,0192 
ILMN_2614432 S Egfr   NM_207655.1 -2,34 -1,71 0,0170 0,0153 
ILMN_2683113 S Ang1   NM_007447 -1,29 -1,71 0,4913 0,0346 
ILMN_1249220 S Col6a3 Mus musculus procollagen, 
type VI, alpha 3 (Col6a3), 
mRNA. 
NM_009935.1 -1,02 -1,71 0,9631 0,0084 
ILMN_1241818 S Cyp2c54 Mus musculus 
cytochrome 





19 NM_206537.1 -3,44 -1,71 0,0065 0,0162 
ILMN_1251504 S Cyp4v3 Mus musculus 
cytochrome 





8 NM_133969.2 -1,45 -1,71 0,0755 0,0050 








7 NM_008434.2 1,09 -1,71 0,7113 0,0122 




14 NM_146317.1 -1,02 -1,72 0,9262 0,0012 


























2 NM_145529.2 -1,06 -1,72 0,7464 0,0381 






2 NM_016719.1 -1,66 -1,72 0,0906 0,0018 







17 NM_144855.2 -1,26 -1,72 0,1464 0,0127 
ILMN_1233339 S Nme4 Mus musculus 
non-metastatic 







17 NM_019731.1 -1,05 -1,73 0,4226 0,0033 








4 NM_007671.2 -1,99 -1,73 0,0543 0,0290 
ILMN_2447658 S Rgp1 Mus musculus 4 NM_172866.3 -1,35 -1,73 0,0863 0,0274 






















ILMN_2570875 S E130309L16Rik  AK053808 1,35 -1,74 0,1121 0,0109 





13 NM_013548.2 1,07 -1,74 0,8186 0,0133 







-1,47 -1,75 0,3304 0,0205 
ILMN_2663281 S 2310045A20Ri
k 
Mus musculus RIKEN cDNA 
2310045A20 gene 
(2310045A20Rik), mRNA. 
NM_172710.3 -1,09 -1,75 0,8041 0,0324 






2 NM_172404.2 -2,32 -1,75 0,0132 0,0125 







11 NM_007912.4 -3,25 -1,76 0,0020 0,0005 





1 NM_015780.1 -1,14 -1,76 0,4485 0,0081 
ILMN_2692527 S 5730593N15Rik  NM_175263 -2,28 -1,76 0,0482 0,0232 
ILMN_2500533 S Amigo2 Mus musculus 
adhesion 
15 NM_178114.3 -2,29 -1,76 0,0688 0,0311 

















Ig like domain 
2 (Amigo2), 
mRNA. 








1,07 -1,77 0,6234 0,0091 
ILMN_3160137 S Aldoc Mus musculus aldolase C, 
fructose-bisphosphate (Aldoc), 
mRNA. 
NM_009657.3 -2,01 -1,77 0,0930 0,0038 







11 NM_007912.4 -3,37 -1,77 0,0025 0,0140 
ILMN_2739797 S Olfr427 Mus musculus olfactory 
receptor 427 (Olfr427), mRNA. 
NM_207158.1 1,18 -1,77 0,7244 0,0213 
ILMN_2773835 S LOC670044 PREDICTED: Mus musculus 
similar to Mothers against 
decapentaplegic homolog 6 
(SMAD 6) (Mothers against 
DPP homolog 6) (Smad6) (Mad 
homolog 7) (LOC670044), 
mRNA. 
XM_978692.1 -1,78 -1,78 0,0472 0,0379 








3 NM_144900.1 -1,68 -1,78 0,0029 0,0017 




19 NM_011255.2 -1,33 -1,79 0,0764 0,0077 

























4 NM_025582.3 -1,80 -1,79 0,0057 0,0077 
ILMN_1221684 S Scp2 Mus musculus 
sterol carrier 
protein 2, liver 
(Scp2), mRNA. 
4 NM_011327.2 -1,41 -1,80 0,1605 0,0104 
ILMN_1245298 S D130050K19Rik  AK051465 -1,21 -1,80 0,5128 0,0107 






8 NM_025436.1 -1,32 -1,80 0,5180 0,0161 
ILMN_1221822 S Rbm12 Mus musculus 
RNA binding 





2 NM_170598.2 -1,48 -1,81 0,2246 0,0053 
ILMN_1224485 S Eme2   XM_128555.4 1,29 -1,82 0,5598 0,0376 
ILMN_1220307 S LOC10004602
5 
PREDICTED: Mus musculus 
similar to mKIAA1230 protein, 




-1,60 -1,82 0,0104 0,0106 
ILMN_1241496 S 9030024J15Rik   -3,45 -1,82 0,0049 0,0238 
ILMN_2678355 S Amigo2 Mus musculus 
adhesion 
molecule with 
Ig like domain 
2 (Amigo2), 
mRNA. 
15 NM_178114.3 -1,90 -1,83 0,0478 0,0094 
ILMN_1221272 S LOC381294 PREDICTED: Mus musculus 
complement factor H-like 
(LOC381294), mRNA. 
XM_981749.1 -1,51 -1,83 0,1699 0,0160 
























14 NM_027464.1 -1,35 -1,83 0,1043 0,0060 





7 NM_009302.2 -1,24 -1,84 0,2126 0,0147 
ILMN_1237259 S Mug-ps1    -1,88 -1,85 0,0661 0,0049 
ILMN_2692927 S Srd5a1   NM_175283.2 -1,89 -1,85 0,0148 0,0008 
ILMN_2468635 S MJ-1000-77_495   -1,02 -1,86 0,9231 0,0368 




3 NM_019911.2 1,55 -1,87 0,1027 0,0455 








9 NM_029792.1 1,15 -1,87 0,5683 0,0150 






2 NM_172404.2 -2,91 -1,87 0,0295 0,0051 
ILMN_1250776 S Arhgap6   AK048162 -1,97 -1,88 0,0365 0,0219 





8 NM_138656.1 -2,03 -1,88 0,4237 0,0465 
ILMN_3150724 A Ppfibp1 Mus musculus 
PTPRF 
interacting 
6 NM_026221.1 -1,08 -1,88 0,7505 0,0167 





















ILMN_1215824 S Sec22l2   NM_133704.3 -1,13 -1,89 0,6216 0,0107 






10 NM_029875.2 -1,29 -1,89 0,0711 0,0083 
ILMN_1243763 S B230349N02Rik  AK046195 1,11 -1,89 0,5293 0,0408 
ILMN_2900042 S Gba2 Mus musculus 
glucosidase 
beta 2 (Gba2), 
mRNA. 
4 NM_172692.1 -2,01 -1,89 0,1192 0,0225 
ILMN_2772077 S Bok   NM_016778 -1,08 -1,90 0,5668 0,0020 
ILMN_2961221 S Slco2a1 Mus musculus solute carrier 
organic anion transporter 
family, member 2a1 (Slco2a1), 
mRNA. 
NM_033314.2 -2,01 -1,90 0,0310 0,0010 
ILMN_1258645 S 4833442A19Rik  AK029468 1,09 -1,90 0,7797 0,0456 





2 NM_146650.2 1,03 -1,91 0,9395 0,0360 




6 NM_008646.1 -2,20 -1,91 0,0244 0,0001 




10 NM_008777.2 1,03 -1,92 0,8392 0,0025 





11 NM_007377.3 -1,64 -1,92 0,0531 0,0248 
















ILMN_1214562 S 4933405P16Rik  AK016678 -1,21 -1,93 0,2980 0,0141 





4 NM_172702.1 -2,29 -1,94 0,0681 0,0159 







11 NM_207655.2 -2,53 -1,95 0,0211 0,0078 
ILMN_1230710 S C730039N23Rik  AK050344 1,79 -1,96 0,0477 0,0009 





6 NM_008645.2 -1,51 -1,96 0,0608 0,0002 




15 NM_009270.3 -1,73 -1,96 0,2189 0,0068 
ILMN_1221503 S Ccnd1   NM_007631.1 -1,97 -1,97 0,0926 0,0148 
ILMN_2740187 S LOC10004444
3 
PREDICTED: Mus musculus 
similar to cytochrome 
P450IIIA25 (LOC100044443), 
misc RNA. 
XR_030683.1 1,09 -1,97 0,7756 0,0091 
ILMN_1242082 S 4632408I12Rik  AK076276 -1,13 -1,98 0,4757 0,0055 
ILMN_1221786 S LOC383698  XM_357193.1 1,37 -1,98 0,4360 0,0352 






15 NM_172402.2 -1,08 -1,99 0,6933 0,0057 




14 NM_178747.2 -1,93 -1,99 0,0071 0,0001 





















2 NM_175093.2 -1,64 -1,99 0,0633 0,0054 
ILMN_1242911 S Hmgb1 Mus musculus 
high mobility 
group box 1 
(Hmgb1), 
mRNA. 
5 NM_010439.3 1,52 -2,00 0,2082 0,0054 








-1,67 -2,01 0,1258 0,0044 








-1,48 -2,02 0,1496 0,0042 
ILMN_2667091 S Ppp1r3c Mus musculus protein 
phosphatase 1, regulatory 
(inhibitor) subunit 3C 
(Ppp1r3c), mRNA. 
NM_016854.2 -1,84 -2,03 0,0250 0,0025 








6 NM_025336.1 -1,41 -2,06 0,4808 0,0184 




15 NM_009270.3 -1,43 -2,08 0,3056 0,0063 
ILMN_2705424 S Slc39a5 Mus musculus 
solute carrier 
family 39 
10 NM_028051.2 1,03 -2,08 0,8323 0,0039 























PREDICTED: Mus musculus 





-1,27 -2,10 0,1958 0,0090 
ILMN_2636004 S 9530064J02  XM_489200 -1,44 -2,13 0,0191 0,0000 
ILMN_2601471 S Ccnd1   NM_007631.1 -1,97 -2,14 0,0728 0,0045 









3 NM_008295.2 -3,28 -2,15 0,3152 0,0041 
ILMN_1254987 S Mbnl2 Mus musculus 
muscleblind-




14 NM_175341.4 -1,10 -2,16 0,5446 0,0033 






3 NM_173763.3 -1,90 -2,18 0,0090 0,0140 







19 NM_007811.1 -1,40 -2,19 0,4908 0,0058 
ILMN_2685157 S Abcc3 Mus musculus 
ATP-binding 
11 NM_029600.3 -2,87 -2,22 0,0116 0,0109 





































9 NM_030069.1 -4,14 -2,26 0,0014 0,0067 









1 NM_028817.2 -1,93 -2,27 0,0491 0,0037 
ILMN_1216539 S Cml4 Mus musculus 
camello-like 4 
(Cml4), mRNA. 
6 NM_023455.2 1,21 -2,27 0,2300 0,0479 











10 NM_182959.2 -2,67 -2,28 0,1045 0,0122 





















19 NM_013541.1 1,11 -2,28 0,4067 0,0000 
ILMN_2685043 S Mug2 Mus musculus murinoglobulin 2 
(Mug2), mRNA. 
NM_008646.3 -2,34 -2,30 0,0331 0,0011 
ILMN_2629191 S Cpm PREDICTED: 
Mus musculus 
carboxypeptida
se M (Cpm), 
mRNA. 
10 XM_994613.1 -1,41 -2,32 0,1738 0,0260 






3 NM_173763.3 -1,66 -2,36 0,0072 0,0010 
ILMN_2769991 S Cyp2c29 Mus musculus 
cytochrome 





19 NM_007815.3 -1,20 -2,36 0,3581 0,0098 






17 NM_146073.3 -1,68 -2,37 0,1053 0,0085 




se 2-like 1 
(Agxt2l1), 
mRNA. 
3 NM_027907.2 -1,34 -2,40 0,5417 0,0203 
ILMN_2627733 S Slc46a3 Mus musculus 
solute carrier 
family 46, 
5 NM_027872.3 -2,06 -2,41 0,0068 0,0144 



















ILMN_1257851 S LOC384273  XM_357532.1 -3,43 -2,41 0,0041 0,0189 




7 NM_007631.2 -2,24 -2,41 0,1204 0,0050 
ILMN_2433848 S Slco2a1   NM_033314 -2,46 -2,41 0,0112 0,0039 




2 NM_015792.1 -1,01 -2,41 0,9506 0,0217 
ILMN_2699052 S Nrn1 Mus musculus 
neuritin 1 
(Nrn1), mRNA. 
13 NM_153529.1 -1,57 -2,42 0,0155 0,0038 





10 NM_153133.2 -2,68 -2,44 0,0043 0,0040 





4 NM_173788.3 -3,10 -2,45 0,0141 0,0233 
ILMN_2961216 S Slco2a1 Mus musculus solute carrier 
organic anion transporter 
family, member 2a1 (Slco2a1), 
mRNA. 
NM_033314.2 -1,89 -2,49 0,0181 0,0053 




se 2-like 1 
(Agxt2l1), 
mRNA. 
3 NM_027907.1 -1,32 -2,51 0,5594 0,0069 
ILMN_2698499 S Nox4 Mus musculus NADPH oxidase 
4 (Nox4), mRNA. 
NM_015760.4 -1,33 -2,51 0,0379 0,0044 




-1,62 -2,53 0,1419 0,0105 





















ILMN_2749717 S Bcl3 Mus musculus 
B-cell 
leukemia/lymp
homa 3 (Bcl3), 
mRNA. 
7 NM_033601.1 -2,34 -2,62 0,0336 0,0169 
ILMN_1238433 S Rbp1   NM_011254.2 -1,03 -2,62 0,8852 0,0047 
ILMN_2436561 S Tmem19 Mus musculus transmembrane 
protein 19 (Tmem19), mRNA. 
NM_133683.3 -1,92 -2,68 0,0220 0,0011 
ILMN_2543285 S Elovl3   AK004901 -1,16 -2,69 0,6936 0,0399 









13 NM_177960.3 -1,98 -2,77 0,1955 0,0045 









12 NM_194069.1 -2,52 -2,77 0,0015 0,0037 
ILMN_2433990 S LOC10004834
6 
PREDICTED: Mus musculus 





-1,92 -2,88 0,1206 0,0041 





14 NM_207131.1 -3,52 -2,91 0,0062 0,0065 

























14 NM_007554.2 -1,18 -2,92 0,4679 0,0035 
ILMN_2772632 S Saa3 Mus musculus 
serum amyloid 
A 3 (Saa3), 
mRNA. 
7 NM_011315.3 -1,55 -2,96 0,2225 0,0020 
ILMN_2752545 S Lama3   XM_128926.3 1,00 -2,98 NA 0,0035 
ILMN_3000236 S F11 Mus musculus 
coagulation 
factor XI (F11), 
mRNA. 
8 NM_028066.1 -3,23 -2,99 0,0002 0,0044 








10 NM_138956.3 -1,68 -3,03 0,0026 0,0027 
ILMN_2504842 S Ugt1a12   NM_201644 -4,08 -3,03 0,0144 0,0017 




8 NM_013602.2 -1,36 -3,04 0,4390 0,0090 










-1,33 -3,12 0,5215 0,0129 
ILMN_2682207 S Elovl3 Mus musculus 
elongation of 
19 NM_007703.1 1,00 -3,12 NA 0,0383 























ILMN_1246137 S 1810005K13Rik   -2,97 -3,14 0,0176 0,0019 









12 NM_194068.1 -2,81 -3,14 0,0011 0,0095 
ILMN_2671435 S LOC223672  XM_128064.4 -2,06 -3,17 0,0153 0,0025 






10 NM_016847.2 -7,01 -3,27 0,0002 0,0108 
ILMN_2609762 S F11 Mus musculus 
coagulation 
factor XI (F11), 
mRNA. 
8 NM_028066.1 -3,32 -3,41 0,0000 0,0003 






6 NM_011909.1 -1,70 -3,43 0,0774 0,0054 
ILMN_2424150 S 1500017E21Rik   -4,60 -3,72 0,0316 0,0057 






18 NM_175164.4 -2,71 -3,74 0,0055 0,0283 
















ILMN_1236044 S F11 Mus musculus 
coagulation 
factor XI (F11), 
mRNA. 
8 NM_028066.1 -4,28 -3,90 0,0002 0,0006 






10 NM_013786.2 1,06 -4,08 0,8426 0,0003 








16 NM_008364.1 -4,09 -4,08 0,0014 0,0013 
ILMN_1239293 S Sulf2 Mus musculus 
sulfatase 2 
(Sulf2), mRNA. 
2 NM_028072.4 -3,29 -4,12 0,0085 0,0016 








16 NM_008364.1 -3,84 -4,28 0,0011 0,0004 
ILMN_2622856 S Apol9b Mus musculus 
apolipoprotein 
L 9b (Apol9b), 
mRNA. 
15 NM_173743.3 -2,77 -4,34 0,0077 0,0001 
ILMN_2677824 S Susd4 Mus musculus sushi domain 
containing 4 (Susd4), mRNA. 
NM_144796.4 -1,01 -4,35 0,4226 0,0119 






1 NM_009539.2 -4,28 -4,36 0,0146 0,0001 




























-2,44 -4,37 0,0212 0,0001 








16 NM_134103.1 -3,75 -4,43 0,0065 0,0013 





19 NM_013541.1 -1,28 -4,46 0,1887 0,0006 





5 NM_013560.1 -5,72 -4,47 0,0077 0,0002 
ILMN_1237485 S 2310040A07Ri
k 
PREDICTED: Mus musculus 
RIKEN cDNA 2310040A07 
gene (2310040A07Rik), mRNA. 
XM_912979.2 -3,47 -4,55 0,1072 0,0068 








14 NM_207131.1 -3,05 -4,66 0,0050 0,0032 




10 NM_016847.2 -4,41 -4,74 0,0058 0,0047 























2 NM_175093.2 -3,34 -4,74 0,0366 0,0366 
ILMN_2621752 S Irf5 Mus musculus interferon 
regulatory factor 5 (Irf5), 
mRNA. 
NM_012057.3 -3,94 -4,74 0,0017 0,0096 
ILMN_1254622 S Pcp4l1 PREDICTED: 
Mus musculus 
Purkinje cell 
protein 4-like 1 
(Pcp4l1), 
mRNA. 
1 XM_484933.5 -5,48 -5,02 0,0176 0,0123 





7 NM_011588.2 -5,36 -5,15 0,0078 0,0013 




15 NM_016704.1 -1,34 -5,25 0,1849 0,0092 
ILMN_1246808 S Serpine2   AK045954 -1,44 -5,26 0,2285 0,0016 
ILMN_2654582 S Cyp2c44 Mus musculus 
cytochrome 







-5,56 -5,41 0,0012 0,0006 
ILMN_2479977 S 2310040A07Ri
k 
PREDICTED: Mus musculus 
RIKEN cDNA 2310040A07 
gene (2310040A07Rik), mRNA. 
XM_912979.2 -3,72 -5,48 0,0599 0,0313 





6 NM_030687.1 -1,91 -6,05 0,0534 0,0015 

























1 NM_009539.2 -9,00 -6,08 0,0093 0,0132 




15 NM_016704.1 -1,87 -6,27 0,1022 0,0093 





19 NM_181796.2 -1,16 -6,27 0,6768 0,0005 








16 NM_134103.1 -4,68 -7,03 0,0012 0,0109 




14 NM_010024.1 -6,61 -7,50 0,0047 0,0017 
ILMN_2643513 S Asns Mus musculus asparagine 
synthetase (Asns), mRNA. 
NM_012055.3 1,00 -7,92 NA 0,0442 




14 NM_010024.2 -9,25 -8,57 0,0107 0,0165 
ILMN_2601215 S Cyp7b1 Mus musculus 
cytochrome 
P450, family 7, 
subfamily b, 
polypeptide 1 
3 NM_007825.3 -6,20 -10,15 0,0072 0,0053 





























-15,35 -48,08 0,0005 0,0005 
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Supporting Table 2. Sequences of primers used in the current study.  
Name Forward (5’-) Reverse (5’-) 
RT-qPCR 
β-actin CTAAGGCCAACCGTGAAAAGAT CACAGCCTGGATGGCTACGT 
18S rRNA CGC CGC TAG AGG TGA AAT TC CCA GTC GGC ATC GTT TAT GG 
FSP27 GAC CTC CTG AAC AAG GTC CA TAG CTG GGC TCT CTT CTT GC 
c-Cbl AAA GGA CGG CAT CTT CCT C  GAT CCT CAC GTC CTT GTC C  
Cyp17a1 TGC CCC TGG TGG GTA GTC TA CAT GCA TAT GAC CAC GTC TGG 
Cyp2a4 AGC AGG CTA CCT TCG ACT GG GCT GCT GAA GGC TAT GCC AT 
Cyp2b13 GAA CTG AGA CTA CCA GCA CCA CTC T TGA GCA TGA GCA GGA AAC CAC T 
Cyp2b9 CTG AGA CCA CAA GCG CCA C CTT GAG CAT GAG CAG GAC TCC 
Cyp2d9 AGT CTC TGG CTT AAT TCC TGA GGT T CGC AAG AGT ATC GGG AAT GC 
Cyp7b1 TGA GGT TCT GAG GCT GTG CTC TCC TGC ACT TCT CGG ATG ATG 
Elovl3 GGA CAG AGG CAC ACA CAA ACA GCG CCT ACC AGG CCT AGA AT 
GSTπ TGA GGA TGG AGA CCT CAC CC AGG TGT CTC AAG ATG GCA TTA GAT T 
Hsd3b5 AGT CCT AAG CAC TTG CCC AGT AAT CAC AGC AGC TGA GTC ACA ACA G 
KAP1 TCA GCT GGC TAC CGA CTC TAC A GGC GAG CAC GAA TCA AGG T 
Krt23 TCA AGG CTG AAA GGA TCT G CTT GAG AAA GAA CGA TTC TTC C 
Lcn13 CCA GTC ACA AGA TAC CCA G CCA TTG TTC CAG AAT ACA ACT G 
Mas1 AAG CCT CTA GCC CTC TGT CC TGG TCC ATG AGG AGT TCT TGC 
mTBP TTG ACC TAA AGA CCA TTG CAC TTC TTC TCA TGA TGA CTG CAG CAA A 
Mup1/2/6/8 GAC TTT TTC TGG AGC AAA TCC ATG GAG CAC TCT TCA TCT CTT ACA G 
Mup3 GAA GAG TGC ACC GAA ATG ACT G TGC CAG CCT TTT CTG TTT GTT 
Rarres1 CAG GAA GGT GGA CGT TTG GCG CAC GTT ACA TTA ACG GC 
RPS9 GAC CAG GAG CTA AAG TTG ATT GGA TCT TGG CCA GGG TAA ACT TGA 
Rsl1 CCT TGG GAC ATG AAG AGA C GAT CAT TGG GTA TTA TTC CTG G 
Rsl2 GTA CCC AGG AAT AAC ACC C GCC TTA CCA AAT TCT CCA C 
Slp AGG TCC GGG ACA TGG TGA ATT TG CGC ACT GTC AAC AGT TTG GAG C 
Spink3 ATG CAG TGG CGG GAT GTC CAG AAC ACA TTC ATT GGC ATA AGT AA 
STAT5a TGC GCC AGA TGC AAG TGT T CAA GTC AAT AGC ATC CCA CGG 
STAT5b GAG AAT TTG CCA GGA CGG AA CAC GCC ATC AAA CCA CTG C 
TRIM24 GAG GCC TCC GTC AAA CAG AAC GAG CCA GAG CTT CCT CGA CTT 
Zfp169 CTA TAG CCA CCT TGT CTC C AAT TCT GTC CTG GGT TCT G 
Zfp445 TCTAGAGGACCACTTGGAG GAGACAGCAGGAGAATCAG 
Zfp780b TAC TAG AGC AGG AGA AAG AG CAT AAT CTG TCT CCA AGT CTG 
Genotyping 
Cre GAA CCT GAT GGA CAT GTT CAG G AGT GCG TTC GAA CGC TAG AGC CTG T 
GAPDH TCC ACC ACC ATG GAG AAG GC GGC ATG GAC TGT GGT CAT GA   
KAP1 - 1 TTG GTG AGT GGG AAG ATA ACC AGG 
KAP1 - 2 AAA GAT CTA GGT CTG GAA GC 
KAP1 - 3 GCG AGC ACG AAT CAA GGT CAG 
Comment: use of those three primers in the PCR 
reaction allows distinguishing between different KAP1 
loci (Cammas et al., 2000). 
X-globin CAA GAT CAT GAC CGC CGT AGG CAT GAA CTT GTC CCA GGC TTC 
ChIP 
Actin TAG GCA CCA GGG TGT GAT GG CAT GGC TGG GGT GTT GAA GG 
FSP27 – promoter  GGG TTC CTC AGT CAG CTA CTA TGC GCA GGG ATC TAA GTG GCT TGA 
FSP27 – peak  GGC GCA TTG GGT CAA AGA GAC CTA GAA CAC AGG CAG AAG CTT 
Cyp2b – peak  TTT CAG CAG TTC AGG ACC TTC TT CAC ATG AAA CAG GAC TTC CAA CA 
c-Cbl - peak CTG AGT TTG AGA TCA GGA TG  TCT CTG TGC TCA TAA GGT TC  
Cyp2b9/13 promoter AAA GTC TAG GGT GGT TGT AAT GGA A CCA GGA ATG TGA GCA CCA TAG TT 
Cyp2d9 – peak1 GAA AAT GGC AAA CCT GGG AAT CAA CAG GAT GCT GGG ACT GA 
Cyp2d9 – peak2 GCC TCT TTC CCT CCA CTG TAG A GCT TGA CTG CCT TCC TGT GAA 
Foxp3 GCT CTG GAA GCC CTG TGA GCCCTGGCTGTCTTCTGA 
GAPDH GGC CGC CGC CAT GT AGC TAG GAA GAA GGA AGG CCT AAG 
GSTπ - peak2  CAA TGT GCG TCC TCT GTG TGT GGC GCA AGT GTC TCA CAA GTT 
GSTπ - promoter  TGA AGC TCT TTG GGA GGA GAA A TCC CCA TCT ACC AAC CTC TGT AG 
GSTπ - peak1 ATC CAC TCG AGG CTT CTC  GGC TTC TAC CCA GAC ATG  
RPS promoter CGA AGG TGG CTG GAA GTT ACA CCA ACT CGG CTC TCA GAG AAA T 
Slp – peak   CCC CTG CGT GGG ATA ACC GTC CTT GCT GCA 
Slp – promoter  GGA GGA TCC AGG AGA GGT CAA TCA AAC TCT GCC CCA AAC CTA 
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